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Zusammenfassung
Alternatives Spleißen ist ein wesentlicher Mechanismus, um Proteindiversität in Eukary-
oten zu gewährleisten. Gewebespezifität sowie entwicklungsrelevante Prozesse werden
unter anderem massgeblich davon beeinflusst. Aberrante (alternative) Spleißvorgänge
können wiederum zu veränderten Proteinisoformen führen, die verschiedenste Krank-
heiten wie Krebs verursachen oder zu veränderter Medikamentenwirksamkeit beitragen
können. In dieser Arbeit untersuchen wir differentielles Spleißen im Kontext von Krebs-
erkrankungen. Dazu betrachten wir drei Aspekte, die uns wichtig erscheinen.
Der erste Teil dieser Arbeit beschäftigt sich mit dem systematischen Vergleich ver-
schiedener Methoden für die Detektion von differentiellem Spleißen in Exon-Array-
Daten. Mehrere Methoden wurden für diese Aufgabe entwickelt, die Übereinstimmung
der jeweiligen Ergebnisse ist jedoch oft gering. Darüber hinaus gibt es bis heute keine
Evaluierung dieser Methoden bezüglich des Einflusses bestimmter Datenparameter auf
die Ergebnisgüte. Aus diesem Grund haben wir artifizielle Daten generiert, um Parame-
ter wie Expressionsintensität oder die Anzahl der differentiell gespleißeten Proben pro
Gruppe zu modellieren. Zusätzlich haben wir alle Methoden auf experimentell validierte
Datensätze angewandt. Mit Hilfe unseres Ansatzes identifizieren wir Methoden, die über
alle Szenarien hinweg robuste Ergebnisse liefern, und ermitteln bestimmte Datenparam-
eter, die die Ergebnisgüte sowie die Qualität der angewandten Methoden beeinflussen.
Im zweiten Teil identifizieren wir Spleiß-regulatorischer Proteine, die für die beobachte-
ten Spleissveränderungen zwischen Krebs, hier Lymphomen, und einer Kontrolle, verant-
wortlich sein könnten. Erkenntnisse derartiger Zusammenhänge ermöglichen ein besseres
Verständnis der zugrundeliegenden Pathomechanismen und folglich bessere Therapie-
möglichkeiten. Zu diesem Zweck stellen wir eine von uns entwickelte Methode basierend
auf einem Netzwerkansatz vor. Hierbei werden Spleißfaktoren und differentiell gesplicete
Exons in ein Netzwerk integriert und anschliessend anhand der Unterschiede in ihrer Zen-
tralität geordnet. Wir untermauern unseren Ansatz, indem wir die Platzierung differ-
entiell exprimierter Regulatoren unter den Topkandidaten untersuchen, und diskutieren
anhand ausgewählter Beispiele die potentiellen Einflussursachen für nicht differentiell
exprimierte Kandidaten.
Im dritten Teil analysieren wir die Vergleichbarkeit zweier Datentypen, generiert
durch unterschiedliche Technologien, in Bezug auf die Detektion von differentiellem
Spleißen. Eine Abschätzung dieser Vergleichbarkeit ist von hohem Interesse, da RNA
Sequenzierung Exon Arrays nach und nach ablöst. Vergleiche dieser Art sind selten
und aufgrund geringer Fallzahlen oder der Verwendung seltener Microarrays wenig aus-
sagekräftig. Um diese Aufgabe zu lösen, entwickeln wir einen Multiebenenansatz, der den
Vergleich nicht auf die Ebene des differentiellen Spleißens reduziert, sondern vorherge-
hende Ebenen miteinbezieht. Um eine Beeinträchtigung der Vergleichbarkeit durch die
Verwendung unterschiedlicher Methoden für die Detektion von differentiellem Spleißen
zu vermeiden, wenden wir Methoden an, die für beide Technologien geeignet sind. Die
Anwendung unseres Ansatzes auf zwei Datensätze identifiziert ähnliche Trends in der
Vergleichbarkeit bei einer sich unterscheidenden Gesamtkonkordanz.
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Abstract
Alternative splicing is a crucial mechanism in eukaryotes, which provides an ample pro-
tein diversity that is necessary for maintaining an organism by, for instance, establishing
tissue diversity and contributing to developmental processes. In contrast, aberrant (al-
ternative) splicing may lead to altered protein isoforms contributing to cellular malfunc-
tioning, diseases such as cancer as well as altered susceptibility towards drug treatment.
In this thesis, we study differential splicing in cancer, i.e. splicing changes observed
between cancerous and control tissues. More precisely, we seek to identify methods
best suited for the detection of differential splicing, we investigate regulatory factors
potentially causal for the splicing changes observed, and we study the comparability of
two data types obtained from different technologies with respect to differential splicing
detection.
The first part of the thesis assesses the performance of methods for detecting differen-
tial splicing from exon arrays. Several methods exist for this task, but their results are
often of low concordance. Moreover, no comprehensive evaluation has been conducted
so far to examine global data parameters and their potential influence on results and
method performance. To this end, we generated artificial data to model different vari-
ables, such as expression intensity or the percentage of differentially spliced samples per
group. Additionally, we applied all methods compared to validated experimental data.
Overall, our evaluation indicates methods that perform robustly well across artificial
and experimental data and identifies parameters impacting result performance.
The second part aims at identifying regulatory factors responsible for splicing changes
observed between cancer, namely lymphoma, and healthy tissue. Determining the under-
lying causes for these events might elucidate the pathological mechanism of the disease
and thus, provide options for targeting carcinogenic enhancers. To this end, we develop
a novel, network based approach which first integrates differentially spliced exons with
splicing regulatory proteins (splicing factors), using transcriptomics data, and then ranks
splicing factors according to their potential involvement in cancer. We strengthen our
approach by assessing the enrichment of differentially expressed splicing factors amongst
our predicted causal regulators and discuss selected examples of alterations potentially
influencing splicing factors highly ranked in our approach, which are not differentially
expressed.
Third, we compare differential splicing detection based on RNA sequencing and exon
array data. As RNA sequencing is gradually replacing microarrays, the comparability
with respect to this task is of crucial interest. While gene based comparisons show
a high result concordance, studies on differential splicing are more seldom and lack
explanatory power due to small sample sizes or rarely used microarrays. We address
this task by developing a multi-level comparison framework, elucidating comparability
on several levels including, for instance, probe and gene level. Additionally, we aim
at improving differential splicing comparability by considering two differential splicing
detection methods applicable to both, RNA sequencing and exon array data, to avoid
method inherent bias. We apply our multi-level framework to two data sets, leading,
despite varying overall concordance, to similar trends in comparability.
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1 Introduction
The finalization of the Human Genome Project [Collins et al., 2003] in 2003 has rev-
olutionized genomics, and, in consequence, biology and medicine [Collins, 1999,Collins
et al., 2003]. Knowledge about the nucleotide sequence constituting a human genome en-
abled a fundamentally new approach to the investigation of all cellular processes giving
rise to several high-throughput technologies. As of that moment, the study of bio-
logical entities, such as genes, emerged from single to all-in-parallel [Kononen et al.,
1998,Mardis, 2008]. Such global approaches allowed for a new understanding about in-
dividual entities, and, more importantly, their interdependence as well as their interplay
and regulation [Mardis, 2008,Sorek and Cossart, 2010].
Different layers are involved in maintaining the subtle equilibrium of life. The genome
encodes this information, which is first transcribed to mRNA and then translated to
the active cellular components, the proteins. A major control instance for this essential
process is the epigenome, defining chemical changes of the DNA and histone proteins
providing or restricting access to the transcription machinery. These different layers
interact and regulate each other [Luco et al., 2011, Fu et al., 2013]. Thus, aberrant
behaviour in any of these layers may lead to malfunction of an organism resulting in
disease or unusual therapeutic responses.
Various large-scale ’omics’ technologies have been developed as investigatory tools
to analyze the individual biological layers and regulatory processes at large. Tran-
scriptomics captures the amount of mRNA present for all transcribed entities, such as
genes, in a sample at a certain time point. It is widely applied to determine differ-
entially expressed genes between two or more conditions. This approach has led over
decades to valuable insights changing the understanding of biological mechanisms as
well as therapeutic approaches successfully. Gene signatures predict susceptibility to
therapy [Van’t Veer et al., 2002], survival [Van De Vijver et al., 2002], and enable
classification and class discovery of disease subtypes [Calon et al., 2015, Golub et al.,
1999,Tibshirani et al., 2002].
However, the early one-gene-one-protein hypothesis has been overcome decades ago,
as the observed number of genes in eukaryotes, about 25,000 genes in human, is not able
to provide the physiological complexity necessary to maintain an organism [Graveley,
2001]. The major mechanism responsible for this augmentation in protein diversity is al-
ternative splicing. Splicing is an inevitable step in the transcription of multi-exon genes,
responsible for the excision of introns. The remaining parts, exons, are the information-
coding genomic sequences that are joint (all or some) into the final transcript, which
is then subjected to translation. Accordingly, splicing is also responsible for variation
of the sequences included into the final transcript. This process, referred to as alterna-
tive splicing, leads to an increase in complexity of the functional proteome by varying
1
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the exons included in the final transcript, and thus, the transcript sequence and protein
function (see Figure 1.1). Different isoforms of the same gene are, for instance, necessary
during development [Giudice et al., 2014,Revil et al., 2010,Barberan-Soler and Zahler,
2008] and for creating tissue specificity [Grosso et al., 2008, Calarco et al., 2011, Yeo
et al., 2004].
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Figure 1.1: Alternative splicing. The information constituting a gene is transcribed
from the DNA to a pre-mRNA. Alternative Splicing leads to different mRNAs
and subsequently to different protein isoforms.
Erroneous splicing can lead to protein products with altered function. While this can
be an evolutionary advantage in few cases, most of the outcomes are physiologically
disadvantageous and lead to severe diseases such as neuro-degenerative disorders [Golde
et al., 1990,Meshorer and Soreq, 2006] and cancer [Piekielko-Witkowska et al., 2010,
Watson et al., 2013, Lenzken et al., 2013, Fackenthal and Godley, 2008]. A biologically
well-documented example of altered protein function due to a different isoform of a gene
is discovered for BCL-X. This gene is a family-member of apoptotic regulators. A short,
BCL-XS , and a long isoform, BCL-XL, is known. While BCL-XL has an anti-apoptotic
effect, BCL-XS displays the adverse function by promoting apoptosis. Accordingly, the
two isoforms of this gene are of high interest as therapeutical targets [Akgul et al., 2004].
Regulation of splicing is mainly accomplished by two types of elements (see Figure 1.2).
The first ones, referred to as cis-regulatory elements, are nucleotide sequences located
in the DNA, which interact with trans-regulatory elements, i.e. proteins involved in
the process of splicing and its regulation. These elements can in turn be influenced by
general superordinate layers.
Several mechanisms can contribute to patho-physiological splicing. For instance,
about 30% of all disease causing mutations unfold their malicious impact by altering
the splicing pattern [Xi et al., 2008]. Furthermore, growing evidence in the last years
suggested a central role of epigenetics in the regulation of alternative splicing. This also
pinpointed to aberrant splicing events linked to epigenetic alterations in cancer [Li et al.,
2015,Zhao et al., 2017,Salton et al., 2014].
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Figure 1.2: Regulation of alternative splicing is controlled by cis-acting splicing reg-
ulatory elements (SRE) and trans-acting splicing factors. Cis-splicing reg-
ulatory elements can be distinguished into intron or exon splicing silencers
or enhancers (ISE, ISS, ESE, and ESS) depending on their relative loca-
tion and their impact on the splicing event. Splicing factors are recruited
by corresponding cis-regulatory factors and promote or inhibit splice site
recognition.
Recent studies emphasized the crucial role of aberrant splicing in cancer [Oltean and
Bates, 2014, Sveen et al., 2015, Dvinge et al., 2016, He et al., 2014]. Yet, the detailed
instances of aberrant (differential) splicing specific for different cancer types or even
general patterns of aberrant splicing in cancer together with the regulatory mechanisms
leading to such aberrant splicing still have to be elucidated.
The detection of different splicing patterns between conditions on the transcriptomic
level can be assessed with two major technologies, (exon) microarrays and RNA sequenc-
ing. The first generation of high-throughput transcriptome technologies were microar-
rays [Schena et al., 1995]. They capture the amount of mRNA of interest by hybridiza-
tion of complementary probes attached to a small chip. This technique is still widely
used, as microarrays have proven themselves worthwhile [Van’t Veer et al., 2002, Tib-
shirani et al., 2002,Calon et al., 2015]. However, they have several drawbacks, the most
obvious being the fact that only known entities represented on the microarray can be
interrogated. With advances in technology, next-generation high-throughput approaches
emerged. Here, identification and quantification of the interrogated genomic entities is
based on sequencing.
While next-generation sequencing (NGS) is applicable to the same scenarios as mi-
croarrays, it additionally enlarges and complements their repertoire mainly through an
unbiased view as no prior knowledge of the sequence is needed. Additionally, NGS
provides a more fine-grained resolution on sequence copies, as it is designed to be ca-
pable of reporting every single transcript encountered as opposed to microarrays, where
expression is represented in an analog rather than discrete way.
1.1 Aim
Accurate prediction of the differential splicing (DS) events distinguishing two conditions
such as cancer and control tissue together with the regulatory malfunctioning causing
3
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such aberrant splicing is essential for understanding the disease pathology and identifying
therapeutical targets.
A plethora of methods for the detction of differential splicing from exon arrays exists.
Nevertheless, the overlap in their prediction of DS events is at times low [Bisognin
et al., 2014]. Additionally, no comprehensive assessment to susceptibility of global data
parameters potentially influencing result performance has been conducted so far. Yet,
these influences can be vital for the adequate selection of a method for a defined study
aim such as biomarker detection [Hartwell et al., 2006]. A central aim of our work
is thus to (1) study and compare algorithms for the identification of aberrant splicing
events characteristic for a certain condition together with their performance according to
different measures and their suceptibility to several global data parameters. Identifying
the method most adequate for the prediction of differential splicing events according to
performance based on the given data parameters and the defined study aim may lead
to the most reliable and appropriate predictions.
Several layers might contribute to the malfunctioning of splicing regulators. While
in principle different omics technologies might be used to interrogate potential causes
for the aberrant regulatory impact on splicing, such an approach is associated with a
tremendous time and cost investment. Additionally, no gold standard for the integrative
analysis of different omics data sets has been established so far. We thus (2) aim at
developing a novel algorithm for the identification of the regulatory elements causal
for the splicing changes observed without restricting potential alterations in regulatory
elements to the transcriptome level, yet, while only using transcriptomic data.
Given the advances NGS technologies provide, they are gradually replacing microar-
rays. Thus, comparability of the two technologies is of great interest to determine
whether research results can be reproduced. For the gene expression level, this compari-
son has been conducted extensively, however, an evaluation based on differential splicing
is rather seldom and lacks explanatory power due to small sample size or rarely used
microarrays [Raghavachari et al., 2012,Bradford et al., 2010]. Therefor, we (3), aim at
identifying comparability of RNA sequencing data to exon array data with respect to
differential splicing detection.
1.2 Contributions
Our aim in this work is to develop methods to improve the understanding of splicing
in cancer, especially in lymphoma. Only a detailed understanding of occurrences of
differential splicing, i.e. differences in splicing between conditions, as well as the cir-
cumstances that provoke this occurrence can lead to a holistic understanding and thus a
targeted therapeutic approach based on specific isoform expressions or causal regulators.
To this end, we address three questions we believe to be most relevant for differential
splicing and its role in cancer.
• First, we tackle the problem of detecting differential splicing based on exon ar-
rays. While a variety of methods for this task exist, result sets differ substantially
4
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and no evaluation based on different global data features influencing results has
been presented to date. We perform a comprehensive study to identify the best
method(s) for a given scenario based on artificial and real data sets comprising
several aspects potentially influencing detection of differential splicing events. We
evaluate and discuss results with regard to the mathematical background of the
methods and give recommendations on which method to use for a certain scenario.
• Second, we aim at elucidating regulatory changes responsible for the differential
splicing observed. To this end, we integrate differential splicing events observed
with potential regulators, i.e., splicing factors (SF), in an expression correlation
network. Hereby, we obtain a list of candidate splicing factors. Our approach is
designed to reflect not only transcription induced changes, but also changes ob-
served in other layers such as epigenetics or genomics even though using only one
technology, i.e. transcriptomics. We corroborate our result by showing a high
ranking of differentially expressed splicing factors in our candidate lists. Further-
more, we investigate and discuss potential sources of influence on the identified
splicing factors.
• Third, we propose a framework for the elucidation of the concordance between
RNA sequencing and exon arrays with respect to differential splicing prediction.
While several works show comparability of results on gene level, result comparison
on differential splicing basis so-far are rare and lack explanatory power. To this
end, we implement a multi-level framework allowing for comparison of the two
technologies on various levels. We also study result comparability by using the
same methods for differential splicing detection on both data types. Our approach
shows substantial comparability throughout data sets. Additionally, we determine
the influence of different factors on result concordance.
1.3 Outline of Thesis
This section gives a brief overview on structure and content of this work. We highlight
the different aims, the solutions developed to achieve our tasks as well as a short overview
on the results in a chapter-based manner.
Chapter 2 gives an introduction to the two main aspects relevant throughout this work:
First, the mechanism of (alternative) splicing, its regulation as well as its implications
for diseases such as cancer. Second, we introduce high-throughput technologies for the
quantification of transcription in the context of differential splicing. We give detailed
insights on the characteristics of exon array and RNA sequencing derived data and
discuss their strengths and weaknesses. Last, we describe the key data set of this thesis
used throughout most of this work.
Chapter 3 introduces several methods for differential splicing detection based on exon
array data and motivates the need for detailed, thorough comparisons based on controlled
data scenarios. Data simulation as well as experimental influences are introduced. Re-
sults on artificial data as well as for two q-PCR validated data sets are presented and
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discussed with respect to the mathematical method background as well as to the sce-
narios created. Finally, we give recommendations for the choice of a differential splicing
detection method for different application scenarios.
Chapter 4 describes a novel, network based method for the detection of regulatory el-
ements causal for the splicing changes observed in a condition. To this end, we perform
an integrated analysis on altered entities, i.e. differentially spliced exons together with
potential regulators, i.e. splicing factors using a network based approach. We evalu-
ate our method by investigating the ranking of differentially expressed splicing factors
amongst our network-based top candidates for aberrant regulators. We contextualize
our findings with literature research and published results in potentially causal layers.
Chapter 5 is dedicated to the comparison of RNA sequencing and exon array derived
differential splicing detection. As microarrays are gradually replaced by RNA sequenc-
ing, we thoroughly evaluate concordance of the differential splicing events detected using
a multi-level approach designated to elucidate changes on several levels. We tackle po-
tentially induced method bias by the application of the same methods on both data
types and evaluate the impact of different factors on result concordance.
Chapter 6 summarizes this thesis, highlights the central contributions of this work
and addresses possible future directions.
1.4 Own Prior Work and Contribution
Chapter 3 describes the comparative assessment of differential splicing detection methods
originally presented in [Zimmermann et al., 2015] and based on previous work from
[Zimmermann and Leser, 2010]. The contributions to this work can be attributed to
the authors as follows: For [Zimmermann and Leser, 2010], Karin Zimmermann and
Ulf Leser conceived the research, Karin Zimmermann wrote and Ulf Leser revised the
manuscript. In [Zimmermann et al., 2015], Karin Zimmermann and Ulf Leser conceived
the research. Karin Zimmermann carried out the experiments, analyzed the results
and drafted the manuscript. Marcel Jentsch developed KLAS, a method for detection
of differential splicing, Marcel Jentsch and Axel Rasche implemented the differential
splicing detection methods. Axel Rasche, Michael Hummel, and Ulf Leser helped to
revise the manuscript and to interpret the data.
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In the last decades high-throughput technologies have revolutionized the way complex
genomic questions can be answered [Li et al., 2014]. By targeting all elements of the
genome at a time and in parallel, a way more fast, cheap and objective investigation
is ensured. On the transcriptome level, this allows for the quantification of exon ex-
pression using technologies such as exon arrays and high-throughput sequencing. This
more fine-grained resolution, as opposed to the quantification on gene level, enables the
detection of alternative splicing. Discovered in the early 70s, the mechanism of alterna-
tive splicing provides the major source of transcript and therefor protein diversity which
is necessary to maintain eukaryotic physiology [Nilsen and Graveley, 2010]. As how-
ever the mechanism is highly complex and depends on various players and their exact
abundance, numerous diseases are known to be associated with aberrant splicing [Golde
et al., 1990,Meshorer and Soreq, 2006,Piekielko-Witkowska et al., 2010,Watson et al.,
2013,Lenzken et al., 2013]. Thus, differences in isoforms between conditions, i.e. varia-
tions of a protein due to different splicing, are of high therapeutic interest.
In this chapter we will describe the mechanism of alternative splicing along with its
regulation and association with diseases. Furthermore, we introduce high-throughput
technologies such as microarrays and high-throughput sequencing that are crucial for
detecting alternative splicing.
2.1 Alternative Splicing
During protein biosynthesis a gene is translated into a protein (Figure 2.1). First, the
genetic code is transcribed into a pre-mRNA which is an exact copy of the genetic
sequence. This sequence contains the exons - the information coding part - as well as
intronic regions, usually not part of the final template. To obtain the mature mRNA, all
sequences which are not intended to be part of the final template are removed, i.e. spliced
out. The resulting mRNA is now translated into the corresponding amino acid sequence
by the ribosomal machinery of the cell which in turn is folded into the functional protein.
However, the process of splicing is not static, i.e. a gene can be translated into different
mRNAs and thus into different proteins by excluding exons from the final transcript.
This process is called alternative splicing and provides the variety of proteins necessary
to maintain the proper functioning of an eukaryotic organism.
Since advances in large-scale technologies such as microarrays and high-throughput
sequencing are substantially alleviating genomic research, the extent of the prevalence
and thus the impact of splicing becomes more and more clear. According to recent stud-
ies over 95% of all multi-exon genes are alternatively spliced [Wang et al., 2008]. This
7
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Figure 2.1: Protein biosynthesis includes transcription of entities encoded in the DNA
and their translation to functional proteins.
underlines the fundamental importance of alternative splicing for the establishment of
the protein diversity necessary for eukaryotes. Being such an integral part of gene regu-
lation, the mechanism of alternative splicing is a highly relevant subject of investigation
in physiological scenarios as well as in aberrant conditions such as diseases.
Here, we will discuss the importance of alternative splicing for eukaryotes, its mecha-
nism, types, and regulation. We will also give an overview on disease associated splicing
with a special focus on lymphoma. We will use the term alternative splicing with the
meaning described above, i.e. referring to the general mechanism. In contrast, aber-
rant splicing refers to non-physiological instances of splicing as, for instance, observed
in diseases. By differential splicing we refer to splicing events which differ between two
groups being analyzed. While these terms might overlap in their meaning, we adhere to
a context-dependent usage.
2.1.1 The Importance of Alternative Splicing for Eukaryotes
When the human genome was decoded, the number of genes encountered was somewhat
surprising. Roughly 25,000 genes constitute the genome. For an organism as complex as
the human a much higher number of proteins is necessary to maintain the intricate pro-
cesses underneath. The increase in protein diversity is achieved by alternative splicing.
This mechanism allows for a number of protein isoforms higher by one magnitude [Hu
et al., 2015].
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On an evolutionary scale, alternative splicing can provide faster adaption to new
environmental challenges. In a prokaryotic scenario the usual point mutation is a rather
slow development towards a new function. For eukaryotes, the in- or exclusion of exons
by, for instance, a point mutation, provides a faster new feature as exons are already
’approved’ components.
Alternative splicing is known to play a central role in several physiological scenarios.
It affects tissue diversity [Grosso et al., 2008, Calarco et al., 2011, Yeo et al., 2004],
development [Giudice et al., 2014,Revil et al., 2010,Barberan-Soler and Zahler, 2008],
protein stability [Jensen and Whitehead, 2001, Sakurai et al., 2001], post-translational
modifications [Naro and Sette, 2013, Liu et al., 2013, Fackenthal and Godley, 2008],
enzymatic activity [Li and Koromilas, 2001], gene expression regulation [Heinzen et al.,
2008], apoptosis [Schwerk and Schulze-Osthoff, 2005], DNA damage repair [Lenzken
et al., 2013] intracellular localization [Indraccolo et al., 2002, Koch et al., 2001], and
binding properties [Birikh et al., 2003]. Correspondingly, the mechanism is indispensable
for all aspects of eukaryotic maintenance. Sometimes, alternative splicing can even lead
to a binary function switch, as in the case of a pro- and anti-apoptotic isoform of a
gene [Akgul et al., 2004,Thorsen et al., 2008].
2.1.2 The Mechanism of Splicing
The basic mechanism of splicing is accomplished by the so-called spliceosome. This
conglomerate of five small nuclear ribonucleic proteins (snRNPs) catalyzes the excision
of introns from the pre-mRNA and mediates the union of the exons. The five snRNPs,
U1, U2, U4, U5, and U6 , are known as the major spliceosome, responsible for canonical
splicing, which is active in the nucleus and accomplishes the splicing of a vast majority of
the introns. Yet, a minor spliceosome exists, accounting for a small number, only about
1%, of introns, which, except for U5, depend on different snRNPs namely U11, U12,
U4atac, and U6atac [Patel and Steitz, 2003]. For the assembly of the spliceosome the
additional factors U2 small nuclear RNA auxiliary factor 1 (U2AF35), U2AF2 (U2AF65)
and SF1 are required [Black, 2003,Matlin et al., 2005].
Three sites in an intron are fundamental for the mechanism of splicing. Two of them,
the splice sites, are found at the 5’ end and the 3’ end of the intron consisting of
the nucleotides GU and AG respectively. The third relevant site, the branch point, is
located upstream from the 3’ end of the intron and contains an adenine, while flanking
nucleotides are somewhat variable. Subsequently, the pyrimidine tract - a series of
pyrimidines - is found.
The actual splicing process is constituted of several steps with different active com-
plexes [Wahl et al., 2009,Will and Lührmann, 2011,Kornblihtt et al., 2013]. An overview
is given in Figure 2.2. First, complex E is formed. To this end, U1 binds to the GU se-
quence at the 5’ splice site of the intron, SF1 attaches to the branch point while U2AF1
binds to the 3’ splice site and U2AF2 to the polypyrimidine tract. Subsequently, the
pre-spliceosome, known as complex A, is assembled. By hydrolyzation of ATP, U2 binds
to the branch point. A trimer consisting of the snRNPs U4, U5 and U6 binds, giving
rise to the pre-catalytic spliceosome (complex B), which is then, by the release of U1
9
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Figure 2.2: The spliceosome catalyzes the excision of introns from the transcribed
pre-mRNA and mediates the concatenation of exons for the final mRNA.
and U4, turned into a catalytically active complex B*. Hence, the first of two transes-
terification steps, catalyzed by U2 and U6 can take place. The intron lariat is formed,
a branched RNA, which results from the nucleophilic attack by the 2’OH group of the
adenosine in the branch point on the 5’ splice site (catalytic spliceosome, complex C).
The second transesterification step produces the spliced mRNA and the excised intron
lariat by attack of the 3’OH group of the upstream exon on the 3’ splice site. As soon
as the exons are joint to the final mRNA, U2, U5 and U6 are released and the lariat is
degraded.
2.1.3 Types of Alternative Splicing
According to current knowledge, not all exons are part of the variety-providing pool.
While some exons are contained in all transcripts produced from a gene, known as
constitutive exons, others may or may not be included in the final transcript and are thus
responsible for the observed protein diversity. These exons are called alternative exons.
Most of the alternative splicing events observed can be classified into the subsequent
categories (Figure 2.3) [Keren et al., 2010]:
a exon skipping - one or more exons are excluded from the final transcript
b alternative 3’ splice site selection - the exon is shortened or elongated on the 3’
splice site
c alternative 5’ splice site selection - the exon is shortened or elongated on the 5’
splice site
10
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d intron retention - the intron is included in the transcript
e mutually exclusive exons - only one of two exons is included in the transcript
f alternative promoters - the transcript starts at a different position
g alternative polyA - the transcript ends at a different position
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Figure 2.3: Different types of alternative splicing exist. Exons can be skipped,
at times mutually exclusive, and different 3’ or 5’ splice sites can be used.
Transcript alteration can also occur due to the use of alternative promoters
or polyadenylation.
While the use of alternative promoters and alternative adenylation sites are not ac-
tually splicing events, they can usually be detected with similar methods using high-
throughput sequencing or adequate microarrays.
Some types of events are much more frequent than others [Sammeth et al., 2008]. In
human, exon skipping is by far the most frequent event (see Figure 2.4). In most cases,
splicing occurs in one transcript, nevertheless trans-splicing is known, where exons from
different pre-mRNA transcripts are ligated together [Iwasaki et al., 2009].
Not all of these events can be detected with the use of exon arrays. By design, only
de- or inclusion of exons can be detected.
2.1.4 Regulation of Alternative Splicing
Besides the elementary splicing signals, the two splice sites at the 5’ and 3’ end of
an intron as well as the branch point located in close proximity upstream to the 3’
splice site, multiple sites and proteins exist, which control splicing in a complex and
interdependent manner. These regulatory elements are referred to as cis- and trans-
acting factors, depending on whether they are located in the genome (cis) or whether
11
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Figure 2.4: Frequency of human alternative splicing types according to Gencode,
RefSeq and Ensembl [Sammeth et al., 2008].
it is a matter of the corresponding regulatory proteins (trans), respectively [Wang and
Burge, 2008]. Trans-acting factors are also referred to as splicing factors, which is the
term of detonation used in this work.
Generally, both types of elements can act as promoters or inhibitors of splicing [Barash
et al., 2010]. In the case of trans-acting factors, they are denoted as activators or
repressors, when referred to cis-acting elements, enhancers and silencers.
The effect of cis-acting elements depends on their sequence, the proximity to the
exon/intron of interest as well as the abundance and type of trans-acting factors present.
A cis-acting sequence can, for instance, repress or enhance the excision of a nearby intron
and therefor act as an intron splicing silencer (ISS) or intron splicing enhancer (ISE).
Similarly, the inclusion of exons can be controlled by cis-acting factors operating as exon
splicing enhancers (ESE) or exon splicing silencers (ESS).
The same principle holds for trans-acting factors. Depending on the cis-acting factors
and additional trans-acting factors they interact whith, they can activate or repress the
splicing of an exon or intron within a certain proximity. Trans-acting factors can be
roughly classified by their effect on splicing. Serine-Arginine rich proteins usually func-
tion as splicing facilitators while heterogeneous nuclear ribonucleoproteins (hnRNPs)
tend to suppress splicing [Matlin et al., 2005,Wang and Burge, 2008].
Another possibility for the influence on splicing is given by the pre-mRNA itself. A
certain 2D structure can either promote or inhibit binding of activators or repressors
by exposing or masking the corresponding cis-regulatory elements [Warf and Berglund,
2010].
Thus, the splicing code ( i.e. all influential factors in the context of splicing together
with their regulation) determining the concrete composition of a mature mRNA is a
highly complex mechanism depending on the combinatorial effects of the involved play-
ers, their abundance in the cell, and the competitive binding effect between activators
and repressors as well as sterical inhibition by the pre-mRNA itself.
Besides the actual players involved in the splicing process, other levels of regulation
exist. Post-translational modifications such as phosphorylation [Naro and Sette, 2013,
12
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Liu et al., 2013, Zhong et al., 2009, Fackenthal and Godley, 2008] are known to play a
central role in the regulation of splicing.
The coupling of splicing to transcription additionally impacts the sequence of the
final mRNA. Altered RNA polymerase II elongation rates favor the inclusion of different
alternative exons, while a fast elongation rate promotes skipping of exons with weak
upstream 3’ splice sites, slower Pol II elongation rates facilitate their inclusion [Merkhofer
et al., 2014].
Moreover, epigenetic modifications can also affect and thus regulate splicing, by en-
hancing or preventing the accession of splicing regulatory sites [Luco et al., 2011,Brown
et al., 2012,Zhou et al., 2012].
Luco et al. [Luco et al., 2011] propose an integrated alternative splice site selection
model, where transcription regulators and histone modifiers alter chromatin for the re-
cruitment of factors activating RNA Pol II elongation kinetics. Additionally, nucleosome
positioning along exons as well as the enrichment of certain histone modifications might
influence the recruitment of splicing factors.
While the regulation of certain splicing events or factors in a fixed scenario [Matera
and Wang, 2014] as well as the mode of influence for certain levels [Luco et al., 2011]
is becoming more clear due to extensive research, the general regulatory mechanisms
including all relevant players and circumstances, i.e. tissue type or developmental stage,
are far from being understood [Matera and Wang, 2014].
2.1.5 Alternative Splicing and Disease
Given the complexity of the process and the high number of players involved, the occur-
rence of errors in the splicing process is biomedically relevant, as a high number of splic-
ing associated diseases is known. Studies suggest that about 30% of all disease causing
mutations are splicing related [Xi et al., 2008]. Prominent examples are neurodegenera-
tive diseases such as Alzheimer’s [Golde et al., 1990] and Parkinson [Meshorer and Soreq,
2006] as well as cancer [Piekielko-Witkowska et al., 2010,Watson et al., 2013, Lenzken
et al., 2013,Fackenthal and Godley, 2008].
The aberrant splicing events caused by mutations are often due to alterations in the
splicing regulatory factors or within basic splicing signals, such as splice sites. Thus,
mutations might either disrupt splicing signals located in the genome (see Figure 2.5),
or impact the function of trans-acting factors.
About 10% of all pathogenic mutations are accounted to splice site alterations [Krawczak
et al., 2007]. An alteration in splice-sites leads to the inclusion of introns or elongation
of the sequence to splice depending on whether the mutation is located in the 5’ or 3’
splice site. Induction of early 3’ or late 5’ splice sites by mutation also affect the final
sequence. Analogously, mutations in other splicing control sequences such as the branch
point, enhancer or silencer sequences can provoke a reduced probability or even the total
deficit of splicing.
An example, where mutations in a regulatory element lead to altered ratios of iso-
forms of a protein resulting in a pathologic phenotype is frontotemporal dementia and
Parkinson [Fu et al., 2013,Kar et al., 2005]. Mutations in the gene MAPT were found to
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be responsible for these ratio changes. The tau protein, which is encoded by this gene,
is indispensable for microtubule assembly and stability. Two isoforms, one with three
and one with four microtubule-binding sites, exist. The different number of binding
sites is due to the inclusion of exon 10. Mutations in regulatory elements of the latter
can lead to its increased inclusion, which alters the ratio of the two isoforms such that
aggregation of tau is provoked [Liu and Gong, 2008].
Beyond neurodegenerative illnesses, cancer is a prominent disease class where alter-
ations in splicing are involved. BCL-X, a gene from a familiy of apoptotic regulators,
gives rise to two different isoforms with opposing functions by encoding a pro-apoptotic
isoform, BCL-XS , as well as the anti-apoptotic isoform, BCL-XL (see Figure 2.5). The
functional switch is due to an alternative 5’-splice site for one of the exons and the
deregulation in the ratio of these isoforms in favor of BCL-XL is associated to various
cancer types and resistance to chemotherapy [Pajares et al., 2007, Akgul et al., 2004].
BRCA1 is a gene known to have predictive potential for breast and ovarian cancer pre-
disposition by the genomic alterations observed. One of these known alterations is an
inherited point mutation in exon 18, which disrupts an ESE and provokes skipping of
the exon [Mazoyer et al., 1998].
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Figure 2.5: BRCA1, BCL-X and their cancer-associated isoforms. A A muta-
tion (*) in an ESE located in exon 18 of BRCA1 prevents the binding of
ASF/SF2 to pre-mRNA and causes inappropriate skipping of this exon. B.
Dephosphorylation modifies the activity of SR proteins. Thereby, a splic-
ing switch of the apoptotic regulator BCL-XL to a pro-apoptotic isoform is
induced.
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The alteration of trans-acting factors by mutation can have an even higher impact
on the cell. While the effects of mutations in cis-acting elements are locally restricted,
splicing factors control a variety of splicing events and can therefor lead to a cascade of
changes in the splicing machinery and thereby massively impact isoform types and their
abundances in a cell. Non-silent mutations in the basal splicing machinery tremendously
impact the whole organism and are thus usually lethal, while changes in ’secondary’
splicing associated proteins might in the best case only reduce the probability for the
physiologically correct splicing event. Recent publications have highlighted the oncogenic
potential of aberrantly behaving splicing factors [Oltean and Bates, 2014, Sveen et al.,
2015,Dvinge et al., 2016] and underlined the need for further investigations.
A trans-acting factor being subject to pathogenic alterations is, for instance, splic-
ing factor SF2. SF2 is a proto-oncogene which is involved in several cancer-associated
regulatory cascades and can lead to tumorgenesis in mice [Karni et al., 2007]. SF2 reg-
ulates alternative splicing of the oncogene Ron which influences cell motility and thus
metastasis [Ghigna et al., 2005].
The role of epigenetics in the regulation of alternative splicing is being gradually
elucidated [Luco et al., 2011, Iannone and Valcárcel, 2013, Zhou et al., 2014, Brown
et al., 2012, Haque and Oberdoerffer, 2014]. While the concrete impact of different
epigenetic modifications on the splicing process and the interplay with other splicing-
associated factors remains to be determined, several links between aberrant splicing and
altered epigenetic modifications in cancer have been established. Aberrant transcripts in
hMLH1, for instance, are associated with lower levels of histone acetylation and specific
histone methylation in gastric cancer [Zhao et al., 2017]. The tumor suppressor gene
CDH1 expresses a short isoform lacking exon 8 in gastric cancer, which is attributed to
different acetylation and methylation pattern of histone H3 [Li et al., 2015].
Aberrant Splicing in Lymphoma. Several publications on aberrant splicing in lym-
phoma exist. Besides the well known CD44 isoforms [Stauder et al., 1995,Terpe et al.,
1994,Khaldoyanidi et al., 1996] cyclin D1 [Slotta-Huspenina et al., 2012,Marzec et al.,
2006, Rosenwald et al., 2003], C/EBPβ [Rehm et al., 2014] and FABP7 [Lock et al.,
2014] are related to aberrant isoforms in lymphoma.
For CD44, a standard isoform, CD44s, and a differing, ’variant’, isoform CD44v is
known. According to Khaldoyanidi et al. [Khaldoyanidi et al., 1996] expression of CD44v
is elevated in peripheral blood cells of non-Hodgkin lymphoma patients and is inversely
correlated with tumor progression. Additionally, response to therapy is frequently ac-
companied by up-regulation of CD44v. The authors thus suggest to use CD44v as a
(therapeutic) marker for monitoring disease progression. Stauder et al. [Stauder et al.,
1995] identify CD44v6 predominantly in aggressive lymphoma and observe a signifi-
cantly shortened overall survival of the corresponding patients. Tzankov et al. in-
vestigate the role of CD44 isoforms in the subtypes of diffuse large B-cell lymphoma
(DLBCL) [Tzankov et al., 2003]. The variant containing Exon 6, CD44v6, is predomi-
nantly expressed in one subgroup, the activated B cell-like types (ABC-DLBCL). Also,
CD44v6 correlates with disease stage and is, for CD44 negative cases, associated with a
15
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lower overall survival. Rosenwald et al. [Rosenwald et al., 2003] showed that mantle cell
lymphoma cases mostly expressing a short Cyclin-D1 isoform, have higher Cyclin-D1
mRNA levels, a higher proliferation signature and a significantly poorer survival than
cases which express the standard full-length transcript. Rehm et al. link the LAP/LAP*
isoform of C/EBPβ to a lymphoma growth-promoting and -immunosuppressive environ-
ment.
2.2 High-Troughput Technologies
While most of this work is based on data derived from exon arrays, we also analyze
differential splicing based on RNA sequencing data. In the following section we introduce
both technologies.
2.2.1 Microarrays
Deciphering the human genome and advances in technology enabled a whole new era of
research in biology and medicine. Without the knowledge of the complete human genome
sequence only isolated components could be analyzed. High-throughput microarrays now
allow for the simultaneous investigation of the entities of interest in a cell at a certain
time point. These types of entities correspond to the different functional units of a cell.
While the transcriptome, i.e. the totality of transcribed mRNAs, can be measured with
expression arrays [Conway et al., 2003], the proteome of a cell is quantified with protein
arrays [Zhu et al., 2001]. Another example are ChIP-chips [Buck and Lieb, 2004], where
the result of a chromatin immunoprecipitation is spotted on a microarray and can thus
be identified and quantified.
The basic idea of an expression microarray is to quantify the expressed mRNA of a
cell by hybridization. To this end, probes are attached to the two dimensional surface
of a (glass-)chip. These probes consist of short nucleotide sequences ideally representing
unique sequences of the gene they target. By adding the whole transcriptome of a cell,
the mRNA complementary to the gene-representing probes hybridizes to the latter and
can then be quantified by the activation of an fluorescent labeling (see Figure 2.6).
A typical microarray experiment consists of several different steps. First, the mRNA
of interest is extracted, and if necessary, transcribed to cDNA. After labeling, usually
with a fluorescent dye, the transcriptome is added to the microarray, where hybridiza-
tion of complementary sequences from probes and mRNAs is achieved. Subsequently,
the dye is activated and images capture the amount of hybridized dye/mRNA. Image
analysis applications detect the different spots and compute numerical quantities from
the dye intensities in the picture. These numerical values, i.e. the expression values, are
normalized such that technical bias between and within arrays is reduced thus facilitat-
ing the observation of biological differences. Downstream analysis can now be applied to
the normalized values, including for example statistical tests for expression differences
in groups, clustering algorithms for detection of groups of genes or samples, as well as
classification methods for the assignment of classes.
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Different types of microarrays exist. ’Two-color’ microarrays are based on two chan-
nels. Thus, two biological samples, each labeled with a different dye, are hybridized to
one chip. These arrays report gene expression ratios between the two channels (see also
Figure 2.6). In contrast, so called single channel arrays, as, for instance, the Affymetrix
Gene Chip, quantify only one biological sample and thus do not report relative expression
values as illustrated in Figure 2.6.
A further distinction possibility is spotted versus in situ hybridized microarrays. While
the probes on spotted microarrays are applied to the surface as a whole, the oligonu-
cleotides on in situ hybridized arrays are spotted on the array nucleotide by nucleotide
using a photolitographic process [Beier and Hoheisel, 2000]. As spotted microarrays are
easier to produce and customize, they are often used as in-house designed solutions for
specific questions. Their downside is a lower sensitivity compared to in situ arrays, usu-
ally produced by big companies with an highly optimized protocol. A further advantage
of in situ arrays, besides their higher resolution and coverage of the genome, is their
comparability across experiments.
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Figure 2.6: Microarray experiment based on dual channel (left) and single channel
(right) technology. Dual channel experiments lead to relative expression
values as two different samples labeled with two different dyes are quantified
on one chip. A single channel microarray educes expression values based on
one sample.
Irrespectively of these differences, replication is a crucial aspect for microarrays [Yang
and Speed, 2002].
• Equal probes should be attached on different locations of the chip to avoid position
bias and ensure a consistent signal.
• Ideally, each biological sample should be measured on different chips as a technical
replicate to help identify errors of various nature in the process.
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• Finally, biological replicates, i.e. samples belonging to the same condition, ideally
in high numbers, are essential for the application of statistical methods and thus
the deduction of reliable insights.
While microarrays are by now well established, technically mature and provide major
insights in the field of biomedicine [Mischel et al., 2004,Glinsky et al., 2005], they do ex-
hibit certain downsides. Two major drawbacks exist. First, microarrays do not quantify
the exact amount of mRNA in the cell, but a function of the abundant transcripts which
is dependent on several factors such as binding specificities or saturation. This allows
only for reliable comparisons of a fixed gene between arrays. Second, microarrays can
only measure genes that are known, as their complementary sequence has to be attached
to the array in advance. Thus, unknown genes and sequences can not be represented on
the microarray. In contrast, RNA sequencing does not require prior knowledge of the
sequences interrogated and provides accurate transcript quantification for high coverage.
Affymetrix Exon Arrays. The GeneChip Human Exon 1.0 ST Array developed by
Affymetrix extends the power of gene expression arrays which lack the ability to account
for alternative splicing and the corresponding variety of isoform abundances. Affymetrix
Exon Arrays address this issue by representing genes on their exon rather than on their
gene level [Affymetrix, 2005d].
To achieve this goal, the GeneChip Human Exon 1.0 ST Array differs in several design
aspects from conventional arrays, like the Affymetrix HG U133 plus 2. While gene arrays
(also called 3’ arrays) choose their probe location close to the 3’ site of a gene trying
to avoid bias induced by mRNA decay beginning at the 5’ end, probes on exon arrays
try to cover the whole gene evenly. Each exon is covered by on average four probes
(Figure 2.7) which are later combined to one signal per exon. The higher coverage of
exon arrays requires a much higher number of probes. While, for instance, the HGU 133
Plus 2 chip contains approximately 1.3 million probes, the exon array contains over 5.5
million probes (see Table 2.1) [Affymetrix, 2005d].
Addressing this equal distribution of probes, the target generation protocol for ampli-
fication has to reflect probe locations. In contrast to most 3’ arrays, which use primers
targeting the poly-A tail of mRNAs, the GeneChip Whole Transcript (WT) Sense Target
Labeling Assay [Affymetrix, 2006] applied for the exon array uses randomly attaching
primers. Thus, a bias towards the 3’ end of transcripts is avoided and the technique of
using random primers leads to evenly distributed probes (see Figure 2.7).
Probe types. Apart from confirmed exons, the exon array explicitly also contains
uncertain and predicted exons to cover as many exons as possible. All probes on the
array are divided into three categories according to their reliability [Affymetrix, 2005d]:
1. The first category comprises the core probes. These probes are derived from RefSeq
[Pruitt and Maglott, 2001] transcripts or full-length mRNAs.
2. The extended loci contain all core probes as well as all cDNA based loci. Among
these are ESTs, mRNAs from Genbank which are not annotated as being full-
length, as well as microRNA annotations [Affymetrix, 2005b].
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Figure 2.7: Exon array probe coverage Evenly distributed probes across all exons
enable the detection of the skipped exon in the first transcript.
GeneChip GeneChip
HG U133 Plus 2.0 Human Exon 1.0 ST Array
Probes per gene 11-20 ~40
Probes per array ~1,300,000 ~5,500,000
Probe sets per array 54,000 1,400,000
Background probes per array 650,000 40,000
Table 2.1: Comparison of 3’ arrays and exon arrays based on different attribute
numbers.
3. The category full loci encompasses all probes from the extended loci plus loci
derived from ab-initio gene predictions.
To avoid cross hybridization, sequences of all probes have been compared to each
other. Sequence similarities to untranslated regions are ignored, i.e. not excluded
from the set of probes, to avoid unnecessary rejection of thermodynamically favorable
probes. Affymetrix classifies all probe sets into three categories according to their cross-
hybridization potential [Affymetrix, 2005d]:
• The about 1.25 million unique probe sets contain only probes that have no known
potential for cross-hybridization with probes of other probe sets.
• Approximately 70,000 probe sets are categorized as similar. These sets contain
probes that are candidates for cross-hybridization, but all probes of the respective
probe set interrogate the same genomic region, i.e. the same gene.
• Approximately 200,000 mixed probe sets exhibit inconsistent hybridizations, i.e.,
they might hybridize to different locations in the genome.
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Background Probes. To estimate a reliable background signal, Affymetrix 3’ arrays
contain as many perfect match probes as mismatch probes [Affymetrix, 2005d]. The
mismatch probes differ in one base from the corresponding perfect match probe and
are used to calculate the unspecific binding signal strength. For exon arrays, a much
higher number of probes is required to cover all exons. Accordingly, these arrays do not
contain probe-specific background probes, but only a set of about 40,000 background
probes in total. To account for the effects of GC-richness on hybridization strengths,
background probes are binned according to their GC-content. 26 bins of different GC
contents are defined, each containing approximately 1,000 background probes. For each
bin, a separate null distribution for probes with this GC content is calculated and used
to estimate robust confidence values. Furthermore, these 40,000 background probes
are divided into genomic and antigenomic background probes, and either can be used
to estimate a background signal. Binning differs according to whether a probe is of
genomic or antigenomic origin:
• Genomic background probes match to regions that are not likely to be transcribed.
To produce reasonable background probes mismatches have been introduced. Each
bin of GC content is covered by about 1,000 mismatch probes.
• Antigenomic background probes originate from sequences that are not found in the
human, mouse or rat genome. Therefore, they are not expected to cross-hybridize
with transcribed human DNA. The 26 bins range from a total absence of G and
C nucleotides to a GC content of 100%.
2.2.2 High-Throughput Sequencing
High-throughput sequencing (HTS), a more recent technology in the field of molecular
genetics compared to microarrays, has now been widely used for over a decade and
provides several advantages over microarrays. HTS is not only able to capture sequences
not previously known, as they do not depend on pre-designed probes, but they also have
a much higher dynamic range, than microarrays [Nagalakshmi et al., 2008]. While for
microarrays expression measurement is limited by signal saturation at the high and
background at the low end, RNA sequencing provides discrete read counts. This allows
for a better qualitative and quantitative transcriptome acquisition. The importance of
this fact is highlighted in studies stating that about three quarters of the genome are
probably transcribed [Djebali et al., 2012].
HTS allows for a whole new perspective on the genome. While microarrays provide
solutions for most investigation levels such as chromatin immunoprecipitation or single
nucleotide polymorphisms (SNPs), sequencing based solutions are more accurate and
sometimes even enable quantification of events or entities for the first time. SNP arrays,
for instance, exist, but they can only be used for predefined mutations on fixed positions.
Thus, only a tiny fraction of all possible mutations can be detected. As an array can
never represent the whole genome or transcriptome with all its combinatorial products,
it is the technology of HTS, that allows for the detection of all novel splice isoforms.
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Sequencing also opens insights into the wide field of RNA classes not formerly captured.
These transcribed entities such as small nuclear RNAs (snoRNAs) or long non-coding
RNAs (lncRNAs) have moved into the focus of attention only since HTS made them
accessible [Qureshi and Mehler, 2012].
Several prevailing technologies use the sequencing-by-synthesis approach, such as Il-
lumina. For an exemplary workflow we outline the basic proceedings of HTS in Figure
2.8.
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Figure 2.8: Overview on Illumina sequencing. For library preparation (a) the DNA
is fragmented (A), ends are repaired (B), adapters are ligated (C) and ligated
DNA is selected (D). In a next step, clusters are generated (b): DNA is
attached to a flow cell (E), bridge amplification is performed (F), clusters
are generated (G) and sequencing primers are annealed (H). For sequencing
(c), the first base is extended, read and deblocked (I). This step is repeated
until the strand is fully extended (J) and base calls can be generated (K).
Library Preparation. The initial set of RNA is gathered in a library. RNA is
extracted from the cells of interest and further selected depending on the aim of the
study. If, for instance, mRNA is the target of investigation, an enrichment of poly-A
carrying entities might be performed. miRNAs, on the other hand, can be selected by
size filtering. The resulting set of targets is subsequently fragmented into smaller pieces
and reverse transcribed to cDNA. The resulting double-stranded cDNA fragments are
ligated with adapter sequences on both ends and are thus ready for amplification.
Cluster generation. The small double-stranded, adapter ligated cDNA fragments
resulting from the library preparation are homodimerized and attached to the surface
of a so-called flow cell, a glass slide with eight flow channels. Subsequently, a bridge
amplification is performed. The name refers to the bridge-like structures arising from the
cDNA fragments bound to the glass slide on both ends due to the adapters attached.
These fragments are amplified by synthesization of the complementary strand. The
double stranded structures are denaturized and the cycle repeats. This procedure leads
to many copies of one fragment in close spatial proximity, referred to as local clusters
[Reuter et al., 2015].
Sequencing. Using the agglomerations of identical fragment representatives, se-
quencing by synthesis is performed. Each sequencing cycle takes four steps according
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to the four nucleotides. The nucleotides are labeled by type and can thus be detected
when they are incorporated in the sequence. Therefor, laser-excited light is used which
is captured by a camera after each step. From these images and the corresponding light,
the sequence structure can be reconstructed.
Sequencing is being constantly improved in accuracy and cost, and the initial goal to
reduce prices per genome to 1,000 US Dollars has been practically achieved [Hayden,
2014]. Yet, the technology still suffers from shortcomings, as it is for example difficult
to optimize accuracy, speed and cost at the same time. While for instance Illumina
indicates its average error rate with 1%, other solutions exist, which show a much higher
error rate of 5%-40% with the advantage of a significant speedup [Goodwin et al., 2015].
For transcriptomics, short reads state a severe problem for encountering spliced iso-
forms, especially in concrete isoform inference, as they rarely span multiple splice junc-
tions. However, not only technological problems impose challenges. The probably
biggest challenge is to develop adequate computational analysis routines for the vast
amounts of data produced by HTS. Though several efforts exist [Nekrutenko and Tay-
lor, 2012], for most omics-technologies a standard is not yet established. With the lack
of uniform analysis routines it is difficult, to compare technologies and thus assess their
accuracy.
Data Analysis. Each investigation level and each corresponding technology have
their specific requirements and specificities concerning analysis. In this work we are
focusing on transcriptome sequencing, especially mRNA sequencing. The basic steps
necessary to gain insights from the data produced are the alignment of the reads, ex-
pression quantification, detection of differentially expressed entities, and, optionally,
downstream analyses.
1. Alignment. The alignment of reads, also referred to as read mapping [Li and
Homer, 2010], searches for the matching position of a read in the genome and
associates this position with the read. One of the widest used algorithms is imple-
mented in the Burrows-Wheeler aligner [Li and Durbin, 2009] though many others
exist [Li and Homer, 2010].
2. Expression Quantification. The information gained in the alignment step al-
lows for the quantification of expression for the entities of interest. Therefor, all
reads falling in the region of such an entity are summed up to obtain an absolute
expression level.
3. Differential Expression. With the computed count values, differences in ex-
pression between two or more conditions can be assessed. Depending on the ag-
gregation level of the data, differences in gene expression, transcript expression or
even on single exon expression can be detected.
4. Downstream Analysis. Further analyses such as classification, clustering, en-
richment analysis or network analysis can be applied to identify biological sub-
classes, infer functional associations for groups of entities or determine biomarkers.
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2.3 Data
Although the focus of this work lies on methodological aspects, the ultimate aim of
biomedical data analysis is an information gain to understand biological conditions.
Throughout this work, we will apply the methods to expression data from different
lymphoma samples pursuing the aim of elucidation of aberrant splicing events as well
as their regulation in different lymphoma subtypes.
2.3.1 Lymphoma Subtypes
Lymphoma is a cancer based on lymphatic cells. The lymph system is part of the im-
mune system and comprises different organs such as lymph nodes, spleen, bone marrow,
thymus and tonsils (see Figure 2.9). As of its immune system based origin, lymphoma
cells can be of T-cell or B-cell origin. Two main classes of lymphoma exist. While
Hodgkin lymphoma are usually curable, non-Hodgkin lymphoma form the therapeuti-
cally more demanding class [Shankland et al., 2012]. The set of expression data used
in this study consists solely of non-Hodgkin lymphoma which are subdivided in several
subgroups with different cellular origin.
 

	

	

	
Figure 2.9: Anatomy of the lymph system. The lymph system comprises the lymph
vessels and lymph organs which include lymph nodes, tonsils, thymus, spleen,
and bone marrow.
• Diffuse large B-cell lymphoma (DLBCL). Diagnosis is based on several as-
pects of the disease such as cellular morphology, immunohistochemistry, and gene
expression. While the first two methodologies are beyond the scope of this work,
gene expression studies on DLBCL reveal a distinction between two groups, ger-
minal center B-cell-like (GCB) and activated B-cell-like (ABC). Cases of GCB are
usually associated with a rather positive prognosis, while ABC cases are expected
to have a poor outcome.
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• Mantle cell lymphoma (MCL). MCL is a rather rare B-cell lymphoma with
a characteristic translocation at t(11;14)(q13;q32) leading to an over-expression
of cyclin D1 [Campo et al., 1999], a cell cycle gene contributing to the abnormal
proliferation of the malignant cells.
• Follicular lymphoma (FL). FL, another B-cell lymphoma, is usually character-
ized by a translocation between chromosome 14 and 18 (t(14;18)(q32;q21)). This
alteration results in the over-expression of BCL-2, a gene with anti-apoptotic func-
tion. This mutation drastically reduced susceptibility to apoptosis, a key feature
of malignant cells.
• Anaplastic large-cell lymphoma (ALCL). This T-cell based lymphoma sub-
type also exhibits a typical translocation (t(2;5)(p23;q35)), resulting in the upreg-
ulation of a tyrosine kinase with oncogenic properties.
• Peripheral T-cell lymphoma (PTCL). For this T-cell based lymphoma sub-
type, no prominent translocation is known.
• B-cell chronic lymphocytic leukemia (CLL) Several chromosomal deletions
(del 11q, del 13q, del 17p) as well as a trisomy in chromosome 12 characterize this
B-cell based disease.
2.3.2 Lymphoma Data
In this work, we will use data generated by both technologies described in Section 2.2,
exon arrays as well as RNA sequencing data. The majority of the data is based on exon
arrays, while a subset of the biological samples represented on exon arrays has also been
sequenced.
Lymphoma subtype No. of exon array samples No. of RNA sequencing samples
BL 3 -
CLL 14 -
DLBCL 40 3
ALCL 10 -
PTCL 6 -
MCL 12 -
FL 22 -
Tonsil 9 3
Table 2.2: Sample number per lymphoma subtype based on exon array and RNA
sequencing expression quantification.
In total, 116 exon arrays were used to measure mRNA expression of 116 biological
samples from seven lymphoma subtypes as well as a control group of tonsil samples.
Group sizes vary drastically. While the smallest group, Burkit lymphoma, comprises
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only 3 samples, the largest group, diffuse large B-cell lymphoma consists of 40 samples.
For an overview see Table 2.2.
The subset of biological samples which were also subject to sequencing consists of three
samples for DLBCL as well as three samples from the tonsil control group. As the biolog-
ical source is identical, this procedure provides an interesting possibility for comparison
of both technologies. DLBCL are a very heterogeneous disease, where several subtypes
are known. Thus, research can benefit a lot from a more detailed characterization.
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3 Detection of Differential Splicing
The analysis of differential splicing (DS) is crucial for understanding pathophysiological
processes in cells and organs [Srebrow and Kornblihtt, 2006]. A widely used technique
for studying DS are exon arrays (see Chapter 2.2.1). Over the last decade, a variety
of algorithms detecting DS events from exon arrays has been developed. However, no
comprehensive, comparative evaluation including assessment of the most important data
features has been conducted so far. To this end, we created multiple data sets based on
simulated data to assess strengths and weaknesses of several published methods as well
as a newly developed method, KLAS. Additionally, we evaluated all methods on two
cancer data sets that comprised RT-PCR validated results.
3.1 Aim
The detection of altered expression on the exon level is a challenging task. It is by
far more demanding than gene-based analyses since relative changes in exon expression
levels might be more subtle, which makes it harder to distinguish signal from noise.
Furthermore, changes in the expression of the gene containing the exon have to be
taken into account to avoid false positives as well as false negatives. To accomplish this
task, exon expression is usually normalized to the corresponding gene expression. Figure
3.1 visualizes a situation in which the second exon of tissue A is differentially spliced,
as it is included less in the final transcript than in tissue B. Yet, as gene expression
is higher in tissue A, a comparison based on exon expression only, would lead to the
lowest evidence for DS in the second exon. Thus, normalization of exon expression with
the corresponding gene expression intensity levels gene expression differences between
groups compared and enables the detection of different exon in- or exclusion levels, i.e.
differential splicing.
Besides these general difficulties, various parameters impact the correct prediction of
DS. The expression level, already impairing the detection of differential gene expres-
sion [Draghici et al., 2006], imposes an even higher difficulty in the discovery of exon
expression alterations. The number of exons in a gene is also known to influence per-
formance, specially for statistical methods [Rasche and Herwig, 2010]. Splicing events
might not necessarily occur in all samples of a condition, which could have a different ef-
fect on method performance. Another impacting factor could be the number of samples
in the conditions under examination.
The wealth of existing expression data from exon arrays constitutes an excellent basis
for many scientific questions. This led to a variety of algorithms for differential splic-
ing detection developed over time. Different approaches were taken to solve the task.
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Figure 3.1: Differential exon expression. The second left exon in tissue A is differ-
entially spliced. A comparison on exon level only would lead to the opposite
of the desired result, as the only exon differentially spliced would gain the
lowest evidence for DS since the expression of this exon is the most similar
in tissue A and B.
Most of the methods, such as MIDAS [Affymetrix, 2005a], use a statistical approach.
Other methods combine statistics with the exploitation of the preprocessing results (e.g.
FIRMA [Purdom et al., 2008]). SplicingCompass [Aschoff et al., 2013], a graphical
approach, is based on angles between exon expression vectors, while ARH, relies on
information theory [Rasche and Herwig, 2010]. These large methodological differences
make it impossible to compare methods analytically, which calls for careful empirical
studies to identify the best tool for a given scenario. We thus conducted the - to our
knowledge - most comprehensive comparative assessment of algorithms for DS detection
on exon arrays. We compared and evaluated nine different methods for the detection
of differential splicing from exon arrays. Subsequently, we discerned the performance
for each method over a range of different parameters. Using a comprehensive artificial
dataset, we compared the impact of different expression levels, numbers of exons per
gene, different amounts of differentially spliced samples per condition as well as the in-
fluence of different group sizes. Additionally, we applied all methods to two well studied
and partly RT-PCR validated cancer data sets [Gardina et al., 2006,Langer et al., 2010].
3.2 Methods for Differential Splicing Detection
In the following, all methods evaluated in this work are introduced in detail. We in-
cluded, to our knowledge, all published methods until 2014 for which an implementation
was available: MADS, MIDAS, SI [Affymetrix, 2005a], PAC [Affymetrix, 2005a, French
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et al., 2007], ANOSVA, ARH, SplicingCompass [Aschoff et al., 2013] and FIRMA. Fur-
thermore, we incorporated the novel method KLAS [Jentsch, 2011]. Note that we did
not use FIRMA for evaluation on artificial data, as we used the model proposed by the
authors of [Purdom et al., 2008] on the basis of which FIRMA was developed for the
generation of our data. However, we applied FIRMA to the two experimental data sets.
We had to leave out methods with no implementation available, like Remas [Zheng et al.,
2009].
The notation defined here refers to the methods presented in the subsequent chapters.
Throughout this chapter, the comparison of two conditions h ∈ c, t is assumed, a control
c as well as a treatment group t. The groups shall consist of s = 1 . . . q samples in the
control group and s = 1 . . . r samples in the treatment group. While some methods are
in theory applicable to more than two conditions, we limit ourselves to the application
of two for comparison purposes. The two case scenario is by far the most common
application.
The probes p on the chip measure a certain intensity λ which depends on condition
h, gene g (comprising n exons), exon e, sample s and probe p:
λg,e,p,h,s ∈ R+ (3.1)
A gene denoted by g shall contain e = 1 . . . n exons. The expression of a gene g or
exon e is denoted by Y or ψ respectively which is an aggregate f over the exons for g
or probes of an exon for e. More precisely,
Y = f(λe,h,s) ∈ R+ (3.2)
ψ = f(λp,h,s) ∈ R+ (3.3)
ANOSVA
ANalysis Of Splice VAriation (ANOSVA) [Cline et al., 2005] uses a two way ANOVA to
detect potential alternative splicing events. Hereby, each observation, i.e., each probe
intensity is described in dependence of a factor for exon dependence αe as well as a
factor for the biological condition βh. More precisely, the following linear model is used
to fit the observed data:
log2(λh,e,p,s) = µ+ αe + βh + γe,h + ϵ (3.4)
The intensity value log2(λh,e,p,s) denotes the observed log2 expression intensity of
probe p in exon e of sample s in condition h. The term µ denotes an intercept used
for all probes while ϵ denominates an error term. Alternative splicing is detected by
use of the term γe,h. It describes the interaction effect for all combinations of αe and
βh, i.e. additional signal not captured by the two factors on their own. Thus, non-zero
interaction terms are thought of as evidence for differential exon inclusion.
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ARH
Alternative splicing robust prediction based on entropy (ARH) [Rasche and Herwig,
2010] is, unlike other approaches, not based on correlation or statistical tests, but applies
an information theoretic approach based on Shannon’s entropy. An advantage of this
method is that it overcomes problems like the dependency of a score on the number of
exons or the inherent variability in exon expression intensities. A drawback of ARH is,
that it can be applied only in the case of two different conditions.
First, the exon splicing deviation δg,e between the two conditions is computed by
subtracting the median log2 ratio of the exon expressions from all median log2 ratio
exon expressions of the associated gene.
δg,e = log2
(
ψg,e,t
ψg,e,c
)
−mediane=1,...,n
⎛⎝log2(ψg,e,t
ψg,e,c
)⎞⎠ (3.5)
The absolute value of the splicing deviation is turned into the probability pg,e of exon
e being differentially spliced.
pg,e =
2|δg,e|∑n
e=1 2|δg,e|
(3.6)
Next, an entropy is computed for each gene, indicating whether the splicing probabil-
ities are equally distributed.
Hg(pg,1, . . . , pg,n) = −
n∑
e=1
pg,e · log2(pg,e) (3.7)
The theoretical maximum max(Hg) of the entropy is log2(n). To make the entropy
independent of the number of exons, it is subtracted from the theoretical maximum.
max(Hg)−Hg = log2(n)−Hg(pg,1, . . . , pg,n) (3.8)
Now the final score ARH for gene g can be computed to indicate whether g is alter-
natively spliced.
ARHg =
Q75,g
Q25,g
· (max(Hg)−Hg) (3.9)
The weighting factor Q75Q25 accounts for the strength of deviation within g. Here, Qxx
denotes the interquartile range of expression range of the xxth quartile. By the compu-
tation of a background distribution for ARH values from various datasets, values larger
than 0.03 are considered to be an indication for alternative splicing by the authors.
FIRMA
Finding Isoforms using Robust Multichip Analysis (FIRMA) [Purdom et al., 2008] has
the major advantage that it can also be used in the scenario of no predefined groups
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or if alternative splicing events are not consistent in the given conditions. The basic
idea is to use a fitted linear model for expression estimation and deduce a score for
alternative splicing for each exon from the model parameters. Robust Multichip Analysis
(RMA) is used to determine these parameters. The fitting of the linear model for
expression estimates leads to the possibility to compute the difference between estimated
and measured expression. This difference is taken as basis for the computation of a score
for differential exon expression. By doing so, the problem of alternative splicing detection
essentially is converted to one of outlier detection.
The model fitted by RMA for every gene g contains a chip effect term as for the sth
chip, a probe effect term bp for the pth probe and an error term ϵs,p An estimate for the
background corrected and normalized expression level of a gene is computed as follows:
log2(λp,s) = as + bp + ϵs,p (3.10)
For exon arrays the model can be adjusted by introducing oe - the relative change in
exon expression for exon e - and the interaction δs,e between chip and exon as well as a
new error term ϵs,e,p.
log2(λe,p,h,s) = as + oe + δs,e + p+ ϵs,e,p (3.11)
As the parameter δs,e represents the difference between an exon in sample s and the
expected expression for this exon, the parameter can be seen as a measure of differential
splicing. Instead of fitting an exon level model, the gene level model is fitted with the
exon array data to improve robustness. δs,e is then estimated by using the residuals ls,p,e
of the fitted gene level model.
ls,p,e = ys,p,e − aˆs − bˆp (3.12)
The actual value is computed by averaging over all residuals of an exon. The final
score for alternative splicing is now calculated as:
Fs,e = medianp∈e
(
ls,p,e
σ
)
(3.13)
where σ, an estimate of the standard error, is derived from the median absolute
deviation (MAD) of the residuals. By introducing this parameter the score is made
more comparable between different genes.
KLAS
KLAS, Kullback-Leibler alternative splicing [Jentsch, 2011] uses a similar approach as
ARH, but relies on the Kullback-Leibler divergence in the last step. The Kullback-
Leibler divergence is an indicator for the variety of two probability distributions. For
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each condition h ∈ t, c the deviation λ of the expression of every exon e from its gene g
is computed.
λe,t = ψe,t −Yt (3.14)
λe,c = ψe,c −Yc (3.15)
Subsequently, these deviations are turned into a probability distribution per gene and
condition, such that the contribution of every exon to the expression of the gene can be
denoted by
pg,e =
2δe,h∑n
e=1 2δe,h
(3.16)
This is a major difference to ARH, which assesses one probability distribution for both
conditions based on the deviation from the median exon ratio between conditions. To
account for the deviation within a gene, the interquartile range is computed.
Qt =
quant0.75(δe,t)
quant0.25(δe,t)
(3.17)
Qc =
quant0.75(δe,c)
quant0.25(δe,c)
(3.18)
This step is similar to ARH, yet here it is used to compare two conditions based on
a modified Kullback-Leibler divergence as formulated in Equation 3.19 instead of the
Entropy corrected by its theoretical maximum as for ARH.
KLAS(g) = Qt ·
n∑
e=1
pe,t · log
(
pe,t
pe,c
)
+Qc ·
n∑
e=1
pe,c · log
(
pe,c
pe,t
)
(3.19)
The main difference between KLAS and ARH is thus, the level at which the entropy,
respectively the Kullback-Leibler divergence, (i.e. relative Entropy), is computed. While
entropy is a feature of one probability distribution, the Kullback-Leibler divergence is
an indicator for the variety of two probability distributions. Where ARH is constrained
to case control studies, the approach to establish the probability distribution within the
samples allows extension of the analyses to more than two conditions.
MADS
Microarray analysis of differential splicing (MADS) [Xing et al., 2008] consists of three
steps: background correction, summarization and detection of differential splicing events.
For background correction, a sequence-specific linear model with many parameters is fit
to predict the background intensity for each probe. The predicted background intensity is
then subtracted from the observed signal. Genomic as well as antigenomic background
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probes are used to train the model. The advantage of this background model is a
nucleotide and position specific model for the 25mer probes.
In the second step the probes with the highest correlation over all samples are selected
for each gene by application of hierarchical clustering. The Li-Wong [Li and Wong, 2001]
model is fitted to these probes to compute an estimate of gene expression. Only probes
are kept that show high correlation between the background corrected values and the
corresponding gene signal estimates over all samples. Similar to iterPLIER [Affymetrix,
2005c], this procedure is repeated until the number of probes stabilizes.
To determine differential splicing, first the Splicing Index is calculated for every probe.
SIMADS =
λe,p,h,s
Yh,g
(3.20)
A t-test is applied to determine the significance of the calculated Splicing Indices. The
resulting probe level p-values are transformed.
x = −2log(p− value) (3.21)
They are now following a χ22 distribution under the assumption of no differential splic-
ing. The sum of these transformed p-values follows a χ22k distribution with k indicating
the number of probes. Using this sum, an exon-level p-value is calculated and all exons
are ranked according to it. The final results are filtered for potentially cross hybridizing
probes. For applicability reasons we adopted MADS to work on our synthetic data, i.e.
we did not apply a MADS-specific background correction and modified MADS to work
on the exon level. We will therefore refer to this modified method as MADS’.
Midas
The idea behind Microarray Detection of Alternative Splicing (MIDAS) [Affymetrix,
2005a] is similar to the idea of SI and is followed by a statistical test. Like for other DS
detection methods, it is assumed that if the ratio of the expression level of an exon to
the expression level of the corresponding gene is constant over all samples, no differential
exon expression has occurred. Thus, for all exons, the exon-gene ratio, i.e. a normalized
intensity NI is computed per sample.
NI =
ψe,d
Yd
(3.22)
Their variance is tested for statistical significance using, for instance, ANOVA in case
of multiple group comparisons. In the two condition scenario a t-test is applied.
PAC
The underlying assumption in Pattern based correlation (PAC) is the proportionality
of exon expression to its corresponding gene expression. Deviation from exon to gene
expression results in low correlation and therefore indicates DS [French et al., 2007,
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Affymetrix, 2005a]. To identify such potential splicing candidates, PAC computes an
expected expression level per exon and compares this value to the actually measured
expression of the exon.
The estimated expression of exon e is defined as
estimate(ψg,e,s) = Yg,s · mean(ψg,e,s)
mean(Yg,s=1,...,q+r)
(3.23)
Scaling of the gene expression of gene g in sample s with the ratio of the average
exon expression mean(ψg,e,s) of exon e over all samples 1...q + r to the average of all
gene expressions mean(Yg,s=1,...,q+r) of gene g in all samples 1...q+ r leads to the final
expression estimate estimate(ψg,e,s).
This estimate is compared to the actually measured exon expression ψg,e,s and is
expected to be the same in the case of no alternative splicing. Originally, PAC was
developped as a multi-condition method, where the estimated and measured exon ex-
pression can be correlated. A low correlation is an indication for alternative splicing. In
the two group scenario correlation is not applicable as correlation will either be 1 or -1
except for the case of exact equality. The difference between the two is assessed instead.
estimate(ψg,e,s)− ψg,e,s = 0 (3.24)
Splicing Index
The splicing index [Affymetrix, 2005a, Srinivasan et al., 2005,Clark et al., 2002] can be
regarded as the exon level analog of the gene level fold change. It is a measure for the
difference of exon specific expression between samples. To avoid false positives due to
differing gene expression between conditions, each exon is set into relation to the gene
expression of the gene it originates from.
As a first step, the expression level of each exon e in sample s is normalized to its
corresponding gene expression g computing a normalized intensity NI.
NIe =
ψe,s
Ys
(3.25)
Based on these normalized measures, the Splicing Index SI(e) measures the relative
change between two conditions:
SI(e) =
NIe,t
NIe,c
(3.26)
In the case of sets of samples, i.e. for multiple samples per condition, several proce-
dures are applicable. On the one hand, the ratio of the medians of each condition can be
calculated. In the case of paired samples, one can also compute the SI for all pairs from
the two conditions, and take the median as an indicator of alternative splicing. A more
sophisticated approach tests for differences in group specific SIs by applying a statistical
test. The SI can only be applied in a two-condition scenario.
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Splicing Compass
We adopted Splicing-Compass, originally developed for NGS data [Aschoff et al., 2013],
to also work for exon array data. The idea is to access the significance of difference
between angles spanned by exon vectors in one condition compared to the ones in the
other condition.
Let vg be the gene expression vector for gene g, where every dimension of g stands for
an exon expression value of an exons e contained in g.
vg = (ψ1, . . . ,ψi, . . . ,ψn) ∈ Rn (3.27)
If the isoform ratios of a gene are constant throughout the conditions, i.e. no alter-
native splicing event occurs, the expression values of this gene will be approximately
parallel between conditions. This leads to a small angle between the two, even in the
case of differential isoform expression between conditions.
To test for differences in splicing, all pairwise angles (q+r2 ) are computed as follows.
Fgni ,gnj = arccos
⎛⎜⎜⎜⎝ vgni · · · vgnjvgni · · ·
vgnj

⎞⎟⎟⎟⎠ (3.28)
Subsequently, a one-sided t-test is applied to determine whether splicing angles within
conditions are significantly smaller than splicing angles between conditions. To account
for multiple testing errors, a Benjamini-Hochberg correction is applied.
3.3 Data
Most studies comparing the performance of methods for DS detection are based on
either synthetic or real data sets. Both approaches have their strong points, while they
do not lack certain downsides. Synthetic data allows for a controlled parameter setting,
enabling an easier deduction of reasons for success or failure of methods applied. On
the other hand, simulation models only approach real scenarios and can thus be subject
to discussion. Real data is limited to specific scenarios, as evaluation is laborious and
expensive. Nevertheless, it is ultimately the latter that analysis methods have to work
on. Thus, we decided to include both evaluation strategies in our study.
Synthetic Data
The performance of each method for differential splicing detection is influenced by many
factors. A systematic analysis of the properties inherent to the different methods can
only be achieved by using specifically designed artificial test data. To this end, we
generated a range of synthetic data sets using the model from [Purdom et al., 2008]:
yi,j = log2(Bj + Ii,j × 2pi+cj ) + ϵi,j (3.29)
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where yi,j equals the log2(PM), with PM denoting the perfect match probe, for chip
i and probe j. Bj denotes the additive background modeled as a log-normal variable.
The chip effect ci is normally distributed while the probe affinity pj and the residuals ϵi,j
are modeled as mean-zero normal variables. To control probe expression, the indicator
variable Ii,j is set to 1 in the case of presence and to 0 otherwise. According to the
authors, values for simulation parameters were chosen by estimates of representative
values from real data. We decided to use this model, as it is the most fine-grained we
were aware of.
We applied multiple parameter allocations in many combinations (see Table 3.1) using
the default settings of the model. Specifically, we studied the influence of the number
of exons per gene (enum ∈ {10, 30}), the expression intensity (expr ∈ {high, low}),
the number of samples (snum ∈ {15 : 15, 15 : 5}) per group as well as the percentage
of differentially spliced samples (pcnt ∈ {60, 100}). The combination of these four
parameters with two allocations each led to a total of 16 scenarios yielding a detailed
insight that is important when choosing the adequate method for a given dataset or for
a certain purpose. For modeling of expression intensity, we used the proposed model
parameter values of cmean = 7 in the low and cmean = 10 in the case of high expression
[Purdom et al., 2008].
Parameter short value 1 value 2
samples per group snum 15 vs. 5 15 vs. 15
exons per gene enum 10 30
expression intensity expr high low
percent differentially spliced samples per
group
pcnt 60 % 100 %
Table 3.1: Values used for the different parameters tested. The combination of 4
parameters with two possible values leads to 16 data scenarios.
In each scenario we generated 200 simulated genes. While 100 genes were specific to
the parameter criteria in addition to displaying differential splicing events (true positives
(TP)) the remaining 100 genes, designed as true negatives (TN), show no altered exon
expression. Thus, probably the most challenging of the 16 data sets for a DS detection
method (see also Table 3.1) consisted of (1) one condition containing 15 samples and
a second condition containing only 5, (2) low expression intensity, (3) only 60% of the
samples in a group exhibiting differential splicing and (4) a high number of exons per
gene.
It is undoubtedly more demanding to detect DS in a small group where not all samples
display the event than in a large group under the same condition. Concerning the
scenarios with an imbalance in group size, we therefore switched the DS event containing
group for half of the TP genes. Thus, in settings with one condition containing 15
samples, the other one 5 samples and DS was only simulated in 60% of the samples,
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half of the TP genes show the DS event in the small group and half of them in the large
group.
Experimental Data
In addition to the synthetic data sets, we evaluated all methods including FIRMA on
two well studied cancer data sets. All exon array data used are from published work
and are publicly available as stated in the corresponding articles.
The first data set is provided by Affymetrix [Gardina et al., 2006] and consists of 20
arrays, 10 colon cancer samples as well as their paired control. DS results were partly
validated by RT-PCR. As a positive control (TP) we used all 18 probe set IDs indicated
in the section ‘differentially spliced between tissue types’ and one additional probe set
from the section ‘previously reported splicing events in colon cancer’ (see supplementary
material [Gardina et al., 2006]) that was positively validated. The negative control
(TN) was formed by the 10 probe set IDs in the section ‘alternatively spliced but not
differential between tissue types’ (see supplementary material [Gardina et al., 2006]).
Mapping to our data (we used only core exons and the human genome version 19) led
to 12 TP and 8 TN probe sets corresponding to 10 (TP) and 8 (TN) genes respectively.
We also applied all methods on a lung cancer data set [Langer et al., 2010] consisting
of 36 paired samples, 18 normal and 18 non small cell lung cancer (NSCLC) samples.
The study provides validation data for 3 TN and 19 TP examples of DS.
Preprocessing and normalization of the data sets was performed as proposed in [Rodrigo-
Domingo et al., 2013]. Background correction according to Irizarry [Irizarry et al., 2003b]
was applied followed by quantile normalization. Summarization on exon and transcript
level was done according to [Irizarry et al., 2003a]. To reduce the number of false posi-
tives due to a high number of statistical tests, ’absent’ transcript clusters and probe sets
were removed. Specifically, probe sets being absent in more than half of the samples of
a group as well as transcript clusters with more than half of the probe sets absent were
removed.
Evaluation
For the evaluation we determined, for each scenario, accuracy (ACC) or the area under
the curve (AUC) in cases where the method yielded a continuous score. Furthermore,
we quantified sensitivity and specificity for more fine-grained insights. Note that in the
case of binary classification (DS event / no DS event) accuracy corresponds to the AUC.
Some of the methods produce p-values indicating the certainty of a DS event taking
place, while PAC, KLAS, ARH and SI output a heuristic score. To achieve comparability
and avoid cutoff problems, we also derived a p-value for all score-based methods using
an exact Monte Carlo permutation test [Fay and Shaw, 2010]. Applied to the scores, a
gene wise p-value is computed with a significance level of α = 0.05. Nevertheless, we
quantify performance on the basis of scores as well.
As stated, score based methods exhibit the difficulty of choosing a cutoff at which
a result is believed to be relevant. There are best practices for some methods (SI is
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mostly used with a cutoff of 1.5 [De La Grange et al., 2010] or 2 [Wang et al., 2009a]) or
recommendations for others (ARH = 0.03 [Rasche and Herwig, 2010]) yet no appropriate
value is known for PAC and KLAS. We therefore add a second evaluation for the score-
based methods only based on AUC.
3.4 Results
Firstly, we report on the results for simulated data. The examined parameters (see
section 3.3) were evaluated by p-value for all methods as well as by score for the score
based methods only. Analysis of variance was applied to determine the significance of
parameter influence.
Subsequently, the results on the colon and lung cancer data sets were reported with
a focus on the RT-PCR validated results. As in the case of simulated data, accuracy,
sensitivity and specificity was used to evaluate performance.
3.4.1 Synthetic Data
An overview on the accuracy for all scenarios, i.e. 16 synthetic data sets, is shown in
Figure 3.2 using hierarchical clustering (euclidean distance, complete linkage) of methods
as well as scenarios. The method performing best for each scenario is indicated by an
asterisk, multiple maxima per column are possible. The most striking observation is the
clear superiority of MADS’, which performed equally well independent of data-imposed
challenges. While most of the methods achieved good results in the ‘easy’ cases of
equal group size and consistent splicing events, accuracy droppes quickly when sample
sizes in groups diverged, less samples per condition were spliced, or expression intensity
decreased. MADS’ is closely followed by ARH, SI, SplicingCompass and KLAS, which
showed similar behavior. The third-best cluster of methods consists of ANOSVA and
MIDAS. The two performed well in the easy scenarios of sufficient sample numbers and
100% AS events in one group. As circumstances got more challenging, a rapid decay in
accuracy could be observed.
Results per Method MADS’. This algorithm showed a unique performance not only
concerning efficiency but also in the sensitivity to parameter influences (see Figure 3.3).
The most obvious interference was incurred by expression level. While in the high
expression range almost no FPs were observed, FP rate increased significantly in the
scenarios with low expression. A second observation correlating with the expression
level was the dependence on the number of exons contained in a gene. In low expression
ranges MADS’ performed consistently better in scenarios with a high number of exons
per gene, while in high-expression scenarios it performed better with a low number of
exons per gene.
ARH, SI, SplicingCompass and KLAS. The four methods behaved similarly in
terms of classifying the genes actually spliced differentially (Figure 3.3). All showed a
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Figure 3.2: P-value based accuracy for all scenarios. Asterisks indicate highest values
per scenario, multiple maxima are possible. Column names encode scenarios
in the order expression.exons.percent.samples, thus H.10.100.5 describes the
scenario with high expression, 10 exons per gene, 100 percent spliced samples
in the respective group and 5 versus 15 samples per group. A light color
indicates high, a dark (red) color indicates lower accuracy.
clear performance advantage in the case of high expression and they also shared the out-
liers: in the scenarios with 60% DS events and low sample size, genes containing the DS
event in the small sample group were mostly not classified correctly. All other methods
performed homogeneously bad or well irrespective of the fact that the DS event was not
contained in the majority class. While ARH displayed a rather homogeneous response
for the control genes, SI was strongly impacted by the number of samples per group.
SplicingCompass displayed the lowest number of FPs in this group, as the consideration
of all pairwise angles requires relatively strong effect sizes. Systematic influences observ-
able by Figure 3.3 were exon number and percentage of samples displaying differential
splicing.
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(h) SplicingCompass
Figure 3.3: Classification by method is displayed for all genes simulated. The upper
half of the genes contain differential splicing events while the lower half serves
as a control. Correctly classified genes are indicated in blue while incorrect
predictions are highlighted in yellow. Genes in the first half of the DS set
contain one while the second half contains two differentially spliced exons.
In the scenarios displaying a different sample number per group and less
than 100 percent differentially spliced samples the group containing the DS
event is switched for half of the genes. Column names encode scenarios in
the order expression_exons_samples_percent, thus H_10_5_100 describes
the scenario with high expression, 10 exons per gene, 5 versus 15 samples
per group and 100 percent spliced samples in the respective group.
ANOSVA, MIDAS and PAC. These methods formed the third method-cluster
showing results very similar to each other throughout all scenarios. While ANOSVA and
MIDAS were highly specific, ANOSVA educed not a single FP at the cost of a slightly
lower sensitivity compared to MIDAS (see Figure 3.3 and Figure 3.5). The most obvious
difference between the two was the difficulty of ANOSVA to deal with a high number
of exons. MIDAS, on the other hand, performed independently of this parameter. As
expected from a statistical method, the parameter impacting the performance most was
the percentage of samples displaying the DS event in one group. Both methods failed
to detect the DS event in most of the TP cases. Thus, if avoiding false positives is of
high importance, MIDAS and even more, ANOSVA, are a suitable choice. PAC failed
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to detect most of the positive events and also led to some FPs independently of the
underlying scenarios.
Sensitivity and Specificity Depending on the aim of a potential study it can be impor-
tant to choose a method explicitly focusing on high sensitivity or high specificity. While
the first assures the correct detection of a sample having a certain property, the latter
describes the ability to not detect samples not having this property, i.e. a certain dis-
ease. High sensitivity is required in all areas of diagnostics; when it comes to biomarker
detection, a high specificity might be of higher interest. As biomarkers are usually used
for screening of large populations for preventive reasons, a high number of false positives
could lead to an increased workload of testing or unnecessary treatment [Hartwell et al.,
2006].
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Figure 3.4: Sensitivity and Specificity for all methods applied on artificial data and
averaged over scenarios.
Sensitivity and specificity for all scenarios are displayed in Figure 3.4 and Figure 3.5.
High specificity values for ANOSVA, PAC and MIDAS came at the cost of sensitivity.
While SI and KLAS presented very similar values - with KLAS showing a slightly better
result - ARH was more focused on specificity.
SplicingCompass shows very high specificity yet lower sensitivity. Figure 3.5 gives a
scenario-wide overview on specificity and sensitivity. Sensitivity was clearly dominated
by MADS’, followed by KLAS, exposing its strength in this category in comparison to
its cluster mates.
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(b) Specificity
Figure 3.5: Sensitivity and Specificity for all scenarios (p-value based evaluation).
Asterisks indicate the highest value(s) per scenario. Column names encode
scenarios in the order expression.exons.percent.samples, thus H.10.100.5 de-
scribes the scenario with high expression, 10 exons per gene, 100 percent
spliced samples in the respective group and 5 versus 15 samples per group.
Significance of Parameter Influence To access parameter influence in a systematic
way, we fitted a linear model to the computed accuracy with a subsequent analysis of
variance. The computed p-values indicate whether single parameters or combinations of
two parameters have a significant influence on accuracy. Results are shown in Table 3.2
and Figure 3.6.
The greatest influence on the performance of all methods was the percentage of samples
displaying a differential splicing event in one group. DS events contained in 100 % of the
samples in one of two conditions led to consistently better results than in the 60% case.
The highest impact was observed in MIDAS, KLAS, SplicingCompass and ANOSVA,
all of them except for KLAS statistical approaches taking variance across samples into
account.
A huge influence on performance was also notable for expression intensity. All meth-
ods except PAC showed a significant dependency on this parameter. The higher the
expression, the easier was the distinction of DS events from background. Methods vir-
tually not impacted by number of samples per group were MADS’ and PAC. On the
other hand, ANOSVA, KLAS, ARH, SI and MIDAS were significantly influenced by this
parameter.
The number of exons per gene showed no impact on the performance of most of
the methods. Two exceptions were ANOSVA and SplicingCompass, being consistently
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Figure 3.6: Heatmap of ANOVA-based p-values. Asterisks indicate significant val-
ues (∗ ∗ ∗ < 0.001, ∗∗ < 0.01, ∗ < 0.1), red represents low, blue repre-
sents high p-values. Analysis of variance reveals the influence of the pa-
rameters as well as the influence of parameter combinations on the perfor-
mance (i.e. accuracy). enum=number of exons, snum=number of sam-
ples, pcnt=percentage of differentially spliced samples in one condition,
expr=expression intensity
superior in the case of lower exon numbers per gene across expression intensity variation.
MADS’ on the other hand showed a contrasting behavior in the high expression intensity
(EI) (better results for low exon numbers) compared to low EI (better results for high
exon numbers).
Influence of parameter combinations. Two out of the six combinations, i.e., enum :
snum , and expr : snum showed no impact on the performance of the methods (see
Figure 3.6). The joint effect of pcnt with expr and enum showed a slight influence
on some methods, but only the one on KLAS was significant (Figure 3.6). A higher
impact could be observed in the combination of pcnt and snum, which significantly
influenced ANOSVA, KLAS and MIDAS and had a notable effect on ARH and SI as
well. The collective impact of expr and enum had a significant influence on MADS’,
43
3 Detection of Differential Splicing
ARH SI KLA MAD MID ANO PAC SCO
snum + + + - + + - -
enum - - - - - + - +
expr + + + + + + - +
pcnt + + + + + + - +
Table 3.2: Analysis of variance reveals the significant influence of parameters
on accuracy. ’+’ indicates a significant influence of the parameter on accu-
racy, ’-’ means no significant influence.
PAC and ANOSVA while no effect was observed for KLAS, ARH, SI, SplicingCompass
and MIDAS (p− value > 0.05).
3.4.2 Score Based Evaluation
Besides the p-value based approach we were interested in comparing the ranking ability
without having to decide on a cutoff. Thus, for each method we used the scores for
computing the AUC. This led to a good performance of most of the methods (see Figure
3.7 left), emphasizing only marginal differences. SI and ARH showed a slight superiority
in performance to KLAS, and were thus - for this scenarios - favorable over the latter
when relied on scores only.
Dissecting the score based results by parameter (see Figure 3.7 right) revealed a de-
pendency on the expression level for KLAS and SI as well as a significant impact of
the combination of exon number and sample number on PAC. For high expression, most
score based methods performed rather good, independently of the percentage of differen-
tially spliced genes per group, the number of samples per group or the number of exons
per gene. When it came to a lower expression level, performance in the ’harder’ sce-
nario decreased. This phenomenon was most obvious for the percentage of differentially
spliced genes per group.
3.4.3 Experimental Data
We applied all nine methods - including FIRMA - to two partly RT-PCR validated data
sets, one consisting of colon cancer and the other of lung cancer samples. First, we
investigated the overall predictions of every method to assess the number of prognosti-
cated differential DS events. Second, we compared the predictions based on TPs and
TNs confirmed by RT-PCR. The p-value cutoff is set to 0.05.
Colon Cancer ARH, KLAS and ANOSVA produced approximately the same gene
number (about 2000) while slightly differing in the gene set. SI and FIRMA proposed
about 1000 differentially spliced genes while PAC, MIDAS and Splicing Compass showed
the most conservative result (less than 500 genes). MADS’ predicted the highest number
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Figure 3.7: Score based AUC for all scenarios (left)). Asterisks indicate the high-
est values per scenario. Column names encode scenarios in the order expres-
sion.exons.percent.samples, thus H.10.100.5 describes the scenario with high
expression, 10 exons per gene, 100 percent spliced samples in the respec-
tive group and 5 versus 15 samples per group. Heatmap of ANOVA-
based p-values (right). Asterisks indicate significant values (∗ ∗ ∗ < 0.001,
∗∗ < 0.01, ∗ < 0.1). Analysis of variance reveals the influence of the param-
eters as well as the influence of parameter combinations on the performance.
(enum=number of exons, snum=number of samples, pcnt=percentage of dif-
ferentially spliced samples in one condition, expr=expression intensity)
of DS events (> 13000) (Figure 3.9) and thus clearly overrates DS in our adaption of
the method.
Thus, MADS’ was an outlier in the number of predicted DS events, claiming the sought
event in over 70% of the genes. When considering only the validated results ARH and
FIRMA appeared as the most accurate methods (see Figure 3.11) closely followed by
MIDAS. KLAS and ANOSVA displayed relatively good results whereas the remaining
three methods showed either a high sensitivity at the cost of specificity (MADS’) or a
high specificity with a sacrifice of sensitivity (SplicingCompass, PAC), see Figure 3.8.
Lung Cancer ARH, KLAS, FIRMA, and ANOSVA predicted about 3000 DS events
with considerable overlap in the gene set. SI nominated about 2000, MIDAS and Splicing
Compass 1000 and PAC showed the most conservative result with less than 200 genes.
Again, MADS’ predicted the highest number of DS events (> 10000) (Figure 3.9). As
the data set provided such a high verification rate, number of TN examples was very
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Figure 3.8: Sensitivity and specificity for RT-PCR validated DS events in the
colon cancer data set (left) and the number of RT-PCR validated DS
events for every method (right).
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Figure 3.9: Number of genes being predicted as differentially spliced per
method for the colon cancer data set (left) and the lung cancer data set
(right).
low (we used non-verified events as TN). Under such circumstances accuracy is not a
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good measure for performance, and we thus focused on sensitivity and specificity instead
(Figure 3.10).
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Figure 3.10: Sensitivity and specificity for RT-PCR validated DS events in the
lung cancer data set (left) and the number of RT-PCR validated DS
events for every method (right).
SplicingCompass, ANOSVA, KLAS, FIRMA, and ARH were the methods performing
best. According to accuracy, FIRMA, KLAS and ARH achieved the highest values
when disregarding MADS’ due to its high prediction rate. Similarly, sensitivity was also
dominated by FIRMA, KLAS and ARH while considering only methods with non-zero
specificity values. When focusing on specificity, SplicingCompass was the clear winner
followed by ANOSVA, KLAS, ARH and SI, all ranging on the second place.
3.5 Discussion
Though a variety of methods for the detection of DS based on exon array data has been
developed over time, no broad evaluation concerning their advantages and drawbacks
in regard to (combined) influences of properties such as the number of samples, expres-
sion intensity or exon number has been performed yet. In this work we evaluated the
impact of an extensive set of parameter combinations on the performance of eight meth-
ods. Additionally, we assessed all methods and a ninth one with respect to validated
experimental data. In contrast to related work which focused on the comparison based
on experimental data [Rasche and Herwig, 2010] and thus on fixed scenarios, we also
exploited simulated data sets to study the (combined) influence of various properties of
differentially spliced genes and their measurements in exon arrays.
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Figure 3.11: Accuracy computed on the RT-PCR validated results for the colon cancer
data set.
A rank comparison of accuracy-based results is shown in Table 3.3, putting results on
synthetic and on real data sets side-by-side together with the ranking reported in [Rasche
and Herwig, 2010]. Here, we present the outcome of synthetic, colon cancer and lung
data. Concerning the accuracy based results, some methods ranked consistently low
(ANOSVA, SI, SplicingCompass and PAC), others consistently high (ARH, FIRMA and
KLAS) while MIDAS included a positive outlier. Note that we did not include MADS’
in this rank comparison, as results on experimental data suggest an overrating of DS
events.
Nevertheless, results on experimental data should be handled with care due to the
unbalanced nature and small size of the evaluation data in these data sets. Recall that
accuracy is highly susceptible to a diverging number of positive and negative examples.
Especially in the case of MADS’, which predicted a high number of differentially spliced
genes, combined with an disproportionate high number of positive examples in the lung
cancer data set this is an issue.
3.5.1 Algorithmic Performance
Clearly, the performance of different algorithms was influenced differently by the various
parameters and the different data properties, such as effect size and variance. To shed
more light into the cause of these differences, we here sought to explain differences in
the method’s performance in terms of their underlying mathematical formulation of the
problem.
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Accuracy AUC
Synthetic Colon Lung Median Rasche
ANOSVA 6 4 4 4 4
ARH 1 1 3 1 1
FIRMA n.a. 1 1 1 5
KLAS 2 3 3 3 n.a.
MIDAS 5 2 6 5 6
Splicing Index 3 7 7 7 2
SplicingCompass 4 6 5 5 n.a.
PAC 7 5 8 7 3
Table 3.3: Result summary and comparison. Per dataset D and method M we show
the rank that M achieves on D, when all methods are sorted by accuracy, i.e.,
the number of truly recognized splicing events. For comparison, we also add
ranks from Rasche et al. [Rasche and Herwig, 2010], which used a different
data set and ranked by AUC.
Exon Number and Differentially Spliced Exons per Gene Two methods - ANOSVA
and SplicingCompass - were significantly affected by the number of exons per gene, i.e.
they display a better performance in the low exon number scenario. This is remarkable,
as a major concern of most other algorithms is a rising number of FPs with increasing
exon number due to parallel tests. In the case of ANOSVA, the reason is that, the higher
the number of exons, the more improbable it becomes to obtain significant predictions for
TPs as the number of differentially spliced exons remains constant. This is underpinned
by the observation that predictions were better in the second half (genes 50 to 100) of
TPs, where two instead of one exon is modeled as differentially spliced. The same reason
applies to SplicingCompass, a statistics-based method, which accesses the difference
between exon angles within and between groups. The higher the number of exons -
while the number of DS events is constant - the lower is the ratio of angles representing
a DS event. This impedes the detection of differences between groups.
Interestingly, MIDAS, also a statistical method, was not affected by these parameters.
Unlike SplicingCompass and ANOSVA, MIDAS directly takes into account the gene
expression normalized exon expression, i.e. effect size, and applies a separate test for
every exon. The number of exons per gene is thus not as important. In contrast,
SplicingCompass and ANOSVA operate on a gene-based level.
Sample Number and Variance For any method based on statistical tests, one expects
that a higher number of samples improves performance as it increases test power. As
expected, this behavior was observed for ANOSVA and MIDAS, both inherently statis-
tical methods. However, the same (positive) effect also could be observed for SI, ARH
and KLAS, which do not perform tests. The explanation is that all these three methods
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use permutation tests, which become more stable with increasing numbers of samples.
The effect was the strongest for SI with those genes which were not differentially spliced
(see Figure 3.3).
Expression Level and Effect Size All methods were significantly affected by the ex-
pression level: The lower, the worse were the results. This is to be expected, as low
expressions means a less clear separation between signal and noise. As expression de-
creases, also the variance decreases, which in turn makes it more probable to confuse
spurious ‘effects’ as splicing events.
MADS’, for instance, showed this behavior for the non differentially spliced genes, by
producing a high number of FPs in the low expression scenarios which is not visible
for similar methods, like for instance MIDAS. While MIDAS computes an exon level SI
and subsequently applies statistical testing, MADS’ produces a gene wise aggregate as
final p-value. The approach of MADS’ is thus more sensitive and yields performance
improvements but can, on the other hand, also be too sensitive for other scenarios (e.g.,
see Figure 3.3).
The rather simple splicing index performed well in most of the scenarios, although
this method does not consider variance and does not perform any kind of deviation
correction. However, this is due to the structure of the generated data, while various
influences alter the challenges imposed by the data, the one affecting SI most - a small
number of rather drastic outliers - was not contained in the scenarios. Thus the focus
on effect size led to remarkable results.
Percent of Spliced Samples The greatest impact due to this parameter is observed
for statistical methods, i.e. ANOSVA, MIDAS and SplicingCompass. As they are by
design susceptible to variance, fluctuations like in the case of decreased sample ratio
with DS events per group (i.e. a lower percentage of differentially spliced samples)
lowers performance as increased variance prevents effects from being significant.
Effect Size, Variance and Gene Level Correction As already mentioned in the pre-
vious paragraph, statistical methods in general are rather conservative in predicting DS
events. One root of this behavior is their test-basis, but other effects come on top. MI-
DAS uses gene-normalized expression values instead of exon expression values and thus
requires a fairly great effect as the normalization is rather drastic. ANOSVA applies
an ANOVA on a so-called interaction term derived from a fitted linear model which
further smooths away differences. Other methods are less strict in these regards. For
instance, ARH uses the median exon ratio between groups for correcting for the under-
lying gene expression. Compared to MIDAS, which directly uses exon to gene ratio, the
approach of ARH often results in a less pronounced correction which better preserves
effect strength. Splicing Compass accesses the difference between exon angles within
and between groups. It does not perform any explicit gene level correction, but implic-
itly all pairwise angels are considered, resulting in an indirect and rather weak form of
normalization. Again, this helps this method to increase its sensitivity.
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The ambivalence of MADS’. Combining the results of simulated and experimental
data completes the picture of MADS’. While leading performance for simulated data,
MADS’ seemed to overrate DS events in the experimental settings. The excellent perfor-
mance in the artificial scenario reflects the strong sensitivity of the method: relatively
’hard’ scenarios are still positively identified, settings in which other methods clearly
voted against an DS event. According to our experiments MADS’ can not be recom-
mended for the pure prediction of DS events, but we consider it highly suitable for
ranking DS candidates because genes with a very low MADS’ p-value very likely show
differential splicing.
Which Method for which Data? Depending on the research question and the exper-
imental data, different methods pose an appropriate choice. As practically all methods
showed a significant dependency on the expression level and the amount of differentially
spliced samples per class the two parameters are of no help for method selection. If sam-
ple number is low and / or imbalanced, SplicingCompass is the most reasonable choice
according to our evaluation. Independence on the number of exons is best achieved
by ARH, while KLAS, SI and MIDAS pose similarly good choices. High specificity
throughout the data sets was provided by ARH, SplicingCompass and MIDAS. When
it comes to the most sensitive methods FIRMA, ARH and KLAS fulfill the task best.
As validation of results is expensive and time-intensive most studies are interested in
high sensitivity and specificity as well as in robustness of the method. According to our
evaluation, ARH meets these requirements best.
3.5.2 Comparison to Related Work
A comparison of MIDAS, FIRMA, SPLICE [Hu et al., 2001], ARH, PAC, SI, ANOSVA,
MADS, and correlation [Shah and Pallas, 2009] has been performed previously [Rasche
and Herwig, 2010]. However, the evaluation of Rasche et al. used only a single scenario
by benchmarking on different tissue data, while our main interest lies in the susceptibil-
ity of the methods to different data properties. Furthermore, [Rasche and Herwig, 2010]
focused on ranking performance and evaluated based on AUC instead of accuracy, sensi-
tivity and specificity. Using AUC avoids the problem of choosing a cutoff, but precisely
the proper selection of a cutoff decides on the usefulness of a method in reality. Due to
such differences, a comparison of our results with those from [Rasche and Herwig, 2010]
should be interpreted carefully as the two measures quantify a different matter.
The most striking difference is the good performance of PAC. PAC strongly depends
on the gene estimate and the exon estimate used. Furthermore, we compute p-values
from PAC scores, which were much more susceptible to noise than for example the SI
and therefore had difficulties leading to significant results. Further comparative work
was done by Laajala et al. [Laajala et al., 2009]. Though focusing on preprocessing,
they implicitly compared FIRMA, SI and MIDAS, indicating that MIDAS develops its
strength with growing number of differentially spliced exons.
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3.6 Conclusion
Over time a variety of methods for the detection of DS has been published, each of them
with different characteristics regarding sensitivity, specificity, interference to certain data
settings and robustness over multiple data sets. In this work, we discerned the various
methodological aspects for the first time. Using synthetic data complemented by vali-
dated experimental data enabled us to obtain a thorough overview on the performance
of the individual methods, including advantages and drawbacks, which is essential for
avoiding a misinterpretation of the respective outcomes.
While some methods, such as ARH, perform consistently well over all data sets and
scenarios, other methods show heterogeneous prediction quality on the different data
sets. The adequate method has to be chosen carefully and with a defined study aim in
mind to prevent, for instance, a high amount of FPs when validation is laborious.
To avoid an unfeasible flood of data scenarios we restricted our simulations to cases,
where one and two exons are differentially spliced per gene. Naturally, this does not
represent the spectrum of actually occurring DS events. Thus, an important question to
address in future work is the susceptibility of the methods to the number of differentially
spliced exons per gene. Further insights into the robustness of a method can be obtained
by varying the noise level during data generation.
Nevertheless, we provided a systematic and elaborate overwiev on a variety of prop-
erties for DS detection methods, enabling researchers a targeted selection to address the
fundamental topic of differential splicing.
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Splicing is a crucial mechanism for establishing eukaryotic protein diversity which is
regulated by splicing factors (see Section 2.1.4). Malfunctioning of these regulatory
proteins may yield aberrant protein isoforms involved in the onset of various diseases
such as cancer. While transcriptomic data enable the identification of differentially
spliced exons (see Chapter 3), the cause of aberrant isoforms often remains unclear, as
transcriptional changes in splicing factors are usually minor and thus difficult to detect.
In some cases there are no changes at the transcriptional level at all, as modifications,
such as phosphorylation, might interfere with the efficiency of a splicing factor.
Here, we aim at identifying splicing factors most probably responsible for changes
in splicing observed between a lymphoma subtype and a control group. To this end,
we developed a network-based approach, ranking known splicing factors according to
the evidence of them causing the observed DS events. We apply our approach to exon
expression data derived from 113 patients in six lymphoma subtypes and a non-malignant
control group (see Section 2.3.2).
4.1 Introduction
Splicing is a complex and still not completely understood process involving various
players in numerous combinatorial settings [Cáceres and Kornblihtt, 2002]. A detailed
description of the regulation of alternative splicing is given in Chapter 2.1.4. Two fun-
damental types of components involved in this process are cis- and trans-acting factors.
Cis-acting factors, also referred to as splicing regulatory elements (SRE) are part of the
genetic code, and located in promoter regions, exons or introns.
SREs interact with trans-acting factors, also known as splicing regulatory proteins
or splicing factors (SFs). Published estimations on the number of SFs in human vary,
depending on the exact definition, between 70 and 250 [Korneta et al., 2012, Wang
and Burge, 2008, Giulietti et al., 2012, Agafonov et al., 2011]. They recognize certain
cis-acting elements due to their binding site and regulate and control splicing [Zhou
et al., 2002] through intercommunication and a subtle and elaborate equilibrium of their
abundances [Dredge et al., 2005,Gunderson et al., 1997]. Perturbations in this fragile
system may lead to a cascade of changes some of which are causal for various diseases.
Amongst the known malfunctions, up to 30 % are involved in the onset of cancer [Xi
et al., 2008,Ghigna et al., 2008]. Elucidation of (1) the precise aberrant splicing events
as well as (2) the regulatory malfunctioning causal for the change in exon inclusion in a
given sample is therefore crucial for understanding effects and origin of cancer.
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The underlying causes for these perturbations can be manyfold. Besides changes in
expression, other effects such as auto-regulation of SFs [Dredge et al., 2005,Gunderson
et al., 1997], epigenetic modifications [Dardenne et al., 2012, Luco et al., 2011,Watson
et al., 2013,Zhou et al., 2012] as well as post-translational modification mechanisms such
as phosphorylation [Wang et al., 1999,Liu et al., 2013,Stamm, 2008] and ubiquitination
[Moulton et al., 2014, Bellare et al., 2006] contribute to the regulation of alternative
splicing.
Detecting alterations on all these levels is a time-intensive and financially demanding
task. Here, we seek to identify SFs involved in the observed splicing differences between
two conditions irrespective of the causal mechanism. Our main idea is to indirectly
analyze such effects using only transcriptome data. This is done by associating observed
splicing changes on the transcriptome level with all known SFs as potential candidates
responsible for the changes observed. To this end, we construct a network for each of the
two conditions, both containing all exons differentially spliced between the conditions as
well as all potentially causal genes, i.e. splicing factors. Thus, both networks initially
contain the same nodes. Edges are labeled with condition-specific expression correlation
and removed when under a certain cutoff to assure high confidence. SFs in these two
networks are then ranked according to their centrality and SFs differeing most between
the networks are candidate SFs for implications in condition-specific splicing [Lichtblau
et al., 2016].
By combining the potentially causal candidates, i.e. SFs, with the known changes,
the differentially spliced exons, we expect to detect not only differentially expressed
SFs - whose identification can be considered a proof-of-concept - but also genes with-
out changes in expression, yet with large network effects, that might help to link alter-
ations on other genomic or biological levels, such as SNPs, phosphorylation or epigenetic
changes, enabling a targeted investigation.
Network approaches have already been widely and successfully used in the biomedical
application field [Aittokallio and Schwikowski, 2006] including splicing regulatory factors
and the exons they control. Dai et al. [Dai et al., 2011] investigated splicing modules, i.e.
exons being controlled by the same splicing factor. Chen et al. [Chen and Zheng, 2009]
seeked to reveal associations between exons and their regulators and targets. A global
approach is pursued by Qu et al. [Qu et al., 2010] predicting genome wide splicing
regulatory networks (SRN) from public gene and exon array data. While Qu et al.
reconstruct a healthy, genome-wide SRN we aim at specifically identifying the SFs related
to splicing changes in lymphoma by using a healthy and a disease network.
We apply our approach to an extensive lymphoma data set comprising 113 samples,
where expression is measured using exon arrays. For more details on the data set see
Chapter 2.3. The samples originate from six different lymphoma subtypes as well as a
tonsil control group. We therefore study DS in six lymphoma subtypes by comparing
each of them to a non-malignant control group (see Table 4.1). For each of these com-
parisons, we construct two networks, one control (tonsil) and one disease (lymphoma
subtype) network. The application of our method leads to candidate SFs which we
extensively discuss and classify according to current knowledge.
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4.2 Methods
In the following we describe the aquisition of all network components as well as the
network analyses performed on the data.
4.2.1 Differential Expression Analysis
We analysed transcription data for 6 lymphoma subtypes and one control group (tonsils)
measured with Affymetrix Exon Arrays (GeneChip Human Exon ST Array). For the
number of samples contained in each subgroup as well as an introduction on the data
see Table 4.1 and Chapter 2.3. Preprocessing of the data was accomplished according
to [Rodrigo-Domingo et al., 2013]. Differential expression as well as differential splicing
was determined as follows. Gene level analysis for all lymphoma subclasses compared
to control (tonsil) was scored using limma [Smyth, 2005], whereby a fold change (FC)
of 2 and a multiple testing (Benjamini Hochberg) corrected p-value [Benjamini and
Hochberg, 1995] of 0.05 were used as cutoff. Based on our evaluation in Chapter 3,
we decided to use the intersection of three methods, FIRMA [Purdom et al., 2008],
ARH [Rasche and Herwig, 2010] and KLAS [Jentsch, 2011] to filter out less certain
events.
The Splicing Factors we used for network construction are derived from SpliceAid-
F [Giulietti et al., 2012], a public, hand-curated database for human splicing factors and
their RNA binding sites. From the 71 SFs contained in the database, we could map 54
to our expression data. A full list is given in Appendix 6.1, Table 6.13.
4.2.2 Network-based Analysis
For every lymphoma subtype we constructed two networks, a control (Tonsil) and a
disease network, both containing all splicing factors and all differentially spliced exons
with respect to the considered subtype-control comparison (see Figure 4.1). Edge weights
were determined by using Pearson correlation of all pairs. Thus, before applying a
correlation cutoff for edges, the only difference between the two networks per lymphoma
is the edge weights determined by the expression correlation.
In both networks, we ranked all splicing factors according to their betweenness cen-
trality (BC) [Freeman, 1977] in the respective network. To determine which of them
display the greatest changes in centrality, i.e. play a different role in the two networks,
we compared the corresponding BC values to each other.
In this work, we are interested in a rather rank-independent difference as slight changes
in the behavior of splicing factors can have a great impact on the splicing machinery.
Neither absolute nor relative changes in centralities are taken into account quantitatively
when assessed on rank difference solely. Thus, this is the least favorable option for the
task. Relying on absolute changes on the other hand does not take into account the
initial BC-rank of the entities. A top ranked candidate can have the same absolute
difference as the last ranked candidate while their relation to each other is not displayed
in this measure. Thus, we use the relative change of each entity, i.e. the difference
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Figure 4.1: Splicing factor network construction. Schematic overview on the net-
work construction and splicing factor ranking. For each comparison of lym-
phoma subtype versus control two networks are constructed both containing
all SFs obtained from a public database and all differentially spliced ex-
ons between the two conditions. For each pair of network components (SF,
exon) expression correlations are computed and used as edge weights. Sub-
sequently, betweenness centrality for all SFs in both networks is computed.
The difference in centrality between the networks is used for ranking of the
SFs. The more different their centrality, the more likely we deem their in-
volvement in aberrant splicing for the respective lymphoma subtype.
between logarithmic BC values. An entity doubling its centrality relative to the other
network is now ranked equally independently of their rank in the networks.
Correlation networks change depending on the correlation cutoff used for their con-
struction. To filter for the most stable results, we applied our method using eight
different correlation cutoffs equally distributed between 0 and 1 (absolute values). For
all cutoffs used, we determined the top ten differentially central SFs. We considered
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those SFs as candidates per lymphoma that occurred in the top ten in at least half of
the network comparisons.
4.3 Results
In the following section, we present the results for the application of our method. More
precisely, we report the differential expression as well as the differential splicing identified
for all subtype-control comparisons. Subsequently, we go into SF showing differential
centrality (DC) and their expression behaviour. We discern functional implications of
differentially altered entities, explore potential drivers behind candidate-SFs and inves-
tigate the possible role of SNPs for interesting SFs.
4.3.1 Expression Changes
The numbers of differentially expressed SFs and differentially spliced exons for each
subtype are shown in Table 4.1. Whereas each subtype displays an impressive number
of DS events, only very few splicing factors show differential expression. This obser-
vation supports the assumption that changes in SF expression are either too small to
be detected by commonly used cutoffs or that alterations not based on expression level
such as epigenetic modifications, mutations or post-translational modifications are in-
volved [Luco et al., 2011,Brown et al., 2012,Zhou et al., 2012,Naro and Sette, 2013,Liu
et al., 2013,Zhong et al., 2009,Xi et al., 2008]. Note that our network centrality based
method captures these influences indirectly.
Samples Differential Expression Enrichment
DE SFs DE SFs fisher test
subtype number (pval & FC) (pval) differentially spliced exons pvalue
CLL 14 2 15 1395 0.43
DLBCL 40 1 14 1152 0.006
ALCL 10 1 7 801 0.0002
PTCL 6 1 3 337 0.05
MCL 12 0 2 496 0.35
FL 22 1 2 879 0.30
Tonsil 9 - - - -
Table 4.1: Sample and result overview. Samples displays the number of samples
for each lymphoma subtype as well as the tonsil control group. Differential
Expression lists the number of differentially expressed SFs (compared to the
control group), with and without fold chance cutoff, as well as differentially
expressed exons per condition. Enrichment Fisher Test based p-value for
enrichment of differentially expressed SF in top differentially central SFs.
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4.3.2 Differentially Expressed SF Tend to be Differentially Central
Based on the idea that SFs with an altered expression between two conditions contribute
to the splicing changes observed, we expect differentially expressed SFs to rank highly in
the list of SFs ordered by differential centrality (but not necessarily vice versa). As only a
small number of SFs meet the criteria of differential expression (FC > 2, p-value < 0.05),
we also include SFs that do not meet the full criteria concerning FC, but display only
p-values according to our restrictions (Table 4.1). For ALCL, p-value based differentially
expressed SFs are shown in Figure 4.2.
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Figure 4.2: Differentially expressed SFs in the comparison ALCL vs. Tonsil.
Hierarchical clustering of gene expression values corresponding to SFs with
a significant p-value for the comparison of ALCL and Tonsil. Except for one
outlier, ALCL_ex_089, a clear separation of the two conditions is visible.
Three out of six lymphoma subtypes showed a very low number of differentially ex-
pressed SFs, even when applying only the p-value as cutoff. Thus, we do not consider
peripheral T-cell lymphoma (PTCL), mantle cell lymphoma (MCL) and follicular lym-
phoma (FL) as a good model to perform this type of validation. ALCL, chronic lympho-
cytic leukaemia (CLL) and diffuse large B-cell lymphoma (DLBCL) show seven to fifteen
DE events and are thus better suited for this purpose. We conducted a fisher exact test
to assess the significance of the top positioning of our candidates. Two out of these three
conditions, ALCL (p = 0.0002) and DLBCL (p = 0.006), result in a highly significant
enrichment of differentially expressed SFs amongst the top ranked differentially central
SFs. CLL, the third condition shows no significant enrichment (p = 0.43).
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4.3.3 Role and Function of Differentially Expressed SFs
SFs differentially expressed between conditions have high evidence of being causal for
splicing changes observed. Thus, their functional characterization is of great interest
for the elucidation of the underlying pathological mechanism. Remarkably, two splicing
factors showed differential expression throughout most subtypes. These two, ESRP1 and
ESRP2, are epithelial splicing regulatory proteins known to play a crucial role in splicing
changes involved in epithelial-mesenchymal transition (EMT) [Warzecha et al., 2009a].
Several publications on the identification of potentially regulated splicing candidates
exist [Dittmar et al., 2012,Warzecha et al., 2009b]. Amongst them is CD44 [Warzecha
et al., 2009b], a protein well known in the context of splicing in lymphoma [Wallach-
Dayan et al., 2001, Salles et al., 1993, Stauder et al., 1995, Yae et al., 2012]. Other
well characterized targets are ENAH and CTNND1 [Warzecha et al., 2009b]. All three
targets showed differential splicing in most of the conditions in our data as well.
Another SF showing differential expression (DE) in several conditions (ALCL, CLL,
DLBCL) is NOVA1, a neural-specific RNA binding protein associated with paraneo-
plastic disorders [Buckanovich et al., 1996], and hepatocellular carcinoma [Zhang et al.,
2014]. Interestingly, a role in some lymphoma cell lines is also reported [Relógio et al.,
2005].
4.3.4 Differentially Spliced Genes and their Functional Implications
A remarkable number of commonly differentially spliced exons, especially in CLL, DL-
BCL and FL, can be observed in different lymphoma subtypes (see Figure 4.3).
Furthermore, a high amount of group specific splicing is detected for ALCL, DLBCL
and CLL. For few subtypes, some SFs themselves showed differential splicing (see Table
4.2). This event occurred in three different conditions, while ESRP1/2 was present in
most of the cases.
SF CLL DLBCL FL
ESRP1 + - +
ESRP2 + + +
NOVA1 - + -
KHSRP - + -
Table 4.2: Splicing factors differentially spliced. ’+’ indicates differential splicing,
’-’ indicates no differential splicing in the respective condition.
For an overview on the main functional involvements of the differentially spliced genes
(Appendix 6.1, Tables 6.1 to 6.6) we applied a DAVID [Huang et al., 2008] analysis on
GO Biological Process terms. Results are shown in Appendix 6.1 Tables 6.7 to 6.12.
Most terms are attributed to differentiation and developmental mechanisms. Table 4.3
shows the intersection of the significantly enriched GO terms for the different subtypes.
Interestingly, a high number of keratin subtypes rank among the top differentially spliced
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Figure 4.3: Hierarchically clustered DS events per comparison. Exon based dif-
ferential splicing events (marked in grey) occurring in at least one subtype-
control comparison are grouped by hierarchical clustering. While a consider-
able overlap for many subtypes is observed, some groups such as CLL, ALCL
and DLBCL show also a substantial amount of specific splicing events. The
highest number of DS events is observed for CLL (1395) while only few DS
events are predicted for PTCL (337).
genes. It has been shown that down-regulation of keratin in cancer promotes migration
and cell growth [Paccione et al., 2008, Fortier et al., 2013]. Consistent with this obser-
vation as well as withe the other results, functional analyses of the differentially spliced
genes show typical characteristics of metastasis like cell adhesion.
4.3.5 SFs not Differentially Expressed but Differentially Central
Several SFs showed differential centrality in a number of conditions (Table 4.4), a few
of them were also differentially expressed (Figure 4.4).
While some occur in most condition comparisons, amongst them DAZAP1, we also
identified condition specific SFs such as RBM25 (see Table 4.4). For the most prominent
candidates we screened literature to identify their known function as well as their involve-
ment in disease. Amongst them are HNRNPM, RBFOX2, KHDRBS2, the ELAV-family
as well as DAZAP1. For a detailed discussion of results see Section 4.4.1.
4.3.6 Who controls the Splicing Factors?
Splicing offers a fine-grained level of control in a cell. Yet, to understand the whole
picture it is of substantial interest to investigate potential regulators who might impact
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GO term description
GO:0007398 ectoderm development
GO:0008544 epidermis development
GO:0030855 epithelial cell differentiation
GO:0060429 epithelium development
GO:0007155 cell adhesion
GO:0022610 biological adhesion
GO:0009913 epidermal cell differentiation
GO:0030216 keratinocyte differentiation
GO:0016337 cell-cell adhesion
GO:0042060 wound healing
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0001942 hair follicle development
GO:0031424 keratinization
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0031069 hair follicle morphogenesis
GO:0048730 epidermis morphogenesis
GO:0007160 cell-matrix adhesion
GO:0031589 cell-substrate adhesion
Table 4.3: Common significantly enriched GO terms in all subtypes related to dif-
ferentially spliced genes.
the behaviour of splicing factors. To this end, we queried different resources, i.e. the
database TRANSFAC [Wingender et al., 1996] and text mining results [Thomas et al.,
2014] containing regulational information on transcription factors (TF) and their tar-
gets. Amongst these targets, we identified the SFs showing differential centrality in our
approach.
For one SF detected as differentially central in our approach, PTBP2, we could identify
a potential regulator in TRANSFAC. miR-133b, normally inhibiting cell proliferation,
migration, invasion, and also promoting apoptosis, is a well known player in various
cancer types. Due to its downregulation in cancer it performs an opposing effect on the
cell [Zhao et al., 2014c, Zhao et al., 2013a,Hu et al., 2010,Xiang and Li, 2014,Novello
et al., 2013].
For the subset of samples where miRNA sequencing data was available (for sample
numbers see Table 4.5 ), we examined differences in expression of miR-133b between
tonsil and the different subtypes. Table 4.5 shows a consistent downregulation for lym-
phoma in all comparisons. Due to a limited number of samples in the control group most
comparisons show a p-value slightly over the significance limit while FC is constantly
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Figure 4.4: Differentially central and differentially expressed splicing factors.
Hierarchical clustering of splicing factors based on their involvement on ex-
pressional and centrality based differences between control and lymphoma
subtype. The heatmap includes all SFs being differentially central in at least
one comparison. SFs can be either differentially central only (DC), differen-
tially expressed but not differentially central (DE), differentially expressed
and differentially central (DE and DC), or none.
high. This suggests a regulatory impact of miR-133b on PTBP2 in DLBCL (PTBP2 is
DC) and CLL (PTBP2 is differentially expressed).
4.3.7 Differentially Central SFs and SNPs
Another important type of alteration which potentially changes the function of a protein
and thus may lead to modified splicing activity of SFs are Single Nucleotide Polymor-
phisms (SNPs). Here we investigate the occurrence of SNPs in the SFs differentially
central in lymphoma. We queried a large data set published by Klijn et al. [Klijn et al.,
2014] comprising data from 675 human cancer cell lines. This data set also provides SNP
information on various different cancer cell lines derived from different tissue types.
We first assessed whether the SFs differentially central in our data carried SNPs in
lymphoma derived samples of the cancer cell line data set. We could identify SNPs for
nine of our differentially central SFs; Table 4.6 shows them together with the number of
SNPs in a group (lymphma / non lymphoma) normalized with the number of samples
per group. Interestingly, a number of them have a higher SNP quantity (normalized to
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entity ALCL CLL DLBCL FL MCL PTCL
TRA2A + + + + +
HNRNPH1 + + + + +
ESRP1 + + + +
HNRNPA3 + + + +
NOVA1 + + + +
DAZAP1 + + + +
SNRPC + + + +
ESRP2 + + +
HNRNPA1 + + +
RBFOX2 + + +
ELAVL2 + +
ELAVL4 + +
ZRANB2 + +
KHDRBS2 + +
HNRNPM +
C2 +
KHDRBS3 +
HNRNPU +
PTBP2 +
SRRM1 +
RBMX +
TIAL1 +
HNRNPD +
RBM25 +
ELAVL1 +
KHSRP +
YBX1 +
Table 4.4: Splicing factors differentially central in a certain lymphoma subtype
compared to a tonsil control are marked with ’+’.
the sample number per group) within the subgroup of lymphoma samples (see Table
4.6). To assess whether the SNP number of a certain gene is significantly higher inside
the lymphoma group, we conducted a fisher exact test [Fisher, 1922] comparing the
number of SNPs per gene in lymphoma samples to the number in all other cancerous
samples.
Two SFs, HNRNPM (p=0.055) and HNRNPU (p=0.006) showed significant or close
to significant p-values. Thus, we consider a lymphoma specific role for them, as with
increased SNP number probability for an altered sequence and/or disease predisposition
can increase.
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entity log2FoldChange pval Sample Number
ALCL -5.5695 0.063238 9
CLL -6.5652 0.032216 12
DLBCL -2.4373 0.17737 39
FL -3.4796 0.17426 20
MCL -5.8855 0.078257 11
PTCL -6.8632 0.065126 6
Tonsil 3
Table 4.5: Mir-133b expression comparison for tonsil versus each lymphoma subtype.
Gene freq in lymphoma freq in other cancers ratio
HNRNPM 0.094 0.049 1.895
YBX1 0.019 0.004 4.295
KHSRP 0.038 0.028 1.357
HNRNPU 0.113 0.038 2.974
RBM25 0.019 0.032 0.586
ESRP1 0.038 0.088 0.430
DAZAP1 0.019 0.038 0.496
ZRANB2 0.038 0.038 0.991
RBFOX2 0.038 0.067 0.560
Table 4.6: Frequency of SNPs per gene in lymphoma and non-lymphoma can-
cer cell lines. The number of SNPs per gene is normalized by group size.
4.4 Discussion
Our goal is to identify splicing factors responsible for aberrant splicing in lymphoma.
In this work, we present a method for identification of such potential regulators using
only transcriptome data. Instead of looking at expression changes only, we use an
indirect measure, which allows to encompass changes on different levels. Specifically, we
integrated differentially spliced exons with the set of known splicing factors in condition-
dependent correlation networks. Those SFs were considered regulatory candidates, which
showed differential centrality between a diseased and a control network.
4.4.1 Biological Assessment of Results
Comparing differentially expressed SFs to those differentially central reveals a rather con-
sistent picture of the ongoing changes in several lymphoma subtypes. Three main motifs,
EMT-alike changes, MEK/ERK pathway related changes as well as neuro-oncological
associated changes are observed in both, DE and DC results.
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EMT, an important mechanism in regular development including altered cell-cell ad-
hesion and cell migration, is often hijacked in cancer and thus leads to metastasis and
reduced susceptibility to apoptosis. EMT related changes are known for different lym-
phoma subtypes as, for instance, mantle cell [Sanchez-Tillo et al., 2014] and diffuse large
B-cell lymphoma [Lemma et al., 2013]. Several additional cancer types such as breast
cancer [Xu et al., 2014, Shapiro et al., 2011, Horiguchi et al., 2011], somatotroph ade-
noma [Lekva et al., 2013] and colon cancer [Venables et al., 2013] exhibit this mechanism.
An epithelial to mesenchymal isoform switch is observed in clear cell renal cancer [Zhao
et al., 2013b] and for pancreatic cancer, ESRP1 is a potential prognostic factor [Ueda
et al., 2013].
HNRNPM is known to play a crucial role in splicing-related breast cancer metastasis
[Xu et al., 2014]. By increasing TGFβ signaling, HNRNPM impacts the splicing of
CD44 through competing for cis-regulatory binding sites with ESRP1. Current research
also suggests a role in colorectal cancer [Chen et al., 2014]. In this condition, HNRNPM
dependent metastasis and cancer recurrence is observed. RBFOX2 is an important
driver of mesenchymal tissue specific splicing in normal and cancer tissue and splicing
differences between normal and tumor are similar to those between mesenchymal and
epithelial [Venables et al., 2013]. KHDRBS2 (alias:SLM1, SAM68) is know to influence
a certain CD44 isoform abundance. More specifically, KHDRBS2 promotes the inclusion
of exon 5 in CD44 due to ERK-mediated phosphorylation [Matter et al., 2002].
An interesting validation approach based on our investigation of the SNP frequency
in differentially central SFs would be the sequencing of HNRNPM and HNRNPU in our
lymphoma samples. A high number of SNPs might lead to altered function, especially
to altered interaction patterns with other (splicing-relevant) proteins such as SFs or
histones, and thus to a potential involvement in lymphoma-related aberrant splicing.
Also, as our analyses suggest DS in ESRP1/2 in some subtypes, a more detailed,
experimental analysis and quantification of the expression status of the two could reveal
the presence of different isoforms.
The second group of changes can be summarized as MEK/ERK pathway related.
An important target of cancer related studies and a high ranked SF in our approach
is HNRNPH1. In colorectal cancer HNRNPH expression showed significant association
with tumor stage, i.e. with metastasis as well as with survival [Hope and Murray, 2011].
In Gliomas, HNRNPH acts as an oncogenic splicing switch by promoting aberrant iso-
forms leading to resistance to apoptosis and metastatic tendencies [LeFave et al., 2011].
The expression of A-RAF, a protein involved in the MEK-ERK signaling pathway, is
controlled by HNRNPH. Suppressing of either A-RAF or HNRNPH leads to apoptosis
while an upregulation promotes resistance to apoptosis [Rauch et al., 2010]. Not only
HNRNPH but also DAZAP1 is known to act in this pathway. A recent publication
identifies DAZAP1 as a MEK/ERK pathway influenced splicing regulator of cell pro-
liferation and migration [Choudhury et al., 2014]. The MEK/ERK signaling pathway
controls the activity of DAZAP1 by phosphorylation, raising the question of a defect
in the phosphorylation cascade. To this end, we examined the expression of all genes
involved in the pathway, which revealed differential expression of pathway members for
ALCL (MRAS, MYC) and CLL (RRAS, MAPK1/ERK2, RAF1/CRAF, BRAF and
65
4 Splicing Factor Network
MAP2K1/MEK1). One condition, DLBCL, showed no differential expression of mem-
bers of the pathway, but of DAZAP1 itself. In summary, we see substantial expression
changes in the MEK/ERK pathway which might lead to an alteration of the function of
DAZAP1 and thus to altered splicing. In this context, the downregulation of miR-133b
in all lymphoma subtypes is interesting, as a recent publication attributes this miRNA
a role in ERK-signalling [Feng et al., 2013].
Neuro-oncological changes in our data comprise, for instance, ELAVL2, a neuron
specific RNA binding protein and tumor antigen. ELAVL2 is associated with small-cell
lung cancer [D’Alessandro et al., 2008,Kazarian and Laird-Offringa, 2011], where mRNA
levels were significantly raised in blood, as well as in renal carcinoma [Stickel et al., 2009].
Not only ELAVL2, but also ELAVL1 and ELAVL4 appear amongst the differentially
central SFs. The ELAV-family is an important post-transcriptional regulator for NOVA1
and impacts the splicing activity of the latter [Ratti et al., 2008].
4.4.2 Network-based Differential Centrality
It is currently technically impossible to capture all changes in a cell leading to aberrant
physiological circumstances. Nevertheless, these alteration influence each other and
might thus be detected indirectly by investigating, as in our example, expression via
networks.
Several reasons favor the differential network approach to DS. First, exons and SFs
are known to have a many-to-many association, meaning one exon can be influenced
by many SFs whereas one SF can influence several exons. Second, networks enable the
discovery of potentially functional modules, such as pathways, which might be disturbed.
A more general argument towards networks is the application to cancer data itself.
On the one hand, this phenotype is a complex disease who’s emergence is based on
multiple malfunctions, on the other hand it might also have very heterogeneous causes.
An observed phenotype can, for instance, be provoked by different defects in a functional
unit, finally leading to the same effect but being caused by different alterations.
For prioritization of entities in networks a variety of centrality measures have been used
[Koschützki and Schreiber, 2008]. Depending on the aim of the study, different measures
are of favor. Detection of essential proteins in protein-protein interaction networks is
better achieved by measures based on interconnectivity such as the clustering coefficient
[Estrada, 2006]. For regulatory networks, on the other hand, betweenness centrality
is preferable [Yu et al., 2007], as so-called bottleneck proteins are more important for
information flow than hub proteins. Our approach thus favors betweenness centrality.
4.4.3 Correlation Cutoff and Result Stability
Our interest in the correlation cutoff dependence of results motivated us to vary the
latter in steps over the whole spectrum. As the smallest group in our setting is the
control group (comprising 9 samples), we used a statistical test for Pearson correlation
to determine the significant correlation cutoff r, which is 0.67 for our control group. We
compared the top ten differentially central SFs for networks (ALCL vs tonsil) based on
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this cutoff to the ones with varying cutoffs to assess whether our results are dependent on
a - potentially arbitrary - cutoff. Eight out of the ten SFs occur in both, the significant
as well as the ’majority vote’ cutoff scenario. For our analysis we used the majority vote,
as we deemed it more robust.
4.4.4 Evaluation
Little is known about splicing and lymphoma. Therefore, no ’gold standard’ of spliced
entities or splicing-regulatory trans-acting factors exists. We thus evaluated our ap-
proach by assessing the enrichment of differentially expressed SFs amongst our differ-
entially central candidates, arguing that these are the most reliably involved regulators
and should thus be highly ranked in our approach. Two (ALCL, DLBCL) out of three
conditions we considered adequate for our purpose showed an enrichment of differen-
tially expressed SFs amongst the top differentially central ones. The third condition,
CLL, contains the highest number of differentially spliced exons as well as differentially
expressed SFs. Potentially, the number of involved SFs is thus higher and it is therefore
harder for differentially expressed SFs to rank under the top positioned ones. As we
apply a rather rigorous cutoff by deeming only the SFs occurring in at least half of the
cutoff settings as relevant, we face the situation that a growing number of differentially
expressed SFs will reduce significance. However, this method aims at comparisons where
little differential expression, and thus little direct evidence for potential causes is given.
4.5 Conclusions
Most of the identified SFs are well known in the context of cancer. While this is a
valuable support for the reliability of our results, the truly interesting results are those
which lead to candidates undiscovered to date. Interestingly, DAZAP1, a SF showing
DC in most subtypes (and DE in two of them) was only recently set into context with
MEK/ERK pathway which is connected to CD44 splicing [Choudhury et al., 2014]. A
new candidate for regulation of splicing in lymphoma based on our results is TRA2A.
While being differentially central in most conditions (as well as differentially expressed in
one of them), little to nothing is known about the role of TRA2A in the context of cancer
or other diseases. This highly ranked SF might thus be an eligible candidate for further
investigations. Based on the SNP frequency in the cancer cell data set queried, the
SNP frequency of HNRNPM in ALCL samples as well as HNRNPU in DLBCL samples
poses a promising investigation target. Interestingly, HNRNPU is also differentially
expressed in DLBCL. Overall, the probably most beneficial aspect of our method is the
fact that alterations in our regulatory candidates are not necessarily restricted to the
transcriptomic level, while only using transcriptomic data.
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5 Multi-level Comparison of Exon
Array and RNA Sequencing Data
For the last two decades, microarrays have been the indisputable method of choice
to quantify the transcriptome in high-throughput manner. However, during the past
decade, RNA sequencing techniques are gradually complementing and replacing mi-
croarrays [Wang et al., 2009b,Zhao et al., 2014b]. To preserve microarray-based knowl-
edge, a thorough evaluation of the comparability of the results produced by the differ-
ent technologies is indispensable. Several studies pursue this task on the gene level,
reporting high concordance on on present/absent entities, correlation of expression val-
ues [Raghavachari et al., 2012], fold change direction [Bottomly et al., 2011] and differ-
entially expressed genes [Wang et al., 2014a,Wang et al., 2014b].
Generally, RNA sequencing is found to complement and extend the merits of microar-
rays [Malone and Oliver, 2011]. This is shown by higher verification rates [Nault et al.,
2015,Wang et al., 2014a,Wang et al., 2014b] of RNA-Seq results as well as the widely
observed finding of higher sensitivity in the lower expression ranges [Bottomly et al.,
2011,Wang et al., 2014a,Wang et al., 2014b].
Nevertheless, splicing microarrays, such as exon arrays or junction arrays, provide the
possibility to study splicing alterations, allowing for comparing the latter one to RNA
sequencing results with respect to differences in detected splicing events. In contrast to
studies on the gene level, these comparisons are rare and often lack explanatory power
due to small sample sizes which impede statistical tests, rarely used types of microarrays,
or a result set too small for representative comparisons.
Irrespective of the technology, two general approaches exist for assessing alterations
in splicing. One possibility is based on the isoform level. Hereby, the expression of each
transcript is quantified separately and subsequently compared to the respective expres-
sion intensity in the control group. This approach requires knowledge on the transcripts,
which either excludes unknown ones or operates with (rather heuristic) transcript predic-
tion algorithms. An alternative is the assessment of differential exon usage (see Section
3.1 and 3.2). Here, the individual exon expression is usually set into relation to the gene
expression intensity. While it is possible to use isoform expression intensities instead,
the gene level normalization approach provides a more neutral solution, omitting the
task of isoform level quantification.
Very few studies examine the comparability of performance on the exon level [Raghavachari
et al., 2012,Xu et al., 2011]. Raghavachari et al. [Raghavachari et al., 2012] analyze the
concordance of Affymetrix Exon Arrays and Illumina sequencing. While gene level re-
sults are meaningful due to a high number of differentially expressed genes, a lower
number of genes displays differential splicing (1 vs 16 without overlap) which impedes
69
5 Multi-level Comparison of Exon Array and RNA Sequencing Data
a robust comparison. A second study by Xu et al. [Xu et al., 2011] is based on a rather
rarely used microarray (Glue Grant Human Transcriptome Array); GEO [Edgar et al.,
2002] reports only 10 studies based on this technology. Bradford et al. [Bradford et al.,
2010] compare the Affymetrix Exon Array to ABI Solid, using only a single sample for
the actual platform comparison. Subsequently, only comparisons in fold change rather
than statistical tests are applicable. The most interesting comparison is published by
Dapas et al. [Dapas et al., 2016], not only comparing differentially expressed genes but
also differentially expressed isoforms based on RNA sequencing and exon arrays. Cor-
relation of expression and fold change for genes and isoforms reveal a higher agreement
for gene comparison. Indeed, isoform quantification is still a hard problem, and various
tools lead to substantially varying results [Dapas et al., 2016]. Even the application of
a multitude of quantification tools does not exceed a maximal correlation coefficient of
0.5 [Dapas et al., 2016]. Thus, a comparison on the exon level, avoiding the supposedly
biasing step of isoform quantification might yield a clearer picture of the ongoing changes
on the splicing level.
In this chapter, we aim at assessing the comparability of differential exon usage de-
tected from exon arrays and RNA sequencing data. To this end, we developed a multi-
level framework, enabling comparison of both technologies not only on the level of dif-
ferential splicing, but on all antecedent levels. We provide insight on (1) the most basic
probe level, by implementing a maximally comparable data pre-processing procedure,
(2) we enable comparison of the next-higher aggregation step for probe set/exon data
as well as (3) a gene level comparative approach. Finally, we (4) quantify differential
splicing based on several methods, one which is typically used for the respective tech-
nology and others which are designed for both technologies. By applying the same DS
detection method to both data types, we aim at reducing method-induced bias, which
can be rather high even for different methods applied to the same technology.
The comparison on several levels enables a detailed understanding of the data charac-
teristics from each technology. Only by this thorough multi-step evaluation, we can fully
understand to what extent the two technologies are comparable and what the limitations
are. We apply our approach to two cancer data sets.
5.1 Levels of Comparison for Exon Array and RNA
Sequencing Data
We first give a detailed insight on the different comparison levels implemented in our
framework. We describe pre-processing steps as well as methods used for the acquisition
of differential expression on various levels together with the mode of comparison applied
on the individual level. For an overview see Figure 5.1.
5.1.1 Probe Level Comparison
The most basic level of comparison is posed by the bare sequence responsible for quan-
tification of expression. For exon arrays, this is the probe level, thus we refer to this
70
5.1 Levels of Comparison for Exon Array and RNA Sequencing Data
comparison step as the probe level comparison in the following. For RNA sequencing,
the genomic positions corresponding to the probe locations are selected. Several aspects
of this step need to be considered to ensure comparability of expression values. First, ge-
nomic positions of the probes have to be assessed based on HG19, as Affymetrix provides
probes positions based on HG16. We therefore used BLAST to map probe sequences to
HG19 and determine the positions of uniquely mapping probes.
Further, the corresponding count values for the sequencing data have to be assessed
based on their genomic positions in HG19, so only reads actually covering the probe
sequence are used. Note that this step ensures the maximally possible comparability of
data as both technologies should measure the exact same expression. All other levels
are less comparable in terms of the genomic input positions, as exon array data is an
aggregate of individual probes, while RNA sequencing data covers the whole region of
the entity under consideration in terms of expression.
Due to differing properties of the two technologies, such as diverging data scales,
filtering of the expression data can be necessary.
The pre-processed and filtered data is then compared for matching samples, giving an
overview on the correspondence of the expression data on the most downstream level.
5.1.2 Probe Set Level Comparison
The second level of comparison is based on the so-called probe sets defined on the
exon array, which group probes corresponding to a certain feature together. Probe sets
represent exons of a gene. The equivalent expression values for the sequencing data are
exon counts. Note that even in the case of an ’injective’ mapping, i.e. a probe set is
mapped to only one exon, the probe set value is based on the values of its probes only,
and does therefore - in most of the cases - not cover the whole exon sequence. Probe sets,
i.e. their corresponding probes, are designed to reduce cross-hybridization with other
genes, nevertheless, cross-mapping with exons within a gene is possible. To maximize
comparability of the used expression values for this level, we filter the exon array data
for injective mapping hits by using only probe sets that match to exactly one exon.
This pre-processed data is then used to assess correlation between corresponding sam-
ples as well as correlation of exon fold changes between groups.
5.1.3 Gene Level Comparison
The next-higher level is the gene level. To this end, data is summarized based on probe
sets in the exon array case. For sequencing data, counts on gene level are assessed.
Subsequently, expression data from both technologies is analyzed for differential gene
expression using state of the art analyses. In the case of array data, a linear model
(limma [Ritchie et al., 2015]) is applied, for sequencing data DESeq2 [Love et al., 2014]
is used to determine genes significantly differing in expression between the two groups.
Using these results, the correlation of fold changes gives an overview on the com-
parability of the data. Furthermore, the overlaps between significantly differentially
expressed genes are quantified and tested for significance.
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5.1.4 Comparison of Differential Splicing
Combining gene level and probe set level data enables the final step of analysis, the
investigation of differential splicing. In contrast to differential gene expression, this ana-
lysis is less established and poses more challenges (see also Chapter 3.1). In consequence,
methods analyzing differential splicing tend to produce rather heterogeneous output. To
avoid that this bias influences our results, we use two methods applicable to data from
both exon arrays and RNA sequencing. These two, ARH and SplicingCompass, have
been introduced in Chapter 3.2. For further comparison, we also apply DEXSeq [Anders
et al., 2012], a method widely used for the detection of differential exon usage in RNA
sequencing data.
Results are then compared by determining the overlaps between different methods
and technologies as well as their significance.
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Figure 5.1: Multi-level framework for the assessment of comparability of exon
array and RNA sequencing data with respect to different analyses.
Each of the four levels includes different expression sets as well as the corre-
sponding analysis strategies and tools.
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5.2 Multi-Level Preprocessing and Analysis
This section describes the data used as well as the pre-processing and analysis steps
taken. Besides the tools applied, references and annotation used for the analyses are
introduced.
5.2.1 Expression Data
For the comparison of exon array data to RNA sequencing data with respect to the
comparability of differential splicing detection, RNA sequencing data for a subset of
unmatched biological samples of the earlier used exon array cohort (see Chapter 2.3)
was generated. Six samples, three DLBCL and three Tonsil samples, were analyzed in
both technologies, enabling direct comparison. Note that due to the generation of the
sequencing data at a later time point, the RNA used is not identical to the one used
for the exon arrays, although it originates from the same biological sample. Tumor
heterogeneity, for instance, might lead to differences, which can not be quantified by
this approach. In the following, we will refer to the samples as Tonsil-1 to Tonsil-3 and
DLBCL-4 to DLBCL-6 respectively. We discuss results based on this data in great detail.
Additionally, we also applied our multilevel-framework to a second data set comprising
four glioblastoma multiforme and four control samples. Results for this data set are
presented and contrasted with results for the DLBCL data set in Chapter 5.3.7.
Samples No. initial reads initial GC% No. trimmed reads
Tonsil-1 75,648,251 52 75,074,381
Tonsil-2 87,542,875 53 87,143,795
Tonsil-3 71,646,252 51 70,994,964
DLBCL-4 85,940,819 51 85,568,553
DLBCL-5 85,464,082 51 84,371,002
DLBCL-6 82,667,161 51 82,381,667
Table 5.1: Result summary of fastQC and trimming.
For sequencing, an Illumina Hi-Seq machine was used, producing single reads of 100
base pairs. An overview on the number of reads before and after trimming with Trim-
momatic [Bolger et al., 2014] is given in Table 5.1. Reads were quality controledl using
FastQC [Andrews et al., 2010] and mapped to the genome (HG19 and HG38) with
STAR [Dobin et al., 2013], an alignment tool allowing for spliced alignment. A result
summary of the alignment is shown in Table 5.2, indicating a good overall output.
Expression matrices for the different comparison levels. To allow for compar-
ison of the expression data from both technologies on the defined levels, each of them
requires its corresponding expression set. In the following, we describe generation of the
data used on the four levels.
Preprocessing of the exon array samples is accomplished as described in Section 4.2.1,
except for the probe level data. For acquisition of the latter see the following paragraph.
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Samples input reads uniquely
mapped
mapped
to mul-
tiple
loci
unmappedAnnotated
(sjdb)
splices
Non-
canonical
splices
Tonsil-1 75,074,381 90.52 % 7.89 % 1.54 % 22,426,796 53,679
Tonsil-2 87,143,795 90.87 % 7.60 % 1.50 % 28,043,725 60,345
Tonsil-3 70,994,964 91.18 % 7.65 % 1.12 % 21,909,709 69,769
DLBCL-4 85,568,553 92.47 % 7.13 % 0.37 % 33,100,432 79,533
DLBCL-5 84,371,002 93.29 % 6.27 % 0.42 % 32,892,221 46,350
DLBCL-6 82,381,667 91.85 % 7.71 % 0.42 % 35,950,647 55,121
Table 5.2: Result summary of read alignment using STAR.
1. Probe level. Probe level data from exon arrays was extracted and quantile nor-
malized with Affymetrix Power Tools [Lockstone, 2011]. To allow reasonable com-
parison with sequencing data, only read counts mapping to the actual probe se-
quences were extracted from RNA-Seq data. Thus, the genomic positions of the
probes, designed based on HG16, were assessed by mapping all probe sequences to
HG19 using BLAST [Altschul et al., 1990], and retaining only uniquely mapping
probes. Based on the probe positions in HG19, counts were assessed with cover-
ageBed, a tool from the genomic analysis suit Bedtools [Quinlan and Hall, 2010].
Both data sets were log2-transformed prior to comparison.
2. Probe set level. Data for the probe set level (i.e. exon level) was compared
based on Ensembl exon ids. For exon arrays, data is preprocessed and aggregated
as described in [Rodrigo-Domingo et al., 2013]. Subsequently, the resulting probe
sets were mapped to Ensembl exon ids using biomaRt [Durinck et al., 2009]. An
extensive filtering was applied, to ensure injectivity of the resulting mapping. Fi-
nally, probe sets mapping to the same Ensembl id were aggregated by using their
mean. For the sequencing data, RPKM counts (reads per kilobase of transcript
per million mapped reads) per exons were used.
3. Gene level. Gene expression values for exon array data were generated by a
further aggregation step as described in [Rodrigo-Domingo et al., 2013]. For se-
quencing data, the corresponding gene transfer format (GTF) annotation file from
Gencode [Harrow et al., 2012] was used to generate gene level count data with HT-
Seq [Anders et al., 2014] as Gencode is preferable in the context of splicing [Frank-
ish et al., 2015].
4. Splicing level. Splicing level data is based on the probe set level, i.e. exon level
data. Additionally, the information of the corresponding gene for each exon is used
as input for the different tools. Most tools for sequencing data require specific
input data. SplicingCompass, for instance, uses CCDS (Consensus coding DNA
sequence) data and requires raw counts from coverageBed, DEXSeq [Anders et al.,
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2012] comes with its own counting script. ARH uses the exon-level expression
quantification.
5.2.2 Analysis and Comparison Methods for the Different
Comparison Levels
For the two most basic levels, probe and probe set level, we used Pearson correlation as
a method of similarity acquisition.
1. On the probe level, we correlated expression values of the corresponding samples.
2. On the probe set level, in addition to correlating expression of corresponding
samples, we used the fold changes per probe set / exon between groups (DLBCL
vs. Tonsil) as correlation input.
3. On gene level, we compared the set of differentially expressed genes as well as
all genes in terms of overlap and their fold change correlation. We thus assess
differentially expressed genes by using state of the art methods for each technology.
For exon array data, limma/Bioconductor [Ritchie et al., 2015] was applied, i.e.
differential expression is determined using a linear model. Sequencing data was
analyzed with DESeq2 [Love et al., 2014]. Here, the variance-mean dependence is
estimated and data is tested for differential expression based on a model using the
negative binomial distribution.
4. For the splicing level we expect differences due to technology. Therefore, we
wanted to minimize bias introduced by different methods and chose to use two
methods, ARH [Rasche and Herwig, 2010,Rasche et al., 2014] and SplicingCompass
[Aschoff et al., 2013], applicable to both data types for comparison. Additionally,
we use a widely applied differential exon usage detection method, DEXSeq [Anders
et al., 2012] for an inner-technological reference.
Our main genome version for comparison is HG19, i.e., GRCh37.p13 from Gencode.
Yet, we reran our RNA sequencing analyses with GRCh38, to also provide insight on
differences induced by the useage of the current genome version.
5.3 Results
The following section presents the results of the comparisons on the four different levels.
Note that each level includes its own filtering steps which are not influenced by other
levels. Thus, probes excluded on the probe level might be part of the gene level and
vice versa. The idea motivating this procedure is twofold. First, we would like to choose
the most unambiguous entities on every level, without, second, loosing too much of the
data along the way, i.e. the levels. While this work can be used to select filter criteria
for better result concordance of exon array and sequencing data, we belief that the most
important application scenario is a comparison of current, sequencing-based results to
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older, public exon array results. Thus, before proposing filter criteria for better result
concordance, we want to assess comparability of the technologies as they are used up to
date. The stricter the filtering criteria, the more coverage of relevant genomic regions is
lost.
5.3.1 Probe Level
For a first overview on the data, we compared the distributions of log2 transformed data
from both technologies as displayed in Figure 5.2. While the count data experienced
no further transformation than the logarithm (except for a pseudo-count of 1 to avoid
problems in logarithmization), exon array data was additionally quantile normalized.
While RNA sequencing is designed to resolve expression of entities on a single transcript
level, quantification with exon arrays returns an approximation of expression. There-
for, scales in Figure 5.2 are not directly comparable. Nevertheless, they illustrate the
expected divergence in size of the represented expression ranges, which is much broader
for RNA sequencing data. The boxplot also illustrates the better expression resolution
for lower expression ranges in RNA sequencing data, the second quartile, i.e. the lower
half of the box, spans a higher range (relative to the third quartile) for RNA sequencing
data compared to exon array data.
In order to determine the genomic categories of the data points, we intersected the
genomic locations of the probe sequences with the positions of the exons and genes in
our annotation gtf (see Table 5.3). From the 1,082,385 core probes used, 961,488 were
uniquely mapped to the genome. Of those, 894,029 were located in consensus coding
sequence (CCDS) exons and 957,950 were found in regions defined by gene coordinates.
Thus, 63,921 core probes map to intronic regions or non-CCDS exons, and 3,538 probes
mapped outside of annotated genes.
number of probes % core % unique
core probes used 1,082,385 100%
uniquely mapping probes 961,488 88.8% 100%
probes in exons 894,029 82.6% 93%
probes in genes 957,950 88.5% 99.6%
probes in introns or non CCDS exons 63,921 5.9% 6.7%
Table 5.3: BLAST results compared to HG19 annotation. The positions of the
probes were intersected with annotated entities.
Based on these preprocessing steps, we selected the most reliable probes for compari-
son, i.e. only uniquely mapping probes are selected.
The filtered values were then used to access a sample-specific correlation of expression
values, comparing each sample in the expression set of one technology to the corre-
sponding sample in the expression set of the other technology. The sample-wise scatter
plots in Figure 5.3 give an overview on the Pearson correlation ranging from r = 0.11
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(a) Exon array data (b) RNA sequencing data
Figure 5.2: Boxplot of log2 probe level expression intensities for exon array
and RNA sequencing data. Only values of probes uniquely mapped to
the genome are considered. Exon array data was quantile normalized and
core probes were extracted before filtering for uniquely mapping probes.
to r = 0.54. Each correlation was highly significant. Correlation is significantly higher
(p = 0.05, Wilcoxon-test) for DLBCL samples compared to Tonsil.
Figure 5.4 shows the distribution of the expression values compared per sample. In
concordance with Figure 5.2, RNA sequencing data is characterized by a high and wide-
spread amount of low expression data points, while exon array data is condensed on a
small expression range with rather normally distributed values.
Last, we visualized expression of all probes for two selected genes to give an impression
on the corresponding level-values as well as to display a gene exhibiting differential
splicing in comparison to one which does not. To this end, we chose DC44 since it is
known to be differentially spliced in lymphoma as well as DRAM2 which was randomly
selected from the set of genes not predicted as differentially spliced by none of the
methods applied in this approach. Figure 5.5 visualizes the two genes on the probe
level. Sequencing data exhibits rather stable probe level expression, while exon array
data shows more variation. Despite expectations, no signs of differential splicing are
visible on this level.
5.3.2 Probe Set Level
Probeset level filtering was done independently from the previous level. We started with
all 284,805 core probe sets in our data and excluded all probe sets containing cross-
hybridizing probes [Rodrigo-Domingo et al., 2013]. This filtering step reduced our set
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Figure 5.3: Probe level scatter plot of sample-wise correlations. The correspond-
ing expression values from both technologies are compared per sample. Only
probe level values of uniquely mapped probes are incorporated. A lowess line
indicating locally weighted regression is included in every plot for a better
visualization of comparability. All correlations are highly significant.
to 229,023 probe sets. Next, we mapped all remaining probe sets to Ensembl exon ids
using Biomart. From this mapping, we extracted all injectively mapping probe sets
(3,887 corresponding to 1,143 exons), and aggregated their expression values using the
mean. For the sequencing data, we extracted the corresponding data based on the
ensembl exon ids, using RPKM values.
The sample by sample correlation improved for all Tonsil samples with respect to
the probe level correlation (r = 0.2, r = 0.3, r = 0.3), but deteriorated slightly in the
group of DLBCLs (r = 0.5, r = 0.44, r = 0.44). All correlations were highly significant.
Figure 5.6 shows scatter plots of all sample wise comparisons and indicates the respective
correlation values. As on the probe level, correlations are superior for the DLBCL
samples with an even lower p-value (p = 0.04). Also, the ranks on correlations of the
samples are stable between comparison levels, i.e. relative comparability is coherent over
levels.
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Figure 5.4: Histogram of probe level expression for all samples and both tech-
nologies based on uniquely mapped probes. Red denotes exon array data,
blue encodes RNA sequencing data.
To gain more group-specific data insight, we assessed the fold changes between DLBCL
and Tonsil samples for each technology based on our filtered data and correlated the two.
Figure 5.7 shows the result, a fold change correlation of r = 0.19(p = 1.9533e− 07).
Sample level probe set correlation (Figure 5.6) shows a high amount of data points
with low to moderate expression values for array data, which have zero or low values
in sequencing data. This specificity is even more clearly notable for the probe level
distributions in Figure 5.4. To test whether these exon array values can be deemed as
noise and are thus the cause of the rather low fold change correlation, we repeated the
analysis with only that 50% of the data points, which had the highest expression in the
exon arrays. This procedure improves correlation to r = 0.29 (p = 7.943459e− 09).
Figure 5.7b shows the same filtering results based on RNA sequencing data. Here, FC
correlation improves to r = 05.
On probe set level, the two example genes are compared based on probe sets for
exon array data and based on exons for sequencing data displayed in Figure 5.8. Both
are sorted based on genomic coordinates. The picture on this level is clearer in terms
of splicing, CD44 shows a region of separation between the group mean values, while
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Figure 5.5: CD44 and DRAM2 expression on probe level. Probes denoted on the
x-axes are sorted according to genomic positions. Samples are color-coded
according to groups, an additional, thicker line denotes the group mean.
DRAM2 is either similarly expressed in all samples based on the sequencing data, or
shows variation in individual samples, according to exon array data, but on a gene-wide
basis, rather than for individual exons.
5.3.3 Gene Level
For comparison on the level of genes, we computed expression values as described in
Section 5.2.1. Each of the two expression sets is then analyzed for differential gene
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Figure 5.6: Probe set level scatterplot of sample correlation. The corresponding
expression values from both technologies are compared per sample. Only
probe sets uniquely mapped to exons are included. A lowess line is included
in every plot for a better visualization of comparability.
expression according to the analysis methods suitable for the respective technology. We
thus obtained a set of differentially expressed genes for the exon array data as well as
the sequencing data, which we correlated by fold change. To assess the concordance
in differential gene expression prediction, we intersected the two result sets. Note that
we did not apply pre-filtering on the data, as the method used for differential gene
expression on sequencing data (DESeq2) requires all unprocessed counts.
Based on the probe level results, where most of the probes matched to CCDS-exonic
regions, but a considerable amount also matched to other regions inside a gene, we
prepared a second gene level data set for the sequencing data, where we included all
reads mapping to the whole gene region instead of the exonic parts only. With this,
we wanted to assess whether the ’extended’ whole-gene data set represents exon array
data better. Details on the differential expression results from these two sequencing
data sets are shown in Table 5.4. Differences in the number of up- and down-regulated
genes (1,381 vs. 7,525 (up) and 847 vs. 6,296 (down)) for CCDS exon and whole gene
respectively, as well as a changes in proportion (1.6 (exon) vs. 1.2 (whole gene) times
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Figure 5.7: Probe set level fold change correlation without (a) and with (b) low
expression filtering based on RNA sequencing data.
DESeq2 results for
exon based data set whole gene data set
nonzero total read count 26408 54230
LFC > 0 (up) 1381, 5.2% 7525, 14%
LFC < 0 (down) 847, 3.2% 6296, 12%
outliers 134, 0.51% 619, 1.1%
low counts 11998, 45% 8383, 15%
p-values (fisher) 0.01243525 2.007481e-17
Table 5.4: Results for DESeq2. Two different gene level data sets are used for the
determination of differential gene expression based on RNA sequencing data.
One count data set, generated with HTSeq, is based on the exons of a gene
(left column), while the second, derived from the use of coverageBed, includes
all reads mapping to intronic regions as well (right column). Additionally, the
fisher test p-value for the significance of the intersect with the exon array gene
level results on differentially expressed genes is displayed.
more upregulated ) within the data sets can be observed. Exon array data analysis for
differential gene expression using limma resulted in 3,221 significantly deregulated genes
(Benjamini-Hochberg corrected p-value ≤ 0.05 and fold change ≥ 2). of which 1,230
were down and 1,991 were up-regulated in DLBCL.
Comparison of the two differential gene expression results based on sequencing data
to the genes differentially expressed in exon array data shows higher comparability for
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Figure 5.8: CD44 and DRAM2 expression on probe set level. Probe sets and ex-
ons denoted on the x-axes are sorted according to genomic positions. Samples
are color-coded according to groups, an additional, thicker line denotes the
group mean. For CD44 differential splicing is visible for both technologies.
The difference between group means is greater in the middle region of the
gene, which corresponds to the spliced region.
the whole-gene data set (see Figure 5.9). Concordance in result sets and correlation of
fold changes improves for the sequencing set covering the whole gene region. For the
set of all genes, correlation raises from r = 0.36 (Subfigure 5.9a) to r = 0.56 (Subfigure
5.9b). For the significantly differentially expressed genes only, correlation increases from
r = 0.71 (Subfigure 5.9c) to r = 0.88 (Subfigure 5.9d). All correlations were highly
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Figure 5.9: Gene level comparison of fold changes. For both gene level data sets,
the exon-based (left picture column) as well as the whole gene-based (right
picture column), fold changes between groups within one technology are
computed and compared to the second technology.
significant. More importantly, the gene-wide count data set reduces the number of fold
change direction switches for the significant genes as shown by the reduction of data
points in the upper left and lower right quadrant in Figure 5.9d compared to Figure
5.9c.
The number of overlapping significantly expressed genes is visualized in Figure 5.10.Note
that we included all genes (ensembl gene ids) found in both gene expression sets to be
compared, i.e. sequencing (14,276 (exon-based) and 45,228 (whole-gene based)) and
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(a) exon array vs seq(exon-based)
p = 0.01
(b) exon array vs seq(whole gene-based)
p = 2.007481e− 17
Figure 5.10: Gene level comparison of differentially expressed genes. For both
sequencing gene level data sets differentially expressed genes (adjusted p-
value < 0.05 and |FC|> 2) are assessed and compared to differentially ex-
pressed genes from the exon array data. Both overlaps are significant. Note
that in each comparison, only genes present in both data sets compared are
included.
exon array (14,871). Thus, as the initial sequencing data sets differ in terms of the genes
they cover (for example due to low counts), also the set of genes compared in Figure
5.10a and Figure 5.10b differ. While this might bias results, we feel that it gives a clearer
picture on the overall differences than working on a reduced set of genes which can be
found in all three data sets. The overlap in differentially expressed genes between exon
array based results and differentially expressed genes from data retrieved on the exonic
parts of the gene only, shows a much higher p-value (fisher exact test) with p = 0.012
compared to the overlap based on the whole gene expression set (p = 2.007481e− 17).
5.3.4 Differential Splicing Level
Both of the methods applied in this step, ARH and SplicingCompass, make predictions
on gene level, i.e. they rank genes based on the probability to have undergone a differen-
tial splicing event. Even though the third method, DEXSeq, operates on exon level, we
have no means to compare exon level results to the other two methods. Thus, DEXSeq
results are reduced to gene level predictions for comparison. Irrespective of the p-values
computed for every gene, we determined fold changes on exon level for all methods
which we used for filtering. Therefore, those genes are classified to experience differen-
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tial splicing that exhibit at least one exon level fold change of 1.5 and a method-specific
p− value < 0.05.
To assess the influence of Benjamini-Hochberg multiple testing correction on the con-
cordance between methods, we used two result sets for comparison. We use a permuta-
tion test to compute p-values for ARH. As of the small sample size, the minimal p-value
is limited. Thus, a multiple testing correction would classify all genes as not differen-
tially spliced for pure technical reasons. To enable a fair comparison, we included all
the methods applied without multiple testing correction and, in a second round, we
compared SplicingCompass and DEXSeq with corrected p-values.
Applying DS detection methods on the data prepared accordingly (see also Section
5.2.1), led to a gene level output as shown in Table 5.5. ARH leads to the highest num-
ber of genes predicted to be differentially spliced, while SplicingCompass gives the most
conservative prediction. The concordance based on numbers of overlap and correspond-
ing p-values is shown in Table 5.8 for the unadjusted, and Table 5.6 for the adjusted
case and is discussed in more detail in the following.
Number of DS genes
Method Technology Genome.version p.value p.adjusted
ARH Exon Array HG19 2508 -
SpComp Exon Array HG19 1805 246
DEXSeq NGS HG19 3316 912
ARH NGS HG19 3909 -
SpComp NGS HG19 762 56
DEXSeq NGS HG38 3759 1023
ARH NGS HG38 3819 -
SpComp NGS HG38 723 58
Table 5.5: Results for differential splicing detection. The number of genes with indication
for DS by p-values and multiple testing corrected p-values (p=0.05) for all
methods, technologies and human genome versions.
Comparing the overlap between technologies on the same genome version without
adjustment yields six result sets. Two of them, namely the intersection between ARH
(array(A)-HG19) and ARH (sequencing (S)-HG19) and SpComp (A-HG19) and ARH
(S-HG19) are significant. None of the two adjusted result sets that are available for
quantifying the comparability is significant. When considering the newer genome version
HG38 instead of HG19 for sequencing data and the results without adjustment, four of
the six intersections are significant. ARH (S-HG38) and SpComp (S-HG38) exhibits a
significant overlap with results of ARH (A-HG19) and SpComp (A-HG19).
Note that DEXSeq displays no significant intersection with both array based results,
yet, exon array results also lack a set based on the same method.
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SpComp (S-HG38) shows a significant overlap with SpComp (A-HG19) while the
intersection with ARH (A-HG19) is close to significance (p = 5.465e− 02). However,
none of the two adjusted result sets are significant.
The overlap within technologies is high in the case of exon arrays, i.e. SpComp (A-
HG19) and ARH (A-HG19). Note that this is the only intra array comparison scenario.
For the three sequencing cases, a significant overlap is observed for the comparison
of SpComp (S-HG19) with ARH (S-HG19) as well as with DEXSeq (S-HG19). The
same result is obtained when comparing sequencing data based on HG38, SpComp (S-
HG38) and ARH (S-HG38) as well as SpComp (S-HG38) and DEXSeq (S-HG38) have
a significant intersection.
When comparing genome versions, nine intersection can be used on basis of se-
quencing data. Besides the comparison of the identical methods, which all had an
highly significant p-value, both comparisons between ARH and SplicingCompass were
significant. For ARH (S-HG38) versus SpComp (S-HG19) as well as for ARH (S-HG19)
versus SpComp (S-HG38) the p-value was highly significant. Note that the only two
significant comparisons in the adjusted case, were the ones between identical methods
with differing genome versions, i.e. the comparisons expected to be highly similar. Fig-
ure 5.11 displays high comparability between genome versions, given the rather stable
numbers in the intersections between HG19 (Figure 5.11a) and HG38 (Figure 5.11b).
Looking at the overlap between methods on the three different comparison levels
A-HG19, S-HG19 and S-HG38, i.e. for fixed technologies and genome versions, yields
very consistent results. Each of the three levels shows a significant overlap between ARH
and SplicingCompass and if present, SplicingCompass and DexSeq. DEXSeq and ARH
never overlapped significantly.
The overlap within methods, i.e. the comparison of the same method between
different technologies and genome versions, provides three intersections for ARH and
SplicingCompass and one for DEXSeq. For ARH and DEXSeq all intersections are
significant. SplicingCompass results only in significant overlaps for two out of three
comparisons, the array-sequencing approach based on HG19 is not significant in overlap.
For the corrected scenario both SplicingCompass and DexSeq are significant in their
overlaps. An overview on the intersections between the three result sets for ARH is
given in Figure 5.12a and for SplicingCompass in Figure 5.12b, respectively.
We also assessed the overlap between all methods, genome versions and technologies
for both the adjusted and unadjusted scenario. The unadjusted set contained 7 genes
shown in Table 5.7. For the adjusted results, only one gene, COX11 cytochrome c
oxidase copper chaperone, was identified in all sets.
5.3.5 The Impact of Filtering
The different levels of data comparison identify several characteristics of data based on
the two technologies. We thus sought to determine whether filtering can improve the
concordance for results in differential splicing between technologies.
To this end, we first compared data on the probe level. Based on the expression
distributions shown in Figure 5.4, we hypothesized that removal of the low expressed
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(a) HG19 (b) HG38
Figure 5.11: The impact of the genome version. Result overlap between methods
for DS detection based on RNA sequencing data annotated with HG19 and
HG38 respectively.
SpComp DEXSeq SpComp DEXSeq SpComp
(A-HG19) (S-HG19) (S-HG19) (S-HG38) (S-HG38)
SpComp (A-HG19) 0 2.028e-01 1.000e+00 2.161e-01 1.000e+00
DEXSeq (S-HG19) 15 0 1.537e-01 0.000e+00 7.771e-01
SpComp (S-HG19) 1 6 0 7.661e-02 2.835e-46
DEXSeq (S-HG38) 16 749 7 0 5.577e-02
SpComp (S-HG38) 1 4 25 8 0
Table 5.6: Size of result overlaps and corresponding p-values with p-value cor-
rection. The lower triangle shows the number of overlapping genes predicted
as DS based on the corresponding methods and genome versions. The up-
per triangle displays the respective p-values. ’A’ (array) and ’S’ (sequencing)
denote the technology used.
probes based on RNA sequencing data might increase expression correlation. We thus
removed the lower half of the probes based on the sequencing expression values in both
data sets. This procedure slightly worsened sample-wise expression correlation, as did
the removal of the lower expressed half of probes based on exon array data.
Based on this finding, we assessed the general relationship of expression correlation and
comparability of differential expression. More precisely, we applied filtering of entities
showing low expression (1) based on exon array data and (2) based on RNA sequencing
data on the exon as well as on gene level and compared correlation of expression as well as
correlation of fold change to assess whether this procedure improves result concordance.
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(a) ARH (b) Splicing Compass
Figure 5.12: Differential splicing result comparability of each method through-
out technologies and genome versions. Genes classified as differen-
tially spliced according to ARH and SPCOMP are intersected for each of
the methods in all applied scenarios.
SYMBOL DESC ENSEMBLID
DTNB dystrobrevin beta ENSG00000138101
AKAP9 A-kinase anchoring protein 9 ENSG00000127914
IGF2BP3 insulin like growth factor 2 mRNA
binding protein 3
ENSG00000136231
WHSC1L1 Wolf-Hirschhorn syndrome candidate
1-like 1
ENSG00000147548
RBM26 RNA binding motif protein 26 ENSG00000139746
XYLT2 xylosyltransferase II ENSG00000015532
COX11 COX11 cytochrome c oxidase copper
chaperone
ENSG00000166260
Table 5.7: Genes predicted as differentially spliced in all technologies, methods
and genome versions. The intersect is derived from unadjusted results, for
adjusted p-values, only one gene, COX11, is contained in every result set.
For the probe set, i.e. exon level, results based on expression correlation showed a
group-dependent behavior. Sample-by-sample correlation improved for Tonsils, while
DLBCL showed a slightly decreased correlation. Fold change correlation improved af-
ter filtering of low expression, when based on array data, to r = 0.29 and based on
sequencing data to r = 0.5.
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For gene level data, expression correlation decreased for all samples. When filtering
based on array genes, correlation of fold changes achieved r = 0.43, and r = 0.31 in the
case of filtering based on sequencing data. Note that the unfiltered baseline is r = 0.36.
For detection of differential splicing, filtering on gene basis instead of exon basis is
advisable. A gene has to be fully represented or discarded from analysis, to avoid genes
with only partial representation of their exons. Thus, we filtered DS results by keeping
only genes showing high expression in exon arrays and genes showing high expression
in sequencing data. The amount and significance of result overlap is compared to the
unfiltered results. For filtering based on sequencing data, results deteriorated. Three
overlaps formerly significant now had a p-value > 0.05. Additionally, the p-values of
those comparisons still significant increased. When filtering based on array data, p-
values also increased for most of the comparisons, but four more overlaps were significant
compared to the unfiltered scenario (see Table 5.9).
5.3.6 Factors Impacting DS Comparability
Several methods, technologies and genome versions lead to a multitude of scenarios com-
pared. To quantify the variables impacting the comparability of results on differential
splicing level most, we fitted a generalized linear model to the three factors enumerated.
Method, technology and genome version were encoded, with respect to their concordance
( x in the case of consensus, y otherwise ) and set into relation to the binary outcome,
i.e. 1 if the overlap was significant and 0 otherwise.
The most impacting variable was the method (p=0.06), i.e. whether the two result
sets intersected were produced by the same method or not. The second important factor
impacting significance of overlaps was the fact that the two sets compared were derived
from the same technology (p = 0.07). The genome version showed no significant impact
on the comparability of results (p = 0.9).
5.3.7 Application to a Glioblastoma Multiforme Data Set
We selected a second, publicly available data set, for which exon array data and RNA
sequencing data were available for a set of samples to validate our framework. This
data set is based on four glioblastoma multiforme samples (GBM), the most aggressive
cancer originating in the brain, and four organ specific control samples derived from
TCGA [Tomczak et al., 2015]. As opposed to the DLBCL data set, the RNA sequencing
GBM data is based on paired-end sequencing. A list of the samples used is given in
Table 6.14 (Appendix).
We applied our multi-level framework to the GBM data set and put results side-by-side
to results obtained from DLBCL data (see Table 5.10). Concordance of RNA sequencing
and exon array analyses is improved on every level. All correlations presented in the
following are highly significant.
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• For probe level and probe set level, sample-wise Pearson expression correlation is
higher in the control group of GBM, while for DLBCL, expression correlation for
cancer samples exceeds the control group.
• Filtering of low expression data on probe set level leads to consistent results for
both data sets, fold change correlation improves even more for filtering based on
sequencing data (DLBCL: r = 0.5, GBM: r = 0.71) compared to array data
(DLBCL: r = 0.29, GBM: r = 0.70).
• For the gene level, result comparability is based on exon-derived gene counts. A
higher concordance in the GBM data set is observed for fold change correlation as
well as for the overlap in differentially expressed genes.
• The overlap in predictions of differentially spliced genes based on array and RNA
sequencing data is in line with results of the previous levels of the GBM data
set. All overlaps between the two methods applicable for both technologies are
significant. This is contrasted by the DLBCL results for SplicingCompass on RNA
sequencing data, which show no significant overlap with array-based results.
• For the multiple testing corrected differential splicing results, the intersection be-
tween differentially spliced genes based on SplicingCompass (array) and Splicing
Compass (seq) was significant (p=1.027e-03). Note that we again did not apply
multiple testing correction on results based on ARH for the same reasons as for
the DLBCL data set.
5.4 Discussion
As RNA sequencing is more and more replacing exon arrays in the detection of dif-
ferential splicing but many previous and important results are based on exon arrays,
knowledge about the comparability of the two technologies is crucial. First and fore-
most it is of high interest, to understand whether the newer technology can be used
synonym to the older, and if not, what the restrictions are. This is also a relevant ques-
tion with regard to, second, comparisons of RNA sequencing results to published exon
array results from literature and the corresponding public databases.
In this section, we presented a multi-level framework for the comparison of differential
splicing results based on exon array data and RNA sequencing data derived from the
same biological samples. For a deep and detailed understanding of comparability and
the related pitfalls, we implemented comparisons on various levels of analysis: From
the basic probe level, to probe set expression, i.e. exon level comparison, gene level
expression as well as differential splicing.
Comparison on different levels was key in understanding the full nature of the data,
and provided valuable filtering approaches ameliorating result comparability. Even
though lower levels of our framework reveal only moderate correlation in sample wise
expression as well as in fold change, a relevant concordance in prediction of differen-
tial splicing is observed. More importantly, our results give room for the hypothesis
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that the application of the same DS detection method has a similar impact on result
comparability of DS as equality of underlying technologies does.
5.4.1 Results on Different Levels.
In the following, we discuss results for the different levels.
Probe Level. On the most basic level of comparison, the probe level, concordance of
results can be assessed on the most controlled data, as we explicitly computed only
those counts for the sequencing set corresponding to the exact probe sequence used
on the microarray. Thus, we expect to see only differences induced by technology and
sample-taking procedures as none of the further aggregation steps are applied. Note
that all further comparison levels are based on values which are acquired differently, i.e.
based on the standard protocol for the respective technology and analysis method. This
means that expression values for exon arrays are always an aggregate of probe values
while sequencing data exactly measures the expressed transcripts for the whole entity
under consideration. For these reasons, we expected expression correlation to be the
most concordant on this level.
However, results reveal a rather moderate overall correlation, which can be traced back
to the distributions of expression values for the respective technologies. The differing
scales, partly responsible for low correlation, are best shown in low expression regions
(see Figure 5.4). Data points which spread over a large scale in count data have a
much denser expression range for exon array data, which, together with additional noise
induced, for instance, by cross-hybridization and different probe affinities in exon arrays,
is counteracting a high correlation. As shown in Figure 5.5, exon array data displays
a high variation (between probes) on this level, which is not found in RNA sequencing
data and this difference impacts correlation substantially.
An additional source of error is induced by a characteristic of RNA sequencing data.
Expression of transcripts in low expression regions are less reliable, as it can not be
doubtlessly determined whether the expression observed is due to biological reality or a
coverage bias induced by potentially overrepresented transcripts.
Even though designed on HG16, most of the core probes (about 90%) of the exon
array uniquely map into HG19. Of these, a relevant amount, about 7%, do not map to
annotated CCDS exons. The impact of these probes is further discussed for the gene
level.
Probe Set Level. The probe set level exhibits a group specific expression correlation
change: tonsil correlation increases, while DLBCL correlation slightly decreases. Even
though this level incorporates the lowest amount of data points, expression correlation
ranges over levels are consistent and thus proof reliability. The most interesting observa-
tion is the low correlation of fold changes. While on the probe level underlying genomic
regions interrogated are unified and on gene level a much higher amount of measuring
points is aggregated to one, the probe set level struggles from injective mappings and
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thus aggregation of data points with a high underlying variability. Also, the different
scales of the two technologies contribute to the result observed, as shown by improve-
ment through low expression filtering. The relative low number of data points might be
due to the exon array probe design. Probes are known be ambiguous sometimes [Liu
et al., 2010], which impedes the unique mapping of probe sets to exons.
Visualization of CD44 and DRAM2 on the probe as well as the probe set level provides
two valuable insights (see Figure 5.5 and 5.8). First, the high variance observed for probe
level exon array data explains a relevant part of the low expression correlation observed
between corresponding samples on the probe level. Second, the probe set level shows
the necessity for aggregation of expression values, as this level displays a much higher
comparability in expression pattern and variance betwenn technologies. Also, DS for
CD44 in both technologies is visually observable only for the probe set level, as here
the group means differ in the middle region of the gene. Note, that this difference is
much more pronounced for the sequencing data, as Figure 5.8d displays a higher relative
difference in the spliced regions compared to Figure 5.5d. This might be due to the fact
that more information is included in RNA sequencing data on the exon level than on
probe level, as the probe level exclusively relies on regions covered by uniquely mapping
probes.
Gene Level. The use of two different data sets on the gene level demonstrates the
impact of the intronic and non CCDS exonic probes as well as the impact of coverage.
Across all comparisons, the data set built from count data in the whole gene regions
shows higher concordance with the gene level exon array data. Both the overall corre-
lation of FCs as well as the correlation of the significant genes only increase with the
whole gene data set. The intersection of differentially expressed genes on basis of the
whole-gene data shows a much lower significant p-value. Nevertheless, both overlaps are
significant. A further aspect pointing to a better representation of the exon array by
the whole-gene data set is the observation of highly reduced fold change contradictions.
While Figure 5.9c displays a relevant number of fold changes with differing signs, these
are reduced to a minimum in Figure 5.9d.
Besides additional probes, two other sources might influence the outcome. Note, (1)
that the two sequencing data sets are necessarily generated by different tools. Also, (2)
the differing number of genes included due to low coverage can influence correlation.
Compared to the probe set level, correlation of fold changes is more stable, which hints
to the general rationale of transcription microarrays: more measuring points are more
reliable and represent entities better.
Level of Differential Splicing. For the comparison on the level of differential splicing
we relied on the result intersections between methods and technologies. While on the
uncorrected results significance in overlaps can be observed for several comparisons, the
multiple testing corrected result set shows no relevant overlap between results of different
technologies or different methods. We thus focus on the comparison of the uncorrected
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result sets, knowing that they contain a relevant number of false positives. Nevertheless,
the tendency they show is valuable and cohesive.
The most interesting comparisons are the overlaps between technologies based on
methods applied in both. For HG19, two out of four sets are significantly overlapping.
Interestingly, the two non-significant intersects are the ones containing SplicingCompass
results, which is the only method exploiting splice junctions in this approach. For
HG38, three out of four comparisons have a significant intersection. The additional one
is based on the same method, SplicingCompass. An important evidence for the impact of
using the same method is the observation that DEXSeq has no significant overlaps with
array based data. Nevertheless, technology does have a great impact, as, for instance,
significant overlaps between DEXSeq and SplicingCompass, when based on the same
technology, show.
5.4.2 The Impact of Splice Junctions.
The methods applied for detection of differential splicing differ significantly in their
approaches. While ARH uses an information theoretical approach, SplicingCompass at-
tempts to solve the task by using analytical geometry. DEXSeq uses a generalized linear
model to test for differences in variance on basis of a negative binomial distribution.
Another major difference is the use of splice junctions. For exon arrays, no such probes
are available. DEXSeq does not make use of the information directly, only by adding
counts derived from spliced reads to the different exons they belong to. ARH is in theory
able to include such information for the sequencing scenario, though, for comparability
reasons, we decided to not use the information in our approach. Thus, SplicingCompass
applied on sequencing data is the only method using exon junction information. This is
reflected in the insignificant overlaps between SplicingCompass on sequencing data and
the array based results, as the use of splice junctions reduces the number of genes classi-
fied as differentially spliced. While based on exon array data the number of differentially
spliced genes is rather high, it reduces significantly for the sequencing data. Numbers
are lower as all the predictions of both other methods, and they further decrease to a
minimum compared to DEXSeq, when multiple testing correction is applied (see Table
5.5). Thus, results on DLBCL data suggest that splice junctions have a profound impact
on the comparability of results. For the GBM data set, both SplicingCompass based
intersections are significant. However, they display the highest p-value compared to the
remaining overlaps.
5.4.3 The Homogeneity of Tumor Data.
Tumor heterogeneity is a wide research field, not only, but also manifesting on the level of
gene expression [Marusyk and Polyak, 2010]. Intra- as well as inter-tumor heterogeneity
is known, giving rise to different treatment options and necessities. As of this facts, we
expected a higher concordance in the tonsil samples, which we do not see in our data.
Interestingly, DLBCL samples correlate better throughout levels, even though not the
same RNA extract is used for both technologies. Nevertheless, the biological material
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originates from the same biological sample. For the GBM data set, the opposite holds,
expression correlation is better for the control samples.
5.4.4 HG38 versus HG19 - the Influence of the Genome Version.
The latest genome version unofficially supported by Affymetrix at the time of analysis
is HG19. Thus, our main comparison is based on this version. Nevertheless, we want to
include current development and thus decided to additionally run analyses for sequencing
data based on HG38. The main difference between HG19 and HG38 is the attempt
to include information on more individuals in the reference genome. This is mainly
reflected in various alternative sequences additionally provided. However, additional
improvements in HG38 make it a better assembly with less gaps, and a higher quality
in terms of the N50 scaffold. As far most of the aligners are not designed to make use
of the alternative sequences, including the splicing-optimized aligner we used, we only
benefited from the general improvements of HG38. The application of a different aligner
able to include alternative sequences would also have de-focused our aim to compare the
two technologies as fair as possible.
For the inner-sequencing comparison, i.e. the intersection between differential splicing
results based on different genome versions, the effect is clearly dictated by methods.
While the overlap between identical methods is highly significant for all three inner-
method comparisons, three out of six inter-method comparison show significant results.
ARH and SplicingCompass have relevant similarity in their results produced, irrespec-
tive of the genome version. SplicingCompass and DEXSeq inter-genome version overlaps
are significant or close to significant, while DEXSeq and ARH do not share relevant pre-
dictions in common. The concrete numbers in overlap between the three methods are -
as expected - similar, yet by far not identical, for the comparison between genomes (as
shown in Figure 5.11).
Interestingly, the genome version makes a relevant difference for the technology com-
parisons. While all overlaps between DEXSeq and ARH lack a relevant size, p-values for
the remaining four sets (ARH vs. SplicingCompass) decrease for Seq-HG38 compared to
Seq-HG19. In the case of SplicingCompass (ArrayHG19) versus SplicingCompass (Se-
qHG38) to the level of significance and for the intersection between ARHArray19 and
SplicingCompassSeqHG30 to a level close to significance.
One explanation of this observation might lie in the design of the exon arrays. As
observed in the more basic levels of our framework, most probe sets can not be bijectively
mapped to Ensembl Exon IDs. Thus, all methods are applied on the probe set values
of a gene. For most of the cases, this leads to an increase in the number of ’exons’
per gene. Together with the fact that the exon array partly covers intronic regions, this
might produced a more fine-grained resolution than by working on exon level only. While
this could be a problem for purely statistical approaches, ARH is designed to perform
independently of the number of exons. On the other hand, HG38 is an improvement in
several aspects in comparison to HG19. Thus, we hypothesize that the more fine-grained
exon level approach is better reflected by the more accurate genome version which in
terms leads to better concordance. One evidence for this theory is the fact that ARH on
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the exon array level forms significant overlaps with all three result sets from sequencing
data based on HG38.
5.4.5 What Impacts Results?
In the following, we will discuss two major areas which impact result comparability.
On the one hand, we have general factors like the methods applied or the underlying
technology. Additionally, filtering impacts results and thus their concordance.
The Impact of Technology and Method. Obviously, the technology applied influences
results in a major way. RNA sequencing and exon arrays produce expression values on
different scales implying different levels of resolution. It is questionable whether, even
in theory, all relations can be preserved. Differences might, especially in low expression
regions, easily be overlaid by various effects such as cross-hybridization, background
noise, probe affinities, amplification artifacts, and others. While in theory, this question
might be best answered on the probe level, as the prerequisites for comparability are
optimized in our probe level approach, variation in exon array data here is much higher
compared to RNA sequencing data. This effect is impressively illustrated in Figure
5.5, while tendencies are the same in both technologies, RNA sequencing data is by far
more stable and conclusive which obviously inhibits good correlation of results. Variance
stabilization is induced by aggregation of measuring points. For the next-higher level,
concordance in probe sets / exons is much higher as displayed in the example of Figure
5.8. This trend continues with higher aggregation, as FC correlation is even better on
gene level. On the differential splicing level, both aggregation levels come into play, as
exon level values are set into relation to the corresponding gene expression. The later
additionally stabilizes expression values.
It is known, that methods for detection of differential splicing differ, at times vastly,
in their predictions. Together with the bias induced by different technologies, most
publications report rather low result concordance between RNA sequencing and exon
array data when it comes to differential splicing [Raghavachari et al., 2012]. We thus
wanted to assess, whether the application of the same methods to both kinds of data can
significantly improve result concordance, i.e. whether the effect of differing technologies
can be overcome by the choice of the adequate method.
According to our findings it is more important, if the same method is applied in-
stead of the same technology. 3/8 (37,5%) of the significant overlaps are based on the
same method while 1/12 (8,3%) of the non-significant intersects are based on the same
method. For technologies, 5/12 (41,67%) of the non-significant intersects are based on
the same technology, while 13/16 (81,25%) of the significant overlaps are based on the
same technology. Thus, the effect of the same method is more than 4 times higher com-
pared to the two-fold increase in technology impact. A model fit to results based on the
potentially impacting factors confirm this finding, while both, technology and methods
impact results, the effect of choosing the same method might be more important.
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The Impact of Filtering. To enhance results and their concordance, several filtering
approaches could be applied. Yet, ’over’-filtering has to be carefully avoided for several
reasons. First and foremost, no gold standard is known, thus, no decision on ’correct’
results can be taken. Second, extensive filtering could eliminate the advantages of the
high-throughput approach or reduce coverage of genes drastically. Due to the latter,
filtering should take place on gene level as opposed to probe or probe set/exon level, to
avoid a sparse coverage of genes examined. As we see an application of our approach
in the comparison of newly analyzed RNA sequencing data with older, published work,
we claim an easy to apply and generic filtering a prerequisite. We believe that a so-
phisticated re-analysis is beyond the scope of researchers interested in comparing their
results to pre-existing knowledge. Further, knowledge of the dataset based on the ’other’
technology should not be necessary, i.e. filtering should be independent.
We thus applied filtering on the different levels to acquire knowledge on comparability
improvement. Results showed no consistent improvement for expression correlation, but
indicated improvements in the correlation of fold changes. We thus filtered DS results
for lowly expressed genes based on array as well as on RNA sequencing data. While
RNA sequencing based filtering decreased result overlaps, array based filtering lead to
an increase in the number of significant overlaps.
5.4.6 Results for Different Data Sets
Comparison of results from our multi-level framework for the DLBCL and the GBM
data sets showed an higher overall concordance for the GBM data set. We attribute this
to the different sequencing mode, paired end versus single end, as well as the fact that
RNA used for the DLBCL data set was extracted a substantial time apart for the two
technologies. Despite the higher absolute concordance for the GBM data, the trend is
similar for both data sets. Aggregation improves correlation for sample wise expression
as well as for fold changes. Filtering of low expression values based on sequencing data
improves fold change correlation more than array based filtering. Even though more
significant overlaps on the level of DS are observed for the GBM data set, the p-value
based ordering is mainly preserved between data sets.
5.5 Conclusion
RNA sequencing is more and more replacing exon arrays in the application of differen-
tial splicing detection. In this work, we aimed at understanding to what extent the two
technologies are comparable with respect to this task. As current research lacks meaning-
ful examination scenarios and classifies concordance as rather low [Raghavachari et al.,
2012,Bradford et al., 2010], we tackled the problem by two major approaches. First, we
developed a detailed multi-level framework examining and comparing RNA sequencing
and exon array data in detail on every level. Second, we chose methods for differen-
tial splicing detection which are applicable to both data types, hypothesizing that a
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great amount of divergence in DS prediction may result from the application of different
methods.
Our multi-level comparison framework contributes substantially to the elucidation of
technology-based data characteristics and comparability. It shows that high expression
correlation on all levels is not necessarily a prerequisite for concordance in differential
expression over levels. Even more, high expression correlation is rather unlikely on
probe level, as array data is subject to high variation in all expression ranges. More
stable values emerge by aggregation, which in turn improves comparability of differential
expression events.
Filtering of low expression values can improve result concordance. Nevertheless, it
poses the risk of loosing true positives and has thus to be carefully applied with the study
aim in mind. Moreover, several methods for RNA sequencing data require unfiltered data
(DESeq) or apply internal filtering themselves (SplicingCompass).
Result trends are similar for the GBM and the DLBCL data set, yet, result concor-
dance is higher for the GBM data. We attribute this to the sequencing mode and the
time points of RNA extraction. Paired end reads, used for sequencing of the GBM data
(opposed to single end reads for the DLBCL data) may improve the overall quality of
the data set, as they are, for instance, more likely to align to a reference. Moreover,
differing timepoints for the extraction of RNA can influence result comparability.
The technology applied does have a slight impact on the comparability of DS results,
nevertheless, the choice of the DS detection method might impact result concordance
more. In our data, we observe several significant result overlaps. Even though for
multiple testing corrected results no significant overlaps are achieved for the DLBCL
data set, common tendencies clearly manifest on the uncorrected level.
Nevertheless, the two technologies can not be used synonymously, as a significant
overlap is, in most cases, not based on an equal result set. Factors such as differing
ranges of expression values, mostly in the lower expression levels, impact comparability.
Moreover, the use of splice junctions, which is crucial for the final proof of an observed
splicing event, is restricted to RNA sequencing data.
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Data sets
DLBCL GBM
Probe level
sample wise correlation (cancer) {0.47, 0.48, 0.54} {0.49, 0.53, 0.57, 0.59}
sample wise correlation (control) {0.11, 0.25, 0.29} {0.57, 0.58, 0.58, 0.59}
Probe set level
sample wise correlation (cancer) {0.44, 0.44, 0.5} {0.66, 0.68, 0.7, 0.71}
sample wise correlation (control) {0.2, 0.3, 0.3} {0.7, 0.72, 0.72, 0.73}
fold change correlation 0.19 0.64
fold change correlation (seq-filter) 0.5 0.71
fold change correlation (array-filter) 0.29 0.7
Gene level
fold change correlation 0.36 0.77
fold change correlation (DE genes) 0.71 0.93
p-value for intersection of DE genes 0.01 0.006
DS level (p-value overlap)
arhA-spcompA 0.000e+00 0.000e+00
spcompS - arhS 2.721e-76 2.016e-189
arhA - arhS 3.339e-07 5.784e-11
arhA - spcompS 2.044e-01 1.709e-04
spcompA - arhS 4.866e-11 2.498e-14
spcompS - spcompA 1.108e-01 2.786e-04
Table 5.10: Comparison of the multi level results for the diffuse large B-
cell lymphoma (DLBCL) and the glioblastoma multiforme (GBM)
data set. The DLBCL data set contains three control and three cancer
samples while the GBM data set comprises four samples for each group.
Samples from the DLBCL data set are based on single end sequencing while
samples of the GBC data set are based on paired-end sequencing. Filters
are applied either on array (array-filter) or on RNA sequencing (seq-filter)
basis; the lower half of expression values based on the indicated technology
is removed in both data sets. For DS comparison, the p-value of the result
overlap based on methods (indicated in lower case letters) and technologies
(A for array, S for sequencing) is displayed for both data sets.
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6 Summary and Outlook
The main aim of this work was to advance the elucidation of the role of differential
splicing in cancer. A detailed knowledge about (A) the occurring differential splicing
events and (B) the main regulators provoking aberrant splicing profoundly improves
the understanding of the underlying pathological mechanisms and can in consequence,
improve therapeutic approaches.
In this work, we compared different methods and technologies for detecting differen-
tial splicing events and proposed a new method for the identification of aberrant splicing
regulators. Assessing the performance of different DS detection methods with respect
to several global data parameters, such as the number of samples per group, enables
an informed method choice based on the data. We developed a novel method for the
detection of potentially causal regulators amongst splicing factors based on transcrip-
tomic data, while predicting candidates with alterations on potentially several influen-
cial levels. Moreover, we proposed a multi-level framework enabling a comprehensive
assessment of the concordance of exon array and RNA sequencing based detection of
differential splicing, thus providing a profound evaluation of their comparability.
Chapter 3 described the comparison of nine methods for differential splicing detection
based on exon arrays. A variety of methods exist for this task, but result overlap is
often low. Furthermore, no comparative assessment addressing the susceptibility of
the different methods to global data parameters has been conducted so far. Hence,
we evaluated various methods available for differential splicing detection with respect
to different data parameters. To this end, we generated artificial data sets with an
altered number of samples per group, varying exon numbers per gene, different expression
intensity as well as a varying percentage of samples differentially spliced per group.
Additionally, we applied all methods to two published data sets for which experimental
validation of predicted splicing events was available. We assessed accuracy, sensitivity
and specificity for each method and data set. Furthermore, we determined the influence
of the different global data parameters represented by the artificial data sets and provided
a detailed discussion on the performance differences of the distinct methods with respect
to the underlying algorithms.
Our results obtained for artificial and experimental data confirm and complement
each other and are thus providing a global view on the performance of the different
methods as well as their susceptibility to the data parameters implemented. According
to our results, all methods are influenced by expression intensity as well as by the
percentage of differentially spliced samples per group. Parameters such as the number
of exons per gene allows for a distinction between methods responsive and unresponsive
to this parameter in terms of accuracy. The same holds for the number of samples per
group. If the sample number is low or unbalanced we recommend SplicingCompass. For
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independence on the number of exons in a gene, ARH, KLAS, SI and MIDAS pose the
best choice. High sensitivity is provided by FIRMA while high specificity is achieved by
ARH, SplicingCompass and MIDAS.
Chapter 4 encompasses our newly developed network-based approach for the de-
tection of regulatory candidates causal for differential splicing events between a cancer
(lymphoma subtype) and a control group (tonsil). While differential splicing events can
be detected with several technologies, the underlying causes for aberrant splicing and
thus the pathological mechanism usually remains unclear. Yet, the understanding of the
latter is essential for the development of therapeutic strategies.
In our approach, we assessed all differential splicing events between each lymphoma
subtype and the control group. These altered entities were then integrated with potential
regulators, i.e. splicing factors from a curated human SF database, into an expression
correlation network. More precisely, we constructed two networks for each subtype, a
cancerous and a control network, each containing the same nodes but varying edges
based on the expression correlation in the respective group samples. We then assessed
betweenness centrality for the SFs in both networks and ranked the SFs based on their
difference in the cancerous and control network. This ranked list of SFs contains candi-
dates with potential regulatory implications in the differential splicing events observed.
To assess the plausibility of our approach we used differentially expressed SFs. As
they are demonstrably altered between conditions, we expected them to rank highly
amongst our differentially central SFs. To this end, we determine the enrichment of
the differentially expressed SFs amongst the differentially central SFs. Three out of six
comparisons showed a significant enrichment. Our approach led to subtype as well as
lymphoma specific candidates. To elucidate their role and potential involvement in can-
cer, we extensively searched the literature from which we obtained coherent findings,
i.e. the known involvement of several candidates in other cancer types. Furthermore, we
encountered new candidates, such as TRA2A, for which no disease-related publications
could be found. As the origin of perturbation leading to aberrant splicing is not on the
expression level for differentially central candidates, we investigated different potential
areas of impact. First, we mined TRANSFAC, a database providing associations be-
tween transcription factors and the targets they control. Here, we found a regulatory
relationship between the microRNA miR-133b and PTBP2, a SF differentially central
in our approach. Expression analysis of this microRNA could confirm a down-regulation
in all lymphoma subtypes investigated. Second, we assessed genomic alterations based
on the relative amount of SNPs in lymphoma samples compared to other cancer cell
lines from a published data set. Several SF showed an increased amount of SNPs in
lymphoma compared to other cancer cell lines.
Chapter 5 covers the multi-level framework we developed for the comparison of RNA
sequencing and exon array data with respect to the prediction of differential splicing
events. Since RNA sequencing is gradually replacing microarrays, an assessment of
comparability of both technologies is indispensable. While several studies exists for
the comparison on gene level, work on the differential splicing level is rare and lacks
explanatory power.
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To ensure high comprehensibility and comparability, we approached the task two-fold.
First, we implemented multiple comparison levels, i.e., not only the level of differential
splicing, but also several preceding levels to elucidate the origin of potential incompara-
bility. Second, we aimed at improving differential splicing comparability by the use of
two DS detection methods applicable to both, RNA sequencing and exon array data to
avoid method inherent bias [Raghavachari et al., 2012].
Our multi-level approach comprises comparisons on the probe level, the exon level and
the gene level as well as on the level of differential splicing. According to the specific
level, we assess expression correlation, expression distribution, fold change correlation
and overlap in differentially expressed entities. To ensure comparability of entities on
every level, we filter those entities who could be unambiguously mapped. On the probe
level, for instance, probe sequences are mapped to the genome, to detect uniquely map-
ping probes and assess the RNA sequencing based expression specifically for the region
interrogated by the respective probe. Two methods, ARH and SplicingCompass, are
selected for the detection of differential splicing from RNA sequencing and exon array
data.
Rather low expression correlation is observed throughout the levels, partly due to
diverging scales in low expression between technologies and a high variation especially
on the probe level. Aggregation of entities on higher levels improves result concordance
with respect to fold change correlation. The comparison of differential splicing events
results in several significant overlaps on data not corrected for multiple testing for the
DLBCL data set. While the technology (RNA sequencing vs. exon array) does have
an effect on the comparability of predicted differential splicing events for the DLBCL
data set, the impact of the DS detection method used is also important according to
our evaluation. For the GBM data set, which differs from the DLBCL data set in terms
of technology (paired end vs. single end) and different RNA extraction time points, not
only the uncorrected, but also the corrected overlaps were significant.
The main achievements of our work can be thus summarized as follows.
• By comparing DS methods for exon arrays according to their performance on differ-
ent data settings, we could establish a link between influencial global data factors
and the performance of the methods based on accuracy, sensitivity and specificity.
This insight provides researchers with the prerequisites to choose methods based
on their data basis and their study aim.
• We developed a network-based method for the prediction of regulatory elements
causal for splicing changes observed between two conditions such as disease and
control. The main advantage of our method is the prediction of causal regulatory
candidates carrying potential alterations on several levels, i.e. also on other than
the transcription level, yet, by only using transcriptomic data.
• We presented a newly developed, comprehensive multi-level framework for the
assessment of comparability of DS events detected from RNA sequencing and exon
array data. The application on two different data sets showed several significant
overlaps with respect to genes predicted as differentially spliced as well as common
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trends in comparability. The use of further data sets might help to elucidate the
influence of additional factors such as the use of different sequencing technologies.
6.1 Future Directions
This work sheds light on several aspects of the detection of differential splicing based on
different methods and technologies as well as on the uncovering of regulatory elements
potentially involved in the aberrant splicing observed. Naturally, not all aspects of
interest can be covered in a limited amount of time. Additionally, growing insight often
leads to further questions arising in the course of research. This section gives an overview
on several aspects deemed worthy to investigate the overall goal of understanding disease-
related mechanisms associated with differential splicing to eventually identify potential
therapeutic targets.
Machine learning and differential splicing. An interesting approach to investi-
gate the distinctive potential of DS events is classification. Feature selection and clas-
sification of cancer subtypes based on differentially spliced exons relative to the control
group could, first, reveal DS events which are central in their tumor-promoting role.
Second, these splicing patterns might be meaningful for diagnosis.
Besides distinguishing lymphoma subtypes from the tonsil control group, the DS
events detectable between lymphoma subtypes have a high potential in elucidating the
differing patho-mechanisms. DLBCL, for instance, is known to consist of (at least)
three different subtypes, ABC, GCB and others. While gene signatures differentiating
between these groups are known, a distinction based on DS patterns would provide an
additional, potentially more fine-grained, view on the underlying molecular mechanisms
separating the three classes.
Finally, clustering of cancer types based on their splicing pattern might reveal com-
mon subclasses over cancer types representing, for instance, susceptibility to the same
treatment.
Extending the comparison of methods for DS detection. Our approach on
the comparison of DS detection methods using artificial and experimental data sub-
stantially elucidates the performance of the methods compared, yet, both data types
have drawbacks. The artificial data naturally represents only a subset of the biolog-
ically observed splicing events with respect to exon number as well as the amount of
differentially spliced exons per gene. A data setting covering further scenarios would
highly increase the number of tested data set, and could lead to relevant insights on
the susceptibility of the methods to the naturally occurring settings. Although exper-
imental data is of high value for evaluations, the number of data points is rather low
and unbalanced. Additional evaluation of methods with confirmed splicing events from
for instance tissue databases could provide a more robust assessment of performance.
Finally, an indispensable step is the experimental validation of the predicted DS events.
Enrichment of the splicing regulatory network approach. Our SF regula-
tory approach leverages transcriptomic data by the emergence of knowledge due to a
network-based approach. While this enables the prediction of candidates with potential
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malfunctions on levels other than the transcriptomic, the approach would profit from an
enrichment of information based on other levels alterations can occur on.
This could be either done, by integrating players from other levels such as epigenet-
ics or components of the phosphorylatory machinery directly into the network based
on their expression values. Potential candidates for this matter are histone modifying
and methylation-associated genes. For influences due to phosphorylation changes ki-
nases and phosphatases can be included. A more sophisticated approach constitutes
the integration of analysis results gained on other levels. Two important areas in this
context are epigenetic changes and genomic alterations. Modified histones or methy-
lated DNA can explain changes in expression, either for splicing factors or for concrete
differential splicing events. Similarly, mutations and other genomic alterations can in-
fluence the function and splicing behavior of genes and the resulting proteins as well the
cis-regulatory elements controlling the splicing events.
Network correlation based approaches rely on a relatively high number of samples.
While expression data based on exon arrays provided necessary group sizes, RNA se-
quencing based sample sizes in our approach do not offer the possibility of robust corre-
lation network analysis. Yet, RNA sequencing data is highly beneficial in determining
accurate splicing events, because of the unbiased nature of the technology. Furthermore,
spliced reads provide the ultimate prove for the existence of a splicing event, while exon
arrays rely on gene-relative exon expression changes. On that account, an evaluation of
the SF network approach based on RNA sequencing data is of high interest and could
reveal an even more accurate picture of potentially deregulated actors.
Several network centrality measures exist. In the past few years, these ’basic’ measures
such as betweenness, degree and closeness centrality have been modified and refined for
the detection of differentially important components especially in biological networks. A
recent comparison of such DiNA (differential network analysis) methods accentuates the
superiority of local and hybrid DiNA methods compared to global approaches [Lichtblau
et al., 2016]. Consequently, an adaption of the SF network approach using measures
highly ranked in the evaluation of Lichtblau et al [Lichtblau et al., 2016] might improve
candidate prediction.
Splicing factors and their targets. It is of high interest to identify regulatory
candidates potentially involved in aberrant DS. Yet, to understand the effect and the
underlying patho-mechanism of such regulators, the concrete targets of SF have to be
identified, i.e. the ’deregulated’ SF and the exons they control have to be associated.
While several attempts to solve the issue exist [Aittokallio and Schwikowski, 2006, Dai
et al., 2011,Chen and Zheng, 2009], this task is non-trivial due to two reasons. First,
exons and SF usually share n:m relations, i.e. a SF may control several exons and one
exon might be controlled by several SFs. Second, most of the SF play rather a meta-role
in the regulation of a certain exon by participating, for instance, in regulatory complexes.
Thus, no direct information on binding to specific DNA regions such as cis-regulatory
elements can be used.
Investigate new candidates. Several of the identified candidates amongst the SFs
are known in the context of cancer. For some, even mechanistic explanations can be
found. While these SF can be interpreted as a substantiation of our approach, the
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truly interesting candidates are the ones not previously associated with cancer such as
TRA2A. Thus, a specific evaluation of these candidates based on different impacting
levels such as epigenetics or genomic alterations might shed light on their supposedly
unknown role in DS.
Exon based comparison. One of our central aims in the comparison of exon array
data to RNA sequencing data related to DS was the warranty of maximal comparability.
Hence, we chose two methods applicable to both data types. These methods provide
predictions of DS on a gene basis, which naturally impedes the comparison of differen-
tially spliced exons. Nevertheless, such a comparison is of high interest and could be
achieved by using different methods for the two technologies.
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Exon.ID Gene.ID Symbol p-value
3394697 3394660 TRIM29 7.514500e-16
3832868 3832865 NCCRP1 9.272199e-16
3757075 3757050 KRT13 1.059239e-14
3394661 3394660 TRIM29 1.157338e-14
3455883 3455865 KRT4 1.723497e-14
3494641 3494629 SCEL 1.723497e-14
3494642 3494629 SCEL 1.934432e-14
3638433 3638411 RHCG 2.714679e-14
3497228 3497195 CLDN10 3.114437e-14
3455882 3455865 KRT4 9.538484e-14
3455885 3455865 KRT4 9.835962e-14
3113183 3113180 MAL2 1.289319e-13
3455236 3455186 KRT5 2.309053e-13
3497233 3497195 CLDN10 4.920022e-13
3455237 3455186 KRT5 5.209625e-13
Table 6.1: Differential Splicing in ALCL
Exon.ID Gene.ID Symbol p-value
3497228 3497195 CLDN10 5.292302e-22
3832868 3832865 NCCRP1 5.292302e-22
3497233 3497195 CLDN10 1.330475e-21
3394697 3394660 TRIM29 2.571146e-20
3497227 3497195 CLDN10 2.571146e-20
3638433 3638411 RHCG 2.571146e-20
3455875 3455865 KRT4 2.160791e-19
3394661 3394660 TRIM29 3.188063e-19
3757075 3757050 KRT13 3.954294e-19
3455885 3455865 KRT4 4.675862e-19
3455883 3455865 KRT4 5.722255e-19
3757098 3757078 KRT15 5.722255e-19
2893795 2893794 DSP 6.888564e-19
3494642 3494629 SCEL 1.077927e-18
3494641 3494629 SCEL 1.187819e-18
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Table 6.2: Differential Splicing in DLBCL
Exon.ID Gene.ID Symbol p-value
3497228 3497195 CLDN10 7.410631e-18
3455883 3455865 KRT4 1.696985e-17
3757075 3757050 KRT13 1.154848e-16
3497233 3497195 CLDN10 1.410789e-16
3494641 3494629 SCEL 1.560160e-16
3832868 3832865 NCCRP1 1.580196e-16
3394661 3394660 TRIM29 2.675233e-16
3783501 3783481 DSG3 2.675233e-16
3832869 3832865 NCCRP1 2.675233e-16
3757098 3757078 KRT15 3.092309e-16
3497227 3497195 CLDN10 3.412170e-16
3394697 3394660 TRIM29 3.589900e-16
3493550 3493543 KLF5 3.589900e-16
3638433 3638411 RHCG 3.589900e-16
3394662 3394660 TRIM29 8.679099e-16
Table 6.3: Differential Splicing in CLL
Exon.ID Gene.ID Symbol p-value
3394697 3394660 TRIM29 2.069926e-20
3638433 3638411 RHCG 5.676567e-20
3497228 3497195 CLDN10 8.795846e-20
3394661 3394660 TRIM29 5.743939e-19
3757075 3757050 KRT13 6.185971e-19
3832868 3832865 NCCRP1 1.186134e-18
3494641 3494629 SCEL 2.799307e-18
3497227 3497195 CLDN10 3.774077e-18
3494642 3494629 SCEL 8.137291e-18
3497233 3497195 CLDN10 8.210589e-18
3455883 3455865 KRT4 9.811480e-18
3455885 3455865 KRT4 9.811480e-18
3455875 3455865 KRT4 1.160549e-17
3455236 3455186 KRT5 1.813686e-17
3455882 3455865 KRT4 3.623111e-17
Table 6.4: Differential Splicing in FL
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Exon.ID Gene.ID Symbol p-value
3757098 3757078 KRT15 8.986443e-14
3497233 3497195 CLDN10 6.175881e-13
3497227 3497195 CLDN10 2.069670e-12
3497228 3497195 CLDN10 1.182240e-11
3832869 3832865 NCCRP1 1.182240e-11
3394661 3394660 TRIM29 2.890094e-11
3455885 3455865 KRT4 2.890094e-11
3455883 3455865 KRT4 4.596178e-11
3757075 3757050 KRT13 5.530383e-11
3394697 3394660 TRIM29 6.881004e-11
3394698 3394660 TRIM29 2.235965e-10
3497220 3497195 CLDN10 3.184868e-10
3832868 3832865 NCCRP1 3.275280e-10
3873104 3873102 ZCCHC3 3.839708e-10
3493553 3493543 KLF5 4.630996e-10
Table 6.5: Differential Splicing in MCL
Exon.ID Gene.ID Symbol p-value
3497228 3497195 CLDN10 1.345192e-12
3832868 3832865 NCCRP1 1.345192e-12
3497233 3497195 CLDN10 1.942635e-12
3638433 3638411 RHCG 2.076993e-12
3494642 3494629 SCEL 2.202101e-12
3455875 3455865 KRT4 8.534811e-12
3394697 3394660 TRIM29 1.231007e-11
3455883 3455865 KRT4 1.392877e-11
3394698 3394660 TRIM29 1.925563e-11
3455882 3455865 KRT4 1.925563e-11
3494641 3494629 SCEL 2.435742e-11
3638455 3638411 RHCG 3.525309e-11
3497227 3497195 CLDN10 4.614446e-11
3455885 3455865 KRT4 5.517594e-11
3394661 3394660 TRIM29 1.712838e-10
Table 6.6: Differential Splicing in PTCL
GO-BP-Term PValue
GO:0007155˜cell adhesion 9.651084e-20
GO:0022610˜biological adhesion 1.026714e-19
GO:0007398˜ectoderm development 2.454536e-17
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GO:0008544˜epidermis development 3.566239e-17
GO:0030855˜epithelial cell differentiation 1.173162e-11
GO:0060429˜epithelium development 1.241629e-09
GO:0030198˜extracellular matrix organization 1.752353e-09
GO:0043062˜extracellular structure organization 1.284571e-08
GO:0009913˜epidermal cell differentiation 2.617371e-08
GO:0031589˜cell-substrate adhesion 7.707046e-08
GO:0042060˜wound healing 1.206190e-07
GO:0030216˜keratinocyte differentiation 1.240062e-07
GO:0016337˜cell-cell adhesion 1.762735e-07
GO:0009611˜response to wounding 7.693936e-07
GO:0007160˜cell-matrix adhesion 2.141154e-06
GO:0018149˜peptide cross-linking 3.451386e-06
GO:0043588˜skin development 6.830011e-06
GO:0044259˜multicellular organismal macromolecule
metabolic process
1.029626e-05
GO:0001568˜blood vessel development 1.493244e-05
GO:0001944˜vasculature development 1.990398e-05
GO:0044236˜multicellular organismal metabolic process 2.991119e-05
GO:0031424˜keratinization 7.217721e-05
GO:0032963˜collagen metabolic process 8.755150e-05
GO:0030199˜collagen fibril organization 1.043685e-04
GO:0001501˜skeletal system development 2.904855e-04
GO:0006928˜cell motion 3.714555e-04
GO:0022404˜molting cycle process 6.272225e-04
GO:0022405˜hair cycle process 6.272225e-04
GO:0001942˜hair follicle development 6.272225e-04
GO:0042303˜molting cycle 7.002548e-04
GO:0042633˜hair cycle 7.002548e-04
GO:0048730˜epidermis morphogenesis 7.161899e-04
GO:0048514˜blood vessel morphogenesis 8.168157e-04
GO:0010033˜response to organic substance 9.379530e-04
GO:0060537˜muscle tissue development 1.147810e-03
GO:0048545˜response to steroid hormone stimulus 1.410180e-03
GO:0016477˜cell migration 2.278116e-03
GO:0032964˜collagen biosynthetic process 2.664497e-03
GO:0007517˜muscle organ development 2.820849e-03
GO:0001525˜angiogenesis 3.323506e-03
GO:0009725˜response to hormone stimulus 3.365417e-03
GO:0031069˜hair follicle morphogenesis 3.613188e-03
GO:0035295˜tube development 3.828357e-03
GO:0048870˜cell motility 5.347931e-03
GO:0051674˜localization of cell 5.347931e-03
GO:0007044˜cell-substrate junction assembly 6.288796e-03
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GO:0018108˜peptidyl-tyrosine phosphorylation 7.039514e-03
GO:0048732˜gland development 7.369119e-03
GO:0009719˜response to endogenous stimulus 7.902488e-03
GO:0018212˜peptidyl-tyrosine modification 8.180662e-03
GO:0044243˜multicellular organismal catabolic process 8.901341e-03
GO:0048745˜smooth muscle tissue development 9.179835e-03
Table 6.7: David result for ALCL
GO-BP-Term PValue
GO:0008544˜epidermis development 1.244998e-18
GO:0007398˜ectoderm development 1.771867e-18
GO:0007155˜cell adhesion 3.044954e-11
GO:0022610˜biological adhesion 3.143533e-11
GO:0009913˜epidermal cell differentiation 4.079993e-11
GO:0030855˜epithelial cell differentiation 4.682975e-10
GO:0030216˜keratinocyte differentiation 1.354111e-08
GO:0060429˜epithelium development 3.232999e-08
GO:0016337˜cell-cell adhesion 1.103497e-06
GO:0007160˜cell-matrix adhesion 2.091860e-05
GO:0042060˜wound healing 4.545833e-05
GO:0018149˜peptide cross-linking 4.693114e-05
GO:0031589˜cell-substrate adhesion 5.197877e-05
GO:0009611˜response to wounding 6.668294e-05
GO:0001942˜hair follicle development 1.004836e-04
GO:0022404˜molting cycle process 1.004836e-04
GO:0022405˜hair cycle process 1.004836e-04
GO:0042633˜hair cycle 1.173426e-04
GO:0042303˜molting cycle 1.173426e-04
GO:0048730˜epidermis morphogenesis 4.223051e-04
GO:0007156˜homophilic cell adhesion 6.812048e-04
GO:0031424˜keratinization 8.526912e-04
GO:0043588˜skin development 8.658579e-04
GO:0048732˜gland development 8.754943e-04
GO:0007584˜response to nutrient 1.180796e-03
GO:0031069˜hair follicle morphogenesis 1.336101e-03
GO:0033273˜response to vitamin 1.691239e-03
GO:0006928˜cell motion 1.745394e-03
GO:0043586˜tongue development 2.547936e-03
GO:0042552˜myelination 3.016158e-03
GO:0021675˜nerve development 3.850792e-03
GO:0051045˜negative regulation of membrane protein
ectodomain proteolysis
4.000575e-03
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GO:0007272˜ensheathment of neurons 4.692407e-03
GO:0008366˜axon ensheathment 4.692407e-03
GO:0033189˜response to vitamin A 4.692407e-03
GO:0008637˜apoptotic mitochondrial changes 8.464369e-03
GO:0035270˜endocrine system development 9.484398e-03
Table 6.8: David result for DLBCL
GO-BP-Term PValue
GO:0008544˜epidermis development 2.617887e-14
GO:0007398˜ectoderm development 4.233548e-14
GO:0030855˜epithelial cell differentiation 8.389885e-09
GO:0007155˜cell adhesion 4.823272e-08
GO:0022610˜biological adhesion 4.971303e-08
GO:0060429˜epithelium development 7.335057e-08
GO:0009913˜epidermal cell differentiation 1.271995e-07
GO:0030216˜keratinocyte differentiation 3.064921e-07
GO:0016337˜cell-cell adhesion 1.013295e-06
GO:0001942˜hair follicle development 7.735445e-05
GO:0022404˜molting cycle process 7.735445e-05
GO:0022405˜hair cycle process 7.735445e-05
GO:0042633˜hair cycle 9.221465e-05
GO:0042303˜molting cycle 9.221465e-05
GO:0006928˜cell motion 9.975445e-05
GO:0031069˜hair follicle morphogenesis 3.661198e-04
GO:0043586˜tongue development 3.751442e-04
GO:0031175˜neuron projection development 5.504453e-04
GO:0048666˜neuron development 6.729412e-04
GO:0007169˜transmembrane receptor protein tyrosine
kinase signaling pathway
7.415843e-04
GO:0048732˜gland development 7.626238e-04
GO:0007160˜cell-matrix adhesion 9.356956e-04
GO:0030030˜cell projection organization 9.491384e-04
GO:0048812˜neuron projection morphogenesis 1.106097e-03
GO:0030182˜neuron differentiation 1.224145e-03
GO:0048730˜epidermis morphogenesis 1.411054e-03
GO:0018149˜peptide cross-linking 1.698309e-03
GO:0033273˜response to vitamin 1.832977e-03
GO:0007156˜homophilic cell adhesion 1.850382e-03
GO:0000904˜cell morphogenesis involved in differentia-
tion
1.951537e-03
GO:0031589˜cell-substrate adhesion 1.960116e-03
GO:0042060˜wound healing 2.492372e-03
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GO:0007229˜integrin-mediated signaling pathway 2.674283e-03
GO:0007584˜response to nutrient 3.224240e-03
GO:0031424˜keratinization 3.308120e-03
GO:0051402˜neuron apoptosis 3.541409e-03
GO:0007167˜enzyme linked receptor protein signaling
pathway
3.659886e-03
GO:0043484˜regulation of RNA splicing 4.308142e-03
GO:0016049˜cell growth 4.759593e-03
GO:0048858˜cell projection morphogenesis 4.808829e-03
GO:0032989˜cellular component morphogenesis 5.345851e-03
GO:0048667˜cell morphogenesis involved in neuron dif-
ferentiation
5.776437e-03
GO:0000902˜cell morphogenesis 5.855899e-03
GO:0007409˜axonogenesis 6.879216e-03
GO:0016477˜cell migration 7.119917e-03
GO:0042981˜regulation of apoptosis 7.326437e-03
GO:0032990˜cell part morphogenesis 7.381775e-03
GO:0007507˜heart development 7.451537e-03
GO:0007242˜intracellular signaling cascade 8.159232e-03
GO:0042127˜regulation of cell proliferation 8.353677e-03
GO:0043067˜regulation of programmed cell death 8.600802e-03
GO:0010941˜regulation of cell death 9.189182e-03
Table 6.9: David result for CLL
GO-BP-Term PValue
GO:0007398˜ectoderm development 3.664522e-20
GO:0008544˜epidermis development 5.445687e-19
GO:0030855˜epithelial cell differentiation 1.292044e-15
GO:0060429˜epithelium development 1.347844e-14
GO:0007155˜cell adhesion 6.914246e-13
GO:0022610˜biological adhesion 7.249979e-13
GO:0009913˜epidermal cell differentiation 1.502323e-11
GO:0030216˜keratinocyte differentiation 1.008115e-09
GO:0016337˜cell-cell adhesion 1.951863e-09
GO:0042060˜wound healing 5.066139e-06
GO:0007156˜homophilic cell adhesion 1.490032e-05
GO:0048732˜gland development 1.979916e-05
GO:0048730˜epidermis morphogenesis 5.587490e-05
GO:0018149˜peptide cross-linking 6.822180e-05
GO:0031424˜keratinization 8.348452e-05
GO:0031069˜hair follicle morphogenesis 2.624236e-04
GO:0009611˜response to wounding 2.949778e-04
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GO:0001942˜hair follicle development 7.065423e-04
GO:0022405˜hair cycle process 7.065423e-04
GO:0022404˜molting cycle process 7.065423e-04
GO:0043586˜tongue development 7.327775e-04
GO:0042303˜molting cycle 7.885236e-04
GO:0042633˜hair cycle 7.885236e-04
GO:0007160˜cell-matrix adhesion 8.121753e-04
GO:0033273˜response to vitamin 8.978528e-04
GO:0048729˜tissue morphogenesis 1.058597e-03
GO:0007229˜integrin-mediated signaling pathway 1.224475e-03
GO:0031589˜cell-substrate adhesion 1.433116e-03
GO:0007584˜response to nutrient 2.773635e-03
GO:0042552˜myelination 3.878236e-03
GO:0008366˜axon ensheathment 5.577025e-03
GO:0007272˜ensheathment of neurons 5.577025e-03
GO:0048878˜chemical homeostasis 6.896339e-03
GO:0050678˜regulation of epithelial cell proliferation 7.256797e-03
GO:0042592˜homeostatic process 9.509398e-03
GO:0042445˜hormone metabolic process 9.610745e-03
Table 6.10: David result for FL
GO-BP-Term PValue
GO:0007398˜ectoderm development 5.613947e-17
GO:0008544˜epidermis development 1.174290e-16
GO:0030855˜epithelial cell differentiation 1.292047e-13
GO:0060429˜epithelium development 1.064189e-11
GO:0007155˜cell adhesion 1.086191e-09
GO:0022610˜biological adhesion 1.124393e-09
GO:0009913˜epidermal cell differentiation 1.673166e-09
GO:0030216˜keratinocyte differentiation 1.025312e-08
GO:0016337˜cell-cell adhesion 1.525707e-08
GO:0042060˜wound healing 3.431587e-05
GO:0022404˜molting cycle process 1.872121e-04
GO:0022405˜hair cycle process 1.872121e-04
GO:0001942˜hair follicle development 1.872121e-04
GO:0031424˜keratinization 2.096723e-04
GO:0042303˜molting cycle 2.096723e-04
GO:0042633˜hair cycle 2.096723e-04
GO:0007156˜homophilic cell adhesion 2.769314e-04
GO:0043586˜tongue development 3.144916e-04
GO:0048732˜gland development 3.396212e-04
GO:0031069˜hair follicle morphogenesis 1.713021e-03
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GO:0001501˜skeletal system development 2.683653e-03
GO:0048730˜epidermis morphogenesis 3.843757e-03
GO:0018149˜peptide cross-linking 4.304688e-03
GO:0042692˜muscle cell differentiation 4.591194e-03
GO:0007160˜cell-matrix adhesion 5.644139e-03
GO:0048878˜chemical homeostasis 6.085985e-03
GO:0050801˜ion homeostasis 6.358789e-03
GO:0019725˜cellular homeostasis 6.907428e-03
GO:0042592˜homeostatic process 7.606665e-03
GO:0009611˜response to wounding 8.147573e-03
GO:0031589˜cell-substrate adhesion 8.427509e-03
GO:0048729˜tissue morphogenesis 8.429813e-03
GO:0007569˜cell aging 8.462436e-03
Table 6.11: David result for MCL
GO-BP-Term PValue
GO:0007398˜ectoderm development 2.923868e-14
GO:0008544˜epidermis development 1.136894e-13
GO:0030855˜epithelial cell differentiation 7.609231e-11
GO:0060429˜epithelium development 4.155874e-09
GO:0009913˜epidermal cell differentiation 1.848859e-06
GO:0030216˜keratinocyte differentiation 1.540328e-05
GO:0007155˜cell adhesion 1.639677e-04
GO:0022610˜biological adhesion 1.666692e-04
GO:0022405˜hair cycle process 3.651095e-04
GO:0022404˜molting cycle process 3.651095e-04
GO:0001942˜hair follicle development 3.651095e-04
GO:0042303˜molting cycle 4.000526e-04
GO:0042633˜hair cycle 4.000526e-04
GO:0031069˜hair follicle morphogenesis 4.610159e-04
GO:0042060˜wound healing 9.370350e-04
GO:0048730˜epidermis morphogenesis 1.056117e-03
GO:0043588˜skin development 1.638697e-03
GO:0016337˜cell-cell adhesion 1.845824e-03
GO:0035295˜tube development 2.111749e-03
GO:0031424˜keratinization 5.096930e-03
GO:0007160˜cell-matrix adhesion 5.949153e-03
GO:0031589˜cell-substrate adhesion 8.326389e-03
GO:0030324˜lung development 8.623702e-03
GO:0030323˜respiratory tube development 9.557112e-03
Table 6.12: David result for PTCL
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Transcript Exon Array ID Symbol
2325526 SRRM1
2328465 KHDRBS1
2335671 ELAVL4
2348060 PTBP2
2418000 ZRANB2
2464499 HNRNPU
2487639 PCBP1
2548871 HNRPLL
2558511 TIA1
2593670 SF3B1
2648141 MBNL1
2709062 TRA2B
2775463 HNRNPD
2775562 HNRPDL
2877141 HNRNPA0
2890148 HNRNPH1
2935475 QKI
2959039 KHDRBS2
2963407 SYNCRIP
3041519 TRA2A
3041550 TRA2A
3042421 HNRNPA2B1
3107548 ESRP1
3117384 KHDRBS3
3201784 ELAVL2
3205033 YBX1
3249738 HNRNPH3
3286286 HNRNPF
3309629 TIAL1
3377044 SF1
3416036 PCBP2
3416483 HNRNPA1
3543411 RBM25
3558745 NOVA1
3656904 FUS
3815834 DAZAP1
3819543 HNRNPM
3848689 ELAVL1
3850960 ELAVL3
3861617 HNRNPL
3865807 NOVA2
3959203 RBFOX2
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3994100 FMR1
2320048 TARDBP
2396415 TARDBP
2406064 SFPQ
2421782 RBMX
2454661 HNRNPH1
2588827 HNRNPA3
2594627 HNRNPA1
2622469 RBM5
2893130 HNRNPA1
3212294 HNRNPK
3336422 RBM4
3378411 RBM4
3465593 HNRNPA1
3696226 ESRP2
3847814 KHSRP
3944273 RBFOX2
3969802 HNRPDL
3984779 HNRNPH2
2902804 C2
2904248 SNRPC
Table 6.13: Splicing Factors derived from SpliceAid-F and mapped to our data.
Sample IDs
TCGA-32-2638-01A-01R-1850-01
TCGA-12-1597-01B-01R-1849-01
TCGA-19-2624-01A-01R-1850-01
TCGA-41-2571-01A-01R-1850-01
TCGA-06-0675-11A-32R-A36H-07*
TCGA-06-0678-11A-32R-A36H-07*
TCGA-06-0680-11A-32R-A36H-07*
TCGA-06-0681-11A-41R-A36H-07*
Table 6.14: Samples for glioblastoma multiforme and four organ-specific control sam-
ples(*) derived from TCGA [Tomczak et al., 2015].
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